

10537407.ttn

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAKM1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR 2):2

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 OCT 02 CA/Caplus enhanced with pre-1907 records from Chemisches
Zentralblatt
NEWS 3 OCT 19 BELLSTEIN updated with new compounds
NEWS 4 NOV 15 Derwent Indian patent publication number format enhanced
NEWS 5 NOV 19 WPIX enhanced with XML display format
NEWS 6 NOV 30 ICSD reloaded with enhancements
NEWS 7 DEC 04 LINDACODS now available on STN
NEWS 8 DEC 14 BELLSTEIN pricing structure to change
NEWS 9 DEC 17 USPATOLD added to additional database clusters
NEWS 10 DEC 17 INSURCONF removed from database clusters and SIN
NEWS 11 DEC 17 USGNE now includes more than 10 million sequences
NEWS 12 DEC 17 TOXCENTER enhanced with 2008 MeSH vocabulary in
MEDLINE segment
NEWS 13 DEC 17 MEDLINE and LMEEDLINE updated with 2008 MeSH vocabulary
NEWS 14 DEC 17 CA/Caplus enhanced with new custom IPC display formats
NEWS 15 DEC 17 STN Viewer enhanced with full-text patent content
from USPATOLD
NEWS 16 JAN 02 STN pricing information for 2008 now available
NEWS 17 JAN 16 CAS patent coverage enhanced to include exemplified
prophetic substances
NEWS 18 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new
custom IPC display formats
NEWS 19 JAN 28 MARPAT searching enhanced
NEWS 20 JAN 28 USGNE now provides USPTO sequence data within 3 days
of publication
NEWS 21 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 22 JAN 28 MEDLINE and LMEEDLINE reloaded with enhancements
NEWS 23 FEB 08 STN Express, Version: 6.3, now available
NEWS 24 FEB 20 PCI now available as a replacement to DPCI
NEWS 25 FEB 25 IPREF reloaded with enhancements
NEWS 26 FEB 25 INSURCONF reloaded with enhancements
NEWS 27 FEB 29 WPIINDEX/WPIUS/WPIX enhanced with ECLA and current
U.S. National Patent Classification

NEWS EXPRESS FEBRUARY 09 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that

10537407.ttn

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 15:20:50 ON 07 MAR 2008

=> file caplus

FILE 'CAPLUS' ENTERED AT 15:21:22 ON 07 MAR 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USABETTERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Mar 2008 VCL 149 ISS 11

FILE LAST UPDATED: 6 Mar 2008 (20080306/20)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s US2006-536407/apps

0 US2006-536407/AP
0 US2006-536407/PBN
L1 0 US2006-536407/APPS
(US2006-536407/AP,PBN)

=> s US2005-536407/apps

1 US2005-536407/AP
0 US2005-536407/PBN
L2 1 US2005-536407/APPS
(US2005-536407/AP,PBN)

=> file reg

FILE 'REGISTER' ENTERED AT 15:22:21 ON 07 MAR 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USABETTERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the 2IC/WNITC data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 MAR 2008 HIGHEST RN 1006749-26-3

DICTIONARY FILE UPDATES: 5 MAR 2008 HIGHEST RN 1006749-26-3

10537407.ttn

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> tra rn l1
'L1' HAS NO ANSWERS

=> tra rn l2
REQUESTED FIELD CODE NOT PRESENT IN ANSWER(S) SPECIFIED.

=> file cplaus
'CPLAUS' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'REGISTRY'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> file caplus
FILE 'CAPLUS' ENTERED AT 13:22:47 ON 07 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Mar 2008 VOL 148 ISS 11
FILE LAST UPDATED: 6 Mar 2008 (20080306/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 13:20:30 ON 07 MAR 2008)

FILE 'CAPLUS' ENTERED AT 13:21:22 ON 07 MAR 2008
L1 C S US2006-536407/APFS

10537407.ttn

L2 1 S US2006-536407/APFS

FILE 'REGISTRY' ENTERED AT 13:22:21 ON 07 MAR 2008

FILE 'CAPLUS' ENTERED AT 13:22:32 ON 07 MAR 2008

FILE 'REGISTRY' ENTERED AT 13:22:32 ON 07 MAR 2008

FILE 'CAPLUS' ENTERED AT 13:22:47 ON 07 MAR 2008

=> d scan l2

10537407.trn

L2 1 ANSWERS CAPLOS COPYRIGHT 2008 ACS on STN
IC ICM GO1N001-00
ICS GO1N027-447; GO1N027-62; GO1N030-60; GO1N030-72; GO1N033-48;
GO1N035-08; GO1N037-00; B01D057-00; B01D057-02; B81C001-00;
B01D049-26
CC 73-8 (Optical, Electron, and Mass Spectroscopy and Other Related
Properties)
Section cross-reference(s): 3, 7, 76
TI Microchip, liquid feeding method using the microchip, and mass analyzing
system
ST microchip liq sampling mass spectrometry
IT Mass spectrometry
Microarray technology
Sampling apparatus
(microchip liquid feeding means for mass spectrometry)

ALL ANSWERS HAVE BEEN SCANNED

10537407.trn

=> s US2005-537407/appa
1 US2005-537407/AP
0 US2005-537407/ERN
L3 1 US2005-537407/AEFS
(US2005-537407/AE,ERN)

=> file reg
FILE "REGISTRY" ENTERED AT 13:23:20 ON 07 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/NINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 MAR 2008 HIGHEST RN 1006749-26-3
DICTIONARY FILE UPDATES: 5 MAR 2008 HIGHEST RN 1006749-26-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:


<http://www.cas.org/support/stngen/stdoc/properties.html>

=> tra rn l3
L4 TRANSFER L3 1- RN : 683 TERMS
L5 683 L4

=> d scan

10537407.trn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[[2-(4-ethoxyphenyl)-4-pyridinyl]methyl]](4-methoxyphenyl)amino)-, 1,1-dimethylethyl ester
MF C31 H39 N3 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):20000

10537407.trn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidineamine, N-(4-bromophenyl)-N-((3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl)-, monohydrochloride (9Cl)
MF C27 H31 Br N2 O3 . Cl H



● HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(2-methoxyphenyl)-N-4-piperidinyl-2-(3,4,5-trimethoxyphenyl)-, dihydrochloride (9CI)
 MF C27 H33 N3 O4 . 2 Cl H



●2 HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-[1-[(2-(3,4-dimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-
 MF C41 H46 N4 O6
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(2-fluorophenyl)-N-[1-[[2-(2-fluorophenyl)-4-pyridinyl]methyl]-4-piperidinyl]-N-(4-methoxyphenyl)-, trihydrochloride (9CI)
MF C36 H34 F2 N4 O . 3 Cl H
C36 H34 F2 N4 O . 3 Cl H



● 3 HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-phenyl-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
MF C42 H47 N3 O6
C42 H47 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(3,4-difluorophenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-, trihydrochloride (3Cl)
 MF C41 H44 F2 N4 O6 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-[4-(trifluoromethyl)phenyl]-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-, dihydrochloride (2Cl)
 MF C43 H46 F3 N3 O6 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-[(4-(methylthio)phenyl)-2-(3,4,5-trimethoxyphenyl)-
N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-
MF C42 H48 N4 O6 S
CI C08



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-butoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinylmethyl]-
MF C46 H55 N3 O7 . 2 Cl H
CI C15



● 2 HCl

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-
MF C42 H48 N4 O7
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(4-chloro-3,5-dimethoxyphenyl)-N-[1-[[2-(4-chloro-
3,5-dimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-N-(4-
methoxyphenyl)-
MF C40 H42 Cl2 N4 O5
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Pyridine, 4-(chloromethyl)-2-(2-methoxyphenyl)-
MF Cl3 H12 Cl1 N1 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-phenyl-2-(3,4,5-trimethoxyphenyl)-N-[1-([2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-, trihydrochloride
(3Cl)
MF C41 H46 N4 O6 . 3 Cl H



● 3 HCl

10537407.trn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(phenylmethyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
 [(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-,
 tetrahydrochloride (9CI)
 MF C42 H48 N4 O6 . 4 Cl H



● 4 HCl

10537407.trn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Benzene, 5-bromo-2-chloro-1,3-dimethoxy-
 MF C8 H8 Br Cl O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

LS 683 ANSWEBS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[4-(trifluoromethyl)phenyl]amino]-,
1,1-dimethylethyl ester
MF C17 H23 F3 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWEBS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinecarboxylic acid, 2-chloro-, ethyl ester
MF C8 H8 Cl N O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[4-(trifluoromethoxy)phenyl][(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]amino]-, 1,1-dimethylethyl ester
MF C32 H38 F3 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(4-fluorophenyl)-N-4-piperidinyl-5-(3,4,5-trimethoxyphenyl)-, dihydrochloride (9CI)
MF C26 H30 F N3 O3 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[4-(methylthio)phenyl]][5-(3,4,5-
trimethoxyphenyl)-3-pyridinylmethylamino]-, 1,1-dimethylethyl ester
MF C32 H41 N3 OS S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[4-(ethoxyphenyl)][5-(3,4,5-
trimethoxyphenyl)-3-pyridinylmethylamino]-, 1,1-dimethylethyl ester
MF C33 H43 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(3,4-difluorophenyl)-N-(4-methoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-
MF C39 H40 F2 N4 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(3-methoxyphenyl)-N-(4-methoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, trihydrochloride (9CI)
MF C40 H44 N4 O5 . 3 Cl H



● 3 HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-fluorophenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-
MF C41 H45 F N4 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-bromophenyl)-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-
3-yl)methyl]-1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-
MF C42 H46 Br N3 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(4-methylphenyl)-2-[(3,4,5-trimethoxyphenyl)-N-[1-
 [[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-,
 trihydrochloride (3Cl)
 MF C42 H48 N4 O6 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-(3-methoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-
 MF C43 H49 N3 O7
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(4-ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
 [(5-(3,4,5-trimethoxyphenyl)-3-pyridinyl)methyl]-4-piperidinyl]-,
 trihydrochloride (3Cl)
 MF C43 H50 N4 O7 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(4-butylphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
 [(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-,
 MF C45 H54 N4 O6
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(phenylmethyl)-6-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C42 H48 N4 O6
CT C08



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10537407.tzn

L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-butylphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
trihydrochloride (9CI)
MF C45 H54 N4 O6 . 3 Cl H



10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN [1,1'-Biphenyl]-4-carboxylic acid, 3',4',5'-trimethoxy-, ethyl ester
MF Cl8 H20 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,1'-Biphenyl, 3'-(chloromethyl)-3,4,5-trimethoxy-
MF Cl6 H17 Cl O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn

L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyrrolidinamine, N-methyl-1-[[2-(3,4,5-trimethoxyphenyl)-4-
pyridinyl]methyl]-, (3S)-
MF C20 H27 N3 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn

L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenamine, 4-bromo-2,6-dimethoxy-
MF C8 H10 Br N O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Methanamine
MF C H5 N
CI COM

H3C-10H2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridineethanamine, 2-(2-methoxyphenyl)-N-(4-methoxyphenyl)-N-4-
piperidinyl-, dihydrochloride (9CI)
MF C25 H29 N3 O2 . 2 Cl H



●2 HCl

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-bromophenyl)[[5-(3,4,5-trimethoxyphenyl)-3-pyridinylmethylamino]-, 1,1-dimethylethyl ester
MF C31 H38 Br N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10537407.tzn

LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(3-methoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-, monohydrochloride (9CI)
MF C28 H34 N2 O4 . Cl H



10537407.tzn


LS 683 ANSRS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, trihydrochloride (9Cl)
 MF C40 H44 N4 O5 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSRS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-[1-([2-(2-fluorophenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-
 MF C39 H41 F N4 O4
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-phenyl-5-(3,4,5-trimethoxyphenyl)-N-[1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-, trihydrochloride (9CI)
MF C41 H46 N4 O6 . 3 Cl H
CI



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-chlorophenyl)-N,1-bis[[3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-
MF C43 H47 Cl N2 O6
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-[4-(trifluoromethyl)phenyl]-2-(3,4,5-trimethoxyphenyl)-N-[1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-
 MF C42 H45 F3 N4 O6
 CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10537407.tzn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-[4-(trifluoromethoxy)phenyl]-N,1-bis[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-, monohydrochloride (9CI)
 MF C44 H47 F3 N2 O7 . Cl H



10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(4-butoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-
MF C45 H54 N4 O7
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10537407.tnn

L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN [1,1'-Biphenyl]-3-carboxamide, 3',4',5'-trimethoxy-N-(4-methoxyphenyl)-N-
[1-[[3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl]methyl]-4-piperidinyl]-,
monohydrochloride (9CI)
MF C44 H48 N2 O8 . Cl H



10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-cyclohexyl-2-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-
MF C41 H52 N4 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-butylphenyl)-1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-
MF C30 H39 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Phenol, 4-[[4-[[[2-(4-hydroxy-3,5-dimethoxyphenyl)-4-pyridinyl]methyl]methylamino]-1-piperidinyl]methyl]-2,6-dimethoxy-, tetrahydrochloride (9CI)
MF C34 H40 N4 O6 . 4 Cl H



● 4 HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-[3,5-dimethoxy-4-(1-methylethoxy)phenyl]-N-[1-[[2-[3,5-dimethoxy-4-(1-methylethoxy)phenyl]-4-pyridinyl]methyl]-4-piperidinyl]-N-(4-methoxyphenyl)-, trihydrochloride (9CI)
MF C46 H56 N4 O7 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-methyl-5-(3,4,5-trimethoxyphenyl)-N-[1-([2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-
MF C36 H44 N4 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Boronic acid, B-(3,4,5-trimethoxyphenyl)-
MF C9 H13 B O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenamine, 3-methoxy-
MF C7 H9 N O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[[2-(4-chlorophenyl)-4-pyridinylmethyl]](4-methoxyphenyl)amino]-, 1,1-dimethylethyl ester
MF C29 H34 Cl N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-fluorophenyl)[2-(3,4,5-
trimethoxyphenyl)-4-pyridinylmethyl]amino]-, 1,1-dimethylethyl ester
MF C31 H38 F N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[4-(methylthio)phenyl]amino]-,
1,1-dimethylethyl ester
MF C17 H26 N2 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-ethoxyphenyl)amino]-, 1,1-dimethylethyl
ester
MF C18 H28 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-[1-[(2-(3,4-difluorophenyl)-4-pyridinyl)methyl]-4-piperidinyl]-N-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-, trihydrochloride (9CI)
MF C39 H40 F2 N4 O4 . 3 Cl H



● 3 HCl

10537407.tzn


L5 683 ANSWEERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(2-methoxyphenyl)-N-(4-methoxyphenyl)-N-[1-[(2-(2-methoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-
MF C38 H40 N4 O3
CT C08



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWEERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-fluorophenyl)-2-[(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, trihydrochloride (9CI)
MF C41 H45 F N4 O6 . 3 Cl H



● 3 HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidine, N-(4-bromophenyl)-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-, dihydrochloride (9CI)
 MF C42 H46 Br N3 O6 . 2 Cl H
 CI



● 2 HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidine, N-[4-(methylthio)phenyl]-N,1-bis[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-
 MF C44 H50 N2 O6 S
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(3-methoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-
MF C43 H49 N3 O7 . 2 Cl H
CI COM



• 2 HCl

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-ethoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-4-piperidinyl]-2-(3,4,5-trimethoxyphenyl)-
MF C44 H51 N3 O7
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn


LS 683 ANSWEERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidineamine, N-(2,3-dihydro-1H-inden-5-yl)-N-[(3',4',5'-
trimethoxy[1,1'-biphenyl]-4-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-
pyridinyl]methyl]-
MF C45 H51 N3 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn


LS 683 ANSWEERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(phenylmethyl)-2-(3,4,5-trimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C42 H48 N4 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-(2,3-dihydro-1H-inden-5-yl)-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-, dihydrochloride (9CI)
 MF C45 H51 N3 O6 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(3,5-dimethoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, trihydrochloride (9CI)
 MF C43 H50 N4 O8 . 3 Cl H



● 3 HCl

10537407.tzn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
 [(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-,
 trihydrochloride (3Cl)
 MF C42 H48 N4 O7 . 3 Cl H




● 3 HCl

10537407.tzn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1-Pyrrolidinecarboxylic acid, 3-[methyl[(2-nitrophenyl)sulfonyl]amino]-,
 1,1-dimethylethyl ester, (3S)-
 MF C16 H23 N3 O6 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,3-Benzodioxol-5-amine
MF C7 H7 N O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
dihydrochloride (9CI)
MF C41 H45 Cl N4 O6 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-methoxyphenyl)[(2-phenyl-4-
pyridinyl)methyl]amino]-, 1,1-dimethylethyl ester
MF C29 H35 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-[4-(trifluoromethyl)phenyl]-N-[(3',4',5'-
trimethoxy[1,1'-biphenyl]-3-yl)methyl]-, monohydrochloride (9CI)
MF C28 H31 F3 N2 O3 . Cl H



● HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(3-methoxyphenyl)[5-(3,4,5-
trimethoxyphenyl)-3-pyridinyl]methylamino]-, 1,1-dimethylethyl ester
MF C32 H41 N3 O6
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(4-chlorophenyl)-N-[1-[[2-(4-chlorophenyl)-4-
pyridinyl]methyl]-4-piperidinyl]-N-(4-methoxyphenyl)-
MF C36 H34 Cl2 N4 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS ON STN
 IN 4-Pyridinemethanamine, 2-(3,4-dimethoxyphenyl)-N-[1-([2-(3,4-dimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl)-N-(4-methoxyphenyl)-, trihydrochloride (3Cl)
 MF C40 H44 N4 O5 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS ON STN
 IN 4-Pyridinemethanamine, N-phenyl-2-(3,4,5-trimethoxyphenyl)-N-[1-([5-(3,4,5-trimethoxyphenyl)-3-pyridinylmethyl]-4-piperidinyl)-, trihydrochloride (3Cl)
 MF C41 H46 N4 O6
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-(4-chlorophenyl)-N-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-
 , dihydrochloride (9CI)
 MF C42 H46 Cl N3 O6 . 2 Cl B



● 2 HCl

10537407.ttn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-[4-(trifluoromethyl)phenyl]-2-[3,4,5-
 trimethoxyphenyl]-N-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-
 piperidinyl-, trihydrochloride (9CI)
 MF C42 H45 F3 N4 O6 . 3 Cl B



● 3 HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-[4-(trifluoromethoxy)phenyl]-N-[(3',4',5'-
 trimethoxy[1,1'-biphenyl]-3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-
 pyridinyl)methyl]-
 MF C43 H46 F3 N3 O7
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(4-butoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
 [[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-,
 trihydrochloride (9CI)
 MF C45 H54 N4 O7 . 3 Cl B



●3 BCL

10537407.tzn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN [1,1'-Biphenyl]-3-carboxamide, 3',4',5'-trimethoxy-N-(4-methoxyphenyl)-N-
[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C43 H47 N3 O8
CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(3,4,5-trimethoxyphenyl)-N-((3S)-1-[[2-(3,4,5-
trimethoxyphenyl)-4-pyridinyl]methyl]-3-pyrrolidinyl)-
MF C34 H40 N4 O6
CI COM

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, 1-[[2-(4-chloro-3,5-dimethoxyphenyl)-4-pyridinyl]methyl]-
N-(4-methoxyphenyl)-
MF C26 H30 Cl N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-methyl-2-(3,4,5-trimethoxyphenyl)-N-[[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, tetrahydrochloride
(9Cl)
MF C36 H44 N4 O6 . 4 Cl H



● 4 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,4-Dioxo-8-azaspiro[4.5]decane, 8-[[2-(3,5-dimethoxy-4-(1-methylethoxy)phenyl)-4-pyridinyl]methyl]-
MF C24 H32 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidino, 1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
MF C20 H24 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-(aminomethyl)-, 1,1-dimethylethyl ester
MF C11 H22 N2 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenamine, 4-fluoro-
MF C6 H6 F N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(3,4-difluorophenyl)-N-(4-methoxyphenyl)-N-4-
piperidinyl-, dihydrochloride (9CI)
MF C24 H25 F2 N3 O . 2 Cl H



● 2 HCl

10537407.ttn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-N-(4-piperidinyl-5-(3,4,5-
trimethoxyphenyl)-, dihydrochloride (9CI)
MF C26 H29 F2 N3 O3 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(4-piperidinyl-N-(4-(trifluoromethoxy)phenyl)-5-(3,4,5-trimethoxyphenyl)-, dihydrochloride (9CI)
MF C27 H30 F3 N3 O4 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-N-(4-piperidinyl-5-(3,4,5-trimethoxyphenyl)-, dihydrochloride (9CI)
MF C27 H33 N3 O4 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(4-fluorophenyl)-N-(4-methoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-
MF C39 H41 F N4 O4
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(2-methoxyphenyl)-N-(4-methoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, trihydrochloride (9CI)
MF C40 H44 N4 O5 . 3 Cl H



● 3 HCL

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(3,4-difluorophenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-1-[(5-(3,4,5-trimethoxyphenyl)-3-pyridinyl)methyl]-
MF C42 H45 F2 N3 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-bromophenyl)-N-1-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-4-piperidinyl-2-(3,4,5-trimethoxyphenyl)-
MF C42 H46 Br N3 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidine, N-[4-(methylthio)phenyl]-N-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-1-[(5-(3,4,5-trimethoxyphenyl)-3-pyridinyl)methyl]-
 , dihydrochloride (9CI)
 MF C43 H49 N3 O6 S . 2 Cl H
 CI COM



• 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
 [(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-
 MF C42 H48 N4 O7
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(4-ethoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
 [(5-(3,4,5-trimethoxyphenyl)-3-pyridinyl)methyl]-4-piperidinyl]-,
 trihydrochloride (3Cl)
 MF C43 H50 N4 O7 . 3 Cl H



● 3 HCl

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(2,3-dihydro-1H-inden-5-yl)-6-(3,4,5-
 trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-
 piperidinyl]-, trihydrochloride (3Cl)
 MF C44 H50 N4 O6 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-6-(3,4,5-trimethoxyphenyl)-N-[1-
 [[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
 MF C42 H48 N4 O7
 CT C08



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(2,3-dihydro-1H-inden-5-yl)-2-(3,4,5-
 trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-
 piperidinyl]-, trihydrochloride (9CI)
 MF C44 H50 N4 O6 . 3 Cl H



• 3 HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN [1,1'-Biphenyl]-2-methanol, 3',4',5'-trimethoxy-
MF Cl6 H18 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinecarboxylic acid, 2-(3,4,5-trimethoxyphenyl)-, ethyl ester
MF Cl7 H19 N O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Pyridine, 4-[(4-piperidinyloxy)methyl]-2-(3,4,5-trimethoxyphenyl)-
MF C20 H26 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzoic acid, 2-bromo-, ethyl ester
MF C9 H9 Br O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN [1,1'-Biphenyl]-3-methanamine, 3',4',5'-trimethoxy-N-(2-methoxyphenyl)-N-
[4-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]cyclohexyl]-,
dihydrochloride (9CI)
MF C44 H50 N2 O7 . 2 Cl H



● 2 HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Pyridine, 4-(chloromethyl)-2-(3-fluorophenyl)-
MF Cl2 H9 Cl F N



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[4-(trifluoromethyl)phenyl][2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]amino]-, 1,1-dimethylethyl ester
MF C32 H38 F3 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[3-methoxyphenyl]amino]-, 1,1-dimethylethyl ester
MF C17 H26 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(4-chlorophenyl)-N-(4-methoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-4-piperidinyl], trihydrochloride (3Cl)
MF C39 H41 Cl N4 O4 . 3 Cl H
CI C3 HCl



●3 HCl

10537407.ttn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-[1-[[2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-N-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-
MF C41 H46 N4 O6
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-fluorophenyl)-N,1-bis[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-, monohydrochloride (9CI)
MF C43 H47 F N2 O6 . Cl H



● HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-
MF C41 H45 Cl N4 O6
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-(4-methylphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-
 MF C43 H49 N3 O6
 CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-[4-(trifluoromethoxyphenyl)-5-(3,4,5-
 trimethoxyphenyl)-N-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-
 piperidinyl]-, trihydrochloride (9CI)
 MF C42 H45 F3 N4 O7 . 3 Cl H



● 3 HCl

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-butoxyphenyl)-2-[(3,4,5-trimethoxyphenyl)-N-[1-
[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-
MF C45 H54 N4 O7
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN [1,1'-Biphenyl]-3-carboxamide, 3',4',5'-trimethoxy-N-(4-methoxyphenyl)-N-4-
piperidinyl-, monohydrochloride (9CI)
MF C28 H32 N2 O5 . Cl H



● HCl

10537407.ttn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-1,3-benzodioxol-5-yl-6-(3,4,5-trimethoxyphenyl)-N-
[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C42 H46 N4 O8
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,4-Dioxo-8-azaspiro[4.5]decane, 8-[[2-(4-chloro-3,5-dimethoxyphenyl)-4-pyridinyl]methyl]-
MF C21 H25 Cl N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-bromophenyl)amino]-, 1,1-dimethylethyl
ester
MF C16 H23 Br N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinecarboxylic acid, 2-[3,5-dimethoxy-4-[1-methylethoxy]phenyl]-,
ethyl ester
MF C19 H23 N O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Carbanic acid, [1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-
piperidinyl]-, ethyl ester (9CI)
MF C23 H31 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Phenol, 4-iodo-2,6-dimethoxy-
MF C8 H9 I O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Cyclohexanamine
MF C6 H13 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[[2-(4-fluorophenyl)-4-pyridinylmethyl](4-methoxyphenyl)amino]-, 1,1-dimethylethyl ester
MF C29 H34 F N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(3,4-difluorophenyl)[(2-(3,4,5-
trimethoxyphenyl)-4-pyridinyl)methyl]amino]-, 1,1-dimethylethyl ester
MF C31 H37 F2 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[4-(trifluoromethoxy)phenyl]amino]-,
1,1-dimethylethyl ester
MF C17 H23 F3 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1-Piperidinecarboxylic acid, 4-[(4-methoxyphenyl)[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]amino]-, 1,1-dimethylethyl ester
 MF C32 H41 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-[1-[(2-(4-fluorophenyl)-4-pyridinyl)methyl]-4-piperidinyl]-N-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-, trihydrochloride (9CI)
 MF C39 H41 F N4 O4 . 3 Cl H



● 3 HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-methoxyphenyl)-2-phenyl-N-[1-[(2-phenyl-4-
pyridinyl)methyl]-4-piperidinyl]-
MF C36 H36 N4 O
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(3,4-difluorophenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
, dihydrochloride (9CI)
MF C42 H45 F2 N3 O6 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(4-bromophenyl)-2-[(3,4,5-trimethoxyphenyl)-N-[1-
 [[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-,
 trihydrochloride (3Cl)
 MF C41 H45 Br N4 O6 . 3 Cl H
 CI



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-[4-(methylthiophenyl)-5-(3,4,5-trimethoxyphenyl)-
 N-[1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-
 MF C42 H48 N4 O6 S
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(3-methoxyphenyl)-N-[1-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-4-piperidinyl]-2-(3,4,5-trimethoxyphenyl)-,
dihydrochloride (9CI)
MF C43 H49 N3 O7 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-methoxyphenyl)-N,1-bis[1-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-
MF C44 H50 N2 O7
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(2,3-dihydro-1H-inden-5-yl)-N-[(3',4',5'-
trimethoxy[1,1'-biphenyl]-2-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-
pyridinyl]methyl]-
MF C45 H51 N3 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C42 H48 N4 O7
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinethanamine, N-[3-(methylthio)phenyl]-6-(3,4,5-trimethoxyphenyl)-
N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-,
trihydrochloride (3Cl)
MF C42 H48 N4 O6 S . 3 Cl H



● 3 HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(3,5-dimethoxyphenyl)-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-,
trihydrochloride (3Cl)
MF C28 H35 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWEBS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, 1-[[2-(4-chloro-3,5-dimethoxyphenyl)-4-pyridinyl]methyl]-
N-methyl-
MF C20 H26 Cl N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWEBS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
MF C21 H26 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN [1,1'-Biphenyl]-3-carboxylic acid, 3',4',5'-trimethoxy-
MF C16 H16 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[4-
[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]cyclohexyl]-
MF C43 H49 N3 O7
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-phenyl-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-, monohydrochloride (9Cl)
MF C27 H32 N2 O3 . Cl H



● HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(4-methylphenyl)-N-4-piperidyl-5-(3,4,5-trimethoxyphenyl)-, dihydrochloride (9Cl)
MF C27 H33 N3 O3 . 2 Cl H



● 2 HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(4-butoxyphenyl)-N-4-piperidinyl-5-(3,4,5-trimethoxyphenyl)-, dihydrochloride (9Cl)
 MF C30 H39 N3 O4 . 2 Cl H



● 2 HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, 2-(3,5-difluorophenyl)-N-1-[(2-(3,5-difluorophenyl)-4-pyridinylmethyl)-4-piperidinyl]-N-(4-methoxyphenyl)-
 MF C36 H32 F4 N4 O
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(4-ethoxyphenyl)-N-([2-(4-ethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl)-N-(4-methoxyphenyl)-, trihydrochloride (9CI)
MF C40 H44 N4 O3 . 3 Cl H
CF C40 H44 N4 O3 . 3 Cl H



● 3 HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-fluorophenyl)-N-([3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-1-[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-
MF C42 H46 F N3 O6
CF C42 H46 F N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-chlorophenyl)-N-[1-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-4-piperidinyl]-2-(3,4,5-trimethoxyphenyl)-
MF C42 H46 Cl N3 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-methylphenyl)-N-[1-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-1-[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
, dihydrochloride (9CI)
MF C43 H49 N3 O6 . 2 Cl H



● 2 HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-[4-(trifluoromethoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-
 MF C42 H45 F3 N4 O7
 CT C08



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn

L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(4-butoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, trihydrochloride (9CI)
 MF C45 H54 N4 O7 . 3 Cl H




10537407.tzn


LS 683 ANSHERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenesulfonamide, 2-nitro-N-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-N-[(3S)-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-3-pyrrolidinyl]-
MF C40 H43 N5 O10 S
C1 C00

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSHERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-1,3-benzodioxol-5-yl-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-2-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
MF C43 H47 N3 O8
C1 C00



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWEBS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-ethyl-N-4-piperidyl-2-(3,4,5-trimethoxyphenyl)-
MF C22 H31 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWEBS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-1,3-benzodioxol-5-yl-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridyl]methyl]-
dihydrochloride (9CI)
MF C43 H47 N3 O8 . 2 Cl H



• 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
 [[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
 trihydrochloride (9CI)
 MF C42 H48 N4 O7 . 3 Cl H



●3 HCl

10537407.tzn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Benzenesulfonamide, 2-nitro-N-[[2-(3,4,5-trimethoxyphenyl)-4-
 pyridinyl]methyl]-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-
 piperidinyl]-
 MF C41 H45 N5 O10 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

LS 693 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-amino-, ethyl ester
MF C8 H16 N2 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 693 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenamine, 4-bromo-
MF C6 H6 Br N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(2-fluorophenyl)-N-(4-methoxyphenyl)-N-4-
piperidinyl-, dihydrochloride (9CI)
MF C24 H26 F N3 O . 2 Cl H



●2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-chlorophenyl)[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]amino]-, 1,1-dimethylethyl ester
MF C32 H39 Cl N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(2,3-dimethoxyphenyl)amino]-,
1,1-dimethylethyl ester
MF C18 H28 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-N-[(1-[(2-(3-methoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, trihydrochloride (9CI)
MF C39 H40 F2 N4 O4 . 3 Cl H



● 3 HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(3-fluorophenyl)-N-(4-methoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-
MF C39 H41 F N4 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-methoxyphenyl)-2-phenyl-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, trihydrochloride
(3Cl)
MF C39 H42 N4 O4 . 3 Cl H



● 3 HCl

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C41 H44 F2 N4 O6
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-[4-(trifluoromethyl)phenyl]-N,1-bis[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-
MF C44 H47 F3 N2 O6
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-[(4-(methylthio)phenyl)-5-(3,4,5-trimethoxyphenyl)-
 N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
 trihydrochloride (3Cl)
 MF C42 H48 N4 O6 S . 3 Cl H



●3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(3-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
 [[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
 MF C42 H48 N4 O7
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-(4-methoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-1-[(5-(3,4,5-trimethoxyphenyl)-5-pyridinyl)methyl]-
 , dihydrochloride (9CI)
 MF C43 H49 N3 O7 . 2 Cl H
 CI COM



● 2 HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-[3-(methylthio)phenyl]-N-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-4-yl)methyl]-1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-
 MF C43 H49 N3 O6 S
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Pyridine, 2-(3,4,5-trimethoxyphenyl)-4-[[4-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methoxy]-1-piperidinyl]methyl]-
MF C35 H41 N3 O7
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-[3-(methylthio)phenyl]-2-(3,4,5-trimethoxyphenyl)-
N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C42 H48 N4 O6 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[methyl[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]amino]methyl]-, 1,1-dimethylethyl ester
MF C27 H39 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Pyridine, 2-(4-chloro-3,5-dimethoxyphenyl)-4-(chloromethyl)-
MF Cl4 H13 Cl2 N O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Isocouder-1,3(2H)-dione, 2-[[2-(3,4,5-trimethoxyphenyl)-4-
pyridinyl]methyl]-
MF C23 H20 N2 O5
CT



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine
MF C6 H8 N2
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(2-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[4-
 [[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]cyclohexyl]-,
 trihydrochloride (3Cl)
 MF C43 H49 N3 O7 . 3 Cl H



● 3 HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1-Piperidinecarboxylic acid, 4-[phenyl[[5-(3,4,5-trimethoxyphenyl)-3-
 pyridinyl]methyl]amino]-, 1,1-dimethylethyl ester
 MF C31 H39 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-methylphenyl)[(2-(3,4,5-
trimethoxyphenyl)-4-pyridinyl)methyl]amino]-, 1,1-dimethylethyl ester
MF C32 H41 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-butoxyphenyl)[(2-(3,4,5-
trimethoxyphenyl)-4-pyridinyl)methyl]amino]-, 1,1-dimethylethyl ester
MF C35 H47 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(3,5-difluorophenyl)-N-(4-methoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, trihydrochloride (3Cl)
MF C39 H40 F2 N4 O4 . 3 Cl H
CI



● 3 HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-[1-[(2-(4-ethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-N-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-, trihydrochloride (3Cl)
MF C41 H46 N4 O5
CI



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSRS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-,
trihydrochloride (9Cl)
MF C41 H45 F N4 O6 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSRS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-chlorophenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-,
trihydrochloride (9Cl)
MF C41 H45 Cl N4 O6 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-[(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
 [[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-4-piperidinyl]-
 MF C42 H48 N4 O6
 CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-[4-(trifluoromethoxyphenyl)-2-(3,4,5-
 trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-
 piperidinyl]-, trihydrochloride (9CI)
 MF C42 H45 F3 N4 O7 . 3 Cl H



• 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-ethoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-1-[(5-(3,4,5-trimethoxyphenyl)-3-pyridinyl)methyl]-
MF C44 H51 N3 O7
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-methyl-2-(3,4,5-trimethoxyphenyl)-
MF C16 H20 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(3,5-dimethoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-
MF C44 H51 N3 O8
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[methyl[(2-(3,4,5-trimethoxyphenyl)-4-
pyridinyl)methyl]amino]-, ethyl ester
MF C24 H33 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-1,3-benzodioxol-5-yl-2-(3,4,5-trimethoxyphenyl)-N-
[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
trihydrochloride (9CI)
MF C42 H46 N4 O8 . 3 Cl H



● 3 HCl

10537407.tzn

LS 683 ANSERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-6-(3,4,5-trimethoxyphenyl)-N-[[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
trihydrochloride (9CI)
MF C42 H48 N4 O7 . 3 Cl H




● 3 HCl

10537407.tzn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinecarboxamide, 2-(3,4,5-trimethoxyphenyl)-N-[1-([2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-, (2E)-2-butenedioate (1:1)
MF C35 H40 N4 O7 . C4 H4 O4

CM 1



CM 2

Double bond geometry as shown.



10537407.tzn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidine, hydrochloride (1:1)
MF C5 H9 N O . Cl H



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenamine, 4-butyl-
MF C10 H15 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[[2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl](4-methoxyphenyl)amino]-, 1,1-dimethylethyl ester
MF C31 H39 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-chlorophenyl)-N-4-piperidinyl-2-(3,4,5-trimethoxyphenyl)-, dihydrochloride (9Cl)
MF C26 H30 Cl N3 O3 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(2-methoxyphenyl)-N-4-piperidinyl-5-(3,4,5-trimethoxyphenyl)-, dihydrochloride (9Cl)
MF C27 H33 N3 O4 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSRS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(4-fluorophenyl)-N-[1-[(2-(3-methoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-
MF C39 H41 F N4 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSRS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-[1-[(2-(3-fluorophenyl)-4-pyridinyl)methyl]-4-piperidinyl]-N-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-, trihydrochloride (9CI)
MF C39 H41 F N4 O4 . 3 Cl H



● S HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-phenyl-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-1-[(3,4,5-trimethoxyphenyl)-3-pyridinylmethyl]-
MF C42 H47 N3 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(3,4-difluorophenyl)-N-[(1-[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-4-piperidinyl)-2-(3,4,5-trimethoxyphenyl)-, dihydrochloride (3Cl)
MF C42 H45 F2 N3 O6 . 2 Cl H



• 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-[4-(trifluoromethyl)phenyl]-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-, dihydrochloride (9CI)
 MF C43 H46 F3 N3 O6 . 2 Cl S



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-[4-(methylthio)phenyl]-2-(3,4,5-trimethoxyphenyl)-N-[1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-
 MF C42 H48 N4 O6 S
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-butoxyphenyl)-N,1-bis[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-, monohydrochloride (9CI)
MF C47 H56 N2 O7 . Cl H



● 9CI

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-methoxyphenyl)-N-[1-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-4-piperidinyl]-2-(3,4,5-trimethoxyphenyl)-
MF C43 H49 N3 O7
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidine, N-[3-(methylthio)phenyl]-N-((3',4',5'-trimethoxy[1,1'-
biphenyl]-2-yl)methyl)-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
MF C43 H49 N3 O6 S
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Pyridine, 4-(chloromethyl)-2-(3,4-dimethoxyphenyl)-
MF Cl4 H14 Cl N O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, 2-(4-chloro-3,5-dimethoxyphenyl)-N-[1-[[2-(4-chloro-3,5-dimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-N-(4-methoxyphenyl)-, trihydrochloride (9CI)
 MF C40 H42 Cl2 N4 O5 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(phenylmethyl)-6-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, tetrahydrochloride (9CI)
 MF C42 H48 N4 O6 . 4 Cl H



● 4 HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinecarboxylic acid, 2-(4-chloro-3,5-dimethoxyphenyl)-, ethyl ester
MF C16 H16 Cl N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinecarboxylic acid, 2-(3,4,5-trimethoxyphenyl)-, ethyl ester
MF C17 H19 N O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenamine, 3-(methylthio)-
MF C7 H9 N S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(2-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[4-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]cyclohexyl]-
MF C43 H49 N3 O7
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-fluorophenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-, monohydrochloride (9CI)
MF C27 H31 F N2 O3 . Cl H



● HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[4-(methylthio)phenyl][(3',4',5'-
trimethoxy[1,1'-biphenyl]-3-yl)methyl]amino]-, 1,1-dimethylethyl ester
MF C33 H42 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-ethoxyphenyl)[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methylamino]-, 1,1-dimethylethyl ester
MF C34 H44 N2 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-[3,4-difluorophenyl]-N-[(2-[3,4-
difluorophenyl]-4-pyridinyl)methyl]-4-piperidyl]-N-(4-methoxyphenyl)-
MF C36 H32 F4 N4 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidine, N-(4-bromophenyl)-N,1-bis[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-
MF C43 H47 Br N2 O6
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-methylphenyl)-N-[1-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-4-piperidinyl]-2-(3,4,5-trimethoxyphenyl)-,
dihydrochloride (9CI)
MF C43 H49 N3 O6 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWEERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(3-methoxyphenyl)-N,1-bis((3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl)-
MF C44 H50 N2 O7
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWEERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-ethoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-
, dihydrochloride (9CI)
MF C44 H51 N3 O7 . 2 Cl H



• 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(4-butylphenyl)-6-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-
MF C45 H54 N4 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(3,5-dimethoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-
N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-
MF C43 H50 N4 O8
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(4-butylphenyl)-6-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
trihydrochloride (3Cl)
MF C45 H54 N4 O6 . 3 Cl H



● 3 HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,1'-Biphenyl, 4'-(chloromethyl)-3,4,5-trimethoxy-
MF Cl6 H17 Cl O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinecarboxylic acid, 6-(3,4,5-trimethoxyphenyl)-, ethyl ester
MF C17 H19 N O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinecarboxamide, 1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
MF C21 H27 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Inden-5-amine, 2,3-dihydro-
MF C9 H11 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propane, 2-iodo-
MF C3 H7 I
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(3-methoxyphenyl)-N-(4-methoxyphenyl)-N-4-
piperidinyl-, dihydrochloride (9CI)
MF C25 H29 N3 O2 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-bromophenyl)[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]amino]-, 1,1-dimethylethyl ester
MF C32 H39 Br N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(2-methoxyphenyl)[(2-(3,4,5-
trimethoxyphenyl)-4-pyridinyl)methyl]amino]-, 1,1-dimethylethyl ester
MF C32 H41 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-[1-[(2-(3,4-dimethoxyphenyl)-4-pyridinyl)methyl]-
4-pyridinyl]-N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-,
trihydrochloride (9CI)
MF C41 H46 N4 O6 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(2-fluorophenyl)-N-(4-methoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-4-piperidinyl]-
MF C39 H41 F N4 O4
CI C08



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-phenyl-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-,
MF C42 H47 N3 O6 . 2 Cl H



• 2 HCl

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(3,4-difluorophenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C41 H44 F2 N4 O6
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-[4-(trifluoromethyl)phenyl]-N-[1-[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-4-piperidinyl]-2-(3,4,5-trimethoxyphenyl)-
MF C43 H46 F3 N3 O6
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-[(4-(methylthio)phenyl)-2-(3,4,5-trimethoxyphenyl)-
N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-, trihydrochloride (3Cl)
MF C42 H48 N4 O6 S . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-butoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-
MF C46 H55 N3 O7
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
[[5-(3,4,5-trimethoxyphenyl)-3-pyridinylmethyl]-4-piperidinyl]-,
trihydrochloride (3Cl)
MF C42 H48 N4 O7 . 3 Cl H
CI COM



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(4-chloro-3,5-dimethoxyphenyl)-N-[1-[[2-(4-chloro-
3,5-dimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-N-phenyl-
MF C39 H40 Cl2 N4 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-methyl-2-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-
MF C36 H44 N4 O6
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-cyclohexyl-2-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, tetrahydrochloride (9CI)
MF C41 H52 N4 O6 . 4 Cl H



● 4 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(phenylmethyl)-2-(3,4,5-trimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-, tetrahydrochloride (9CI)
 MF C42 H48 N4 O6 . 4 Cl H



● 4 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Pyridine, 3-(chloromethyl)-5-(3,4,5-trimethoxyphenyl)-
 MF C15 H16 Cl N O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-methoxyphenyl)amino]-,
1,1-dimethylethyl ester
MF C17 H26 N2 O3
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinecarboxylic acid, ethyl ester
MF C8 H15 N O2
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-[4-(methylsulfonyl)phenyl]-N-[(3',4',5'-
trimethoxy[1,1'-biphenyl]-3-yl)methyl]-
MF C28 H34 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-fluorophenyl)[(5-(3,4,5-
trimethoxyphenyl)-3-pyridinyl)methyl]amino]-, 1,1-dimethylethyl ester
MF C31 H38 F N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-(methylthio)phenyl)-N-4-piperidinyl-2-(3,4,5-
trimethoxyphenyl)-, dihydrochloride (9Cl)
MF C27 H33 N3 O3 S . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-ethoxyphenyl)-N-4-piperidinyl-2-(3,4,5-
trimethoxyphenyl)-, dihydrochloride (9Cl)
MF C28 H35 N3 O4 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(3,4-difluorophenyl)-N-(4-methoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, trihydrochloride (3Cl)
MF C39 H40 F2 N4 O4 . 3 Cl H
CI



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-methoxyphenyl)-N-[1-[(2-(3-methoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-2-(3,4,5-trimethoxyphenyl)-, trihydrochloride (3Cl)
MF C40 H44 N4 O5
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-fluorophenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-,
trihydrochloride (9CI)
MF C41 H45 F N4 O6 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-bromophenyl)-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-
3-yl)methyl]-1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-,
dihydrochloride (9CI)
MF C42 H46 Br N3 O6 . 2 Cl H



● 2 HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(4-methylphenyl)-2-[(3,4,5-trimethoxyphenyl)-N-[1-
 [(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-
 ME C42 H48 N4 O6
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-(3-methoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-1-[(5-(3,4,5-trimethoxyphenyl)-3-pyridinyl)methyl]-
 ME C43 H49 N3 O7 . 2 Cl H
 CI COM



● 2 HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(4-ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C43 H50 N4 O7
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-butylphenyl)-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-
2-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
MF C46 H55 N3 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(phenylmethyl)-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-
3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
MF C43 H49 N3 O6
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-butylphenyl)-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-
2-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-,
dihydrochloride (9CI)
MF C46 H55 N3 O6 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(3,5-dimethoxyphenyl)-6-(3,4,5-trimethoxyphenyl)-
N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-,
trihydrochloride (3Cl)
MF C43 H50 N4 O8 . 3 Cl H



● 3 HCL

10537407.tzn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN [1,1'-Biphenyl]-3-methanol, 3',4',5'-trimethoxy-
MF C16 H18 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn

LS 693 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenesulfonamide, N-methyl-2-nitro-N-([38]-1-[[2-(3,4,5-
trimethoxyphenyl)-4-pyridinyl]methyl]-3-pyrrolidinyl)-
MF C26 H30 N4 O7 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn

LS 693 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenesulfonamide, N-methyl-2-nitro-
MF C7 H9 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Methane, iodo-
MF C H3 I
CI COM

H₃C-I

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-methoxyphenyl)[(2-(2-methoxyphenyl)-4-pyridinyl)methyl]amino]-, 1,1-dimethylethyl ester
MF C30 H37 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWEBS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-bromophenyl)-N-4-piperidinyl-2-(3,4,5-trimethoxyphenyl)-, dihydrochloride (9CI)
MF C26 H30 Br N3 O3 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWEBS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(3-methoxyphenyl)[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]amino]-, 1,1-dimethylethyl ester
MF C33 H42 N2 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-[4-(methylsulfonyl)phenyl]-N-[(3',4',5'-
trimethoxy[1,1'-biphenyl]-3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-
pyridinyl)methyl]-
MF C43 H49 N3 O8 S
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-[1-[[2-(2-fluorophenyl)-4-pyridinyl)methyl]-4-
piperidinyl]-N-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-,
trihydrochloride (9CI)
MF C39 H41 F N4 O4 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-phenyl-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-
MF C41 H46 N4 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-chlorophenyl)-N,1-bis[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-, monohydrochloride (9Cl)
MF C43 H47 Cl N2 O6 . Cl H



● HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-[4-(trifluoromethyl)phenyl]-2-(3,4,5-trimethoxyphenyl)-N-[1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-, trihydrochloride (3Cl)
MF C42 H45 F3 N4 O6 . 3 Cl H
CI



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-[4-(trifluoromethoxy)phenyl]-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-
MF C43 H46 F3 N3 O7
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(4-butoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
 [[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-,
 trihydrochloride (3Cl)
 MF C45 H54 N4 O7 . 3 Cl H



● 3 HCl

10537407.trn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN [1,1'-Biphenyl]-3-carboxamide, 3',4',5'-trimethoxy-N-(4-methoxyphenyl)-N-
 [1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-
 MF C43 H47 N3 O8
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-ethyl-2-(3,4,5-trimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-
MF C37 H46 N4 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(2,3-dihydro-1H-inden-5-yl)-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-
MF C29 H35 N3 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-methyl-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-,
(2E)-2-butanedioate (1:2)
MF C37 H45 N3 O6 . 2 C4 H4 O4

CM 1




CM 2

Double bond geometry as shown.



10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, 1-[[2-[3,5-dimethoxy-4-(1-methylethoxy)phenyl]-4-pyridinyl]methyl]-N-(4-methoxyphenyl)-
MF C29 H37 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn

LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN [1,1'-Biphenyl]-3-carboxamide, 3',4',5'-trimethoxy-N-methyl-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-,
dihydrochloride (9CI)
MF C37 H43 N3 O7 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Pyridine, 4-(chloromethyl)-2-phenyl-
MF C12 H10 Cl N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenamine, 4-(trifluoromethoxy)-
MF C7 H6 F3 N O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(3,5-difluorophenyl)-N-(4-methoxyphenyl)-N-4-piperidinyl-, dihydrochloride (9CI)
MF C24 H25 F2 N3 O . 2 Cl H



● 2 HCl


10537407.trn

LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(3,4-difluorophenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-, monohydrochloride (9CI)
MF C27 H30 F2 N2 O3 . Cl H




10537407.trn

LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-[4-(trifluoromethoxy)phenyl]-N-[(3',4',5'-
trimethoxy[1,1'-biphenyl]-3-yl)methyl]-, monohydrochloride (9CI)
MF C28 H31 F3 N2 O4 . Cl H



10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-methoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-, monohydrochloride (9CI)
MF C28 H34 N2 O4 . Cl H



● HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(4-fluorophenyl)-N-1-[(2-(4-fluorophenyl)-4-
pyridinyl)methyl]-4-piperidinyl]-N-(4-methoxyphenyl)-
MF C36 H34 F2 N4 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(2-methoxyphenyl)-N-(4-methoxyphenyl)-N-[1-[(2-(2-methoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, trihydrochloride (3Cl)
MF C39 H40 N4 O3 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(3,4-difluorophenyl)-N,1-bis[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-
MF C43 H46 F2 N2 O6
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(4-bromophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
 [(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-
 MF C41 H45 Br N4 O6
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-[4-(methylthiophenyl)-N,1-bis[(3',4',5'-
 trimethoxy[1,1'-biphenyl]-3-yl)methyl]-, monohydrochloride (9CI)
 MF C44 H50 N2 O6 S . Cl H



● HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
 [(5-(3,4,5-trimethoxyphenyl)-3-pyridinyl)methyl]-4-piperidinyl]-
 MF C42 H48 N4 O7
 CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10537407.tzn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(4-ethoxyphenyl)-N-[1-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-4-piperidinyl]-2-(3,4,5-trimethoxyphenyl)-,
 dihydrochloride (9CI)
 MF C44 H51 N3 O7 . 2 Cl H



10537407.ttn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(2,3-dihydro-1H-inden-5-yl)-N-([3',4',5'-
trimethoxy[1,1'-biphenyl]-4-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-
pyridinyl]methyl]-, dihydrochloride (9CI)
MF C45 H51 N3 O6 . 2 Cl H



● 2 HCl

10537407.ttn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-[3,5-dimethoxy-4-(1-methylethoxy)phenyl]-N-[1-[[2-
[3,5-dimethoxy-4-(1-methylethoxy)phenyl]-4-pyridinyl]methyl]-4-
piperidinyl]-N-(4-methoxyphenyl)-
MF C46 H56 N4 O7
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(2,3-dihydro-1H-inden-5-yl)-2-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, trihydrochloride (9CI)
 MF C44 H50 N4 O6 . 3 Cl H



●3 HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-(3,5-dimethoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-2-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-, dihydrochloride (9CI)
 MF C44 H51 N3 O8 . 2 Cl H



●2 HCl

10537407.tnn

15 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Pyridine, 3-(chloromethyl)-2-(3,4,5-trimethoxyphenyl)-
MF C15 H16 Cl N O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

15 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Pyrrolidinecarboxylic acid, 3-[[[(2-nitrophenyl)sulfonyl]amino]-,
1,1-dimethylethyl ester, (3S)-
MF C15 H21 N3 O6 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Erythropoietin
MF Unspecified
CI COM, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

PROPERTY DATA AVAILABLE IN THE 'PROP' FORUM

10537407.ttn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN [1,1'-Biphenyl]-3-methanamine, 3',4',5'-trimethoxy-N-(2-methoxyphenyl)-N-[4-[[[5-(5,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]cyclohexyl]-, dihydrochloride (9CI)
MF C44 H50 N2 O7 . 2 Cl H



● 2 HCl

10537407.trn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Pyridine, 4-(chloromethyl)-2-(3,5-difluorophenyl)-
MF Cl2 H8 Cl F2 N



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[4-(trifluoromethyl)phenyl]([3',4',5'-
trimethoxy[1,1'-biphenyl]-3-yl)methyl]amino]-, 1,1-dimethylethyl ester
MF C33 H39 F3 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(3-methoxyphenyl)-N-4-piperidinyl-2-(3,4,5-trimethoxyphenyl)-, dihydrochloride (9CI)
MF C27 H33 N3 O4 . 2 Cl H



● 2 HCl

10537407.ttn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(4-chlorophenyl)-N-1-[[2-(4-chlorophenyl)-4-pyridinyl]methyl]-4-piperidinyl]-N-(4-methoxyphenyl)-, trihydrochloride (9CI)
MF C36 H34 Cl2 N4 O . 3 Cl H



● 3 HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(3,4-dimethoxyphenyl)-N-(4-methoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C41 H46 N4 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-phenyl-2-(3,4,5-trimethoxyphenyl)-N-[1-[[5-(3,4,5-
trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-, trihydrochloride
(3Cl)
MF C41 H46 N4 O6 . 3 Cl H



● 3 HCl

10537407.trn


L5 683 ANSHERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-chlorophenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-
MF C42 H46 Cl N3 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn


L5 683 ANSHERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-methylphenyl)-N,1-bis[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-
MF C44 H50 N2 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidine, N-[4-(trifluoromethoxy)phenyl]-N-[(3',4',5'-
 trimethoxy[1,1'-biphenyl]-3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-
 pyridinyl)methyl]-, dihydrochloride (9CI)
 MF C43 H46 F3 N3 O7 . 2 Cl F
 CI



● 2 HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(4-butoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-4-piperidinyl-2-(3,4,5-trimethoxyphenyl)-
 MF C46 H55 N3 O7
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN [1,1'-Biphenyl]-3-carboxamide, 3',4',5'-trimethoxy-N-(4-methoxyphenyl)-N-
 [1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
 dihydrochloride (9CI)
 MF C43 H47 N3 O8 . 2 Cl H




● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, 2-(3,4,5-trimethoxyphenyl)-N-[(3S)-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-3-pyrrolidinyl]-, trihydrochloride (9CI)
 MF C34 H40 N4 O6 . 3 Cl H

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



● 3 HCl

10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, 1-[[2-(4-chloro-3,5-dimethoxyphenyl)-4-pyridinyl]methyl]-
N-phenyl-
MF C25 H28 Cl N3 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN [1,1'-Biphenyl]-3-carboxamide, 3',4',5'-trimethoxy-N-[[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, (2Z)-2-butenedioate
[1:1]
MF C36 H41 N3 O7 . C4 H4 O4

CM 1




CM 2

Double bond geometry as shown.



10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Pyridine, 4-(chloromethyl)-2-[3,5-dimethoxy-4-(1-methylethoxy)phenyl]-
MF C17 H20 Cl N O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,4-Dioxo-8-azaspiro[4.5]decane, 8-([2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl)-
MF C22 H28 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinone, 1-(4-pyridinylmethyl)-
MF C11 H14 N2 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,4-Dioxo-8-azaspiro[4.5]decane
MF C7 H13 N O2
CI COM, RFS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[[2-(3,4-difluorophenyl)-4-pyridinyl]methyl](4-methoxyphenyl)amino]-, 1,1-dimethylethyl ester
MF C29 H33 F2 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(3,4-difluorophenyl)[(5-(3,4,5-trimethoxyphenyl)-3-pyridinyl)methyl]amino]-, 1,1-dimethylethyl ester
MF C31 H37 F2 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[4-(trifluoromethoxy)phenyl][(5-(3,4,5-trimethoxyphenyl)-3-pyridinyl)methyl]amino]-, 1,1-dimethylethyl ester
MF C32 H38 F3 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[4-(4-methoxyphenyl][(5-(3,4,5-trimethoxyphenyl)-3-pyridinyl)methyl]amino]-, 1,1-dimethylethyl ester
MF C32 H41 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, 2-(4-fluorophenyl)-N-(4-methoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-, trihydrochloride (3Cl)
 MF C39 H41 F N4 O4 . 3 Cl H
 CI



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(4-methoxyphenyl)-N-[1-[[2-(2-methoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-2-(3,4,5-trimethoxyphenyl)-, trihydrochloride (3Cl)
 MF C40 H44 N4 O5
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-(3,4-difluorophenyl)-N-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-1-[(5-(3,4,5-trimethoxyphenyl)-3-pyridinyl)methyl]-
 , dihydrochloride (9CI)
 MF C42 H45 F2 N3 O6 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(4-bromophenyl)-N-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-4-piperidinyl-2-(3,4,5-trimethoxyphenyl)-,
 dihydrochloride (9CI)
 MF C42 H46 Br N3 O6 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS ON STN
IN 4-Piperidinamine, N-[4-(methylthio)phenyl]-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
MF C43 H49 N3 O6 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS ON STN
IN 3-Pyridinemethanamine, N-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
trihydrochloride (9CI)
MF C42 H48 N4 O7 . 3 Cl H



● 3 HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-ethoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C43 H50 N4 O7
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(2,3-dihydro-1H-inden-5-yl)-N-[(3',4',5'-
trimethoxy[1,1'-biphenyl]-3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-
pyridinyl]methyl]-
MF C45 H51 N3 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-(4-methoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-
 MF C43 H49 N3 O7
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-2-propynyl-2-(3,4,5-trimethoxyphenyl)-N-[1-[(2-
 (3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-,
 tetrahydrochloride (9CI)
 MF C38 H44 N4 O6 . 4 Cl H



● 4 HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN [1,1'-Biphenyl]-2-carboxylic acid, 3',4',5'-trimethoxy-, ethyl ester
MF C18 H20 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-methoxyphenyl)-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
MF C27 H33 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methoxy]-, phenylmethyl ester
MF C28 H32 N2 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzoic acid, 4-bromo-, ethyl ester
MF C9 H9 Br O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN [1,1'-Biphenyl]-3-methanamine, 3',4',5'-trimethoxy-N-(2-methoxyphenyl)-N-
[4-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]cyclohexyl]-
MF C44 H50 N2 O7
CT C08



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Pyridine, 4-(chloromethyl)-2-(2-fluorophenyl)-
MF Cl2 H9 Cl F N



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWEERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-methylphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-, monohydrochloride (9CI)
MF C28 H34 N2 O3 . Cl H



● HCl

10537407.tnn


LS 683 ANSWEERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-butoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-, monohydrochloride (9CI)
MF C31 H40 N2 O4 . Cl H



● HCl

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-[1-([2-(4-chlorophenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-
MF C39 H41 Cl N4 O4
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-[1-([2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-, trihydrochloride (9CI)
MF C41 H46 N4 O6 . 3 Cl H



● 3 HCl

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidine, N-(4-fluorophenyl)-N-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-
 MF C42 H46 F N3 O6
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(4-chlorophenyl)-5-[(3,4,5-trimethoxyphenyl)-N-[1-
 [[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-,
 trihydrochloride (9CI)
 MF C41 H45 Cl N4 O6 . 3 Cl H



●S HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-(4-methylphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl)methyl]-
 , dihydrochloride (9CI)
 MF C43 H49 N3 O6 . 2 Cl H



● 2 HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-[4-(trifluoromethoxyphenyl)-5-[(3,4,5-
 trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-
 piperidinyl]-
 MF C42 H45 F3 N4 O7
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(4-butoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
 [(5-(3,4,5-trimethoxyphenyl)-3-pyridinyl)methyl]-4-piperidinyl]-,
 trihydrochloride (3Cl)
 MF C45 H54 N4 O7 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1-Piperidinecarboxylic acid, 4-[(4-methoxyphenyl)[(3',4',5'-
 trimethoxy[1,1'-biphenyl]-3-yl)carbonylamino]-, 1,1-dimethylethyl ester
 MF C33 H40 N2 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-1,3-benzodioxol-5-yl-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-
MF C43 H47 N3 O8
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-phenyl-1-[(2-(3,4,5-trimethoxyphenyl)-4-
pyridinyl)methyl]-
MF C26 H31 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-1,3-benzodioxol-5-yl-N-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-4-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-
 , dihydrochloride (9CI)
 MF C43 H47 N3 O8 . 2 Cl H



● 2 HCl

10537407.tzn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Boronic acid, [3,5-dimethoxy-4-(1-methylethoxy)phenyl]- (9CI)
 MF Cl1 H17 B O5




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, 2-(3,4,5-trimethoxyphenyl)-N-[[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, (2E)-2-butenedioate
 (1:2)
 MF C35 H42 N4 O6 . 2 C4 H4 O4

CM 1




CM 2

Double bond geometry as shown.



10537407.trn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1-Piperidinecarboxylic acid, 4-hydroxy-, phenylmethyl ester
 MF C13 H17 N O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWEERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenamine, 4-methyl-
MF C7 H9 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWEERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-[3-fluorophenyl]-N-(4-methoxyphenyl)-N-4-
piperidinyl-, dihydrochloride (9CI)
MF C24 H26 F N3 O . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(3,4-difluorophenyl)amino]-,
1,1-dimethylethyl ester
MF C16 H22 F2 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(2,3-dimethoxyphenyl)-N-4-piperidinyl-2-(3,4,5-trimethoxyphenyl)-, dihydrochloride (9Cl)
MF C28 H35 N3 O5 . 2 Cl H



● 2 HCl

10537407.tnn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-[1-([2-(3-methoxyphenyl)-4-pyridinylmethyl]-4-
piperidinyl)-N-[4-(methylthio)phenyl]-5-(3,4,5-trimethoxyphenyl)-
MF C40 H44 N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(3-fluorophenyl)-N-[1-([2-(3-fluorophenyl)-4-
pyridinylmethyl]-4-piperidinyl)-N-(4-methoxyphenyl)-
MF C36 H34 F2 N4 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-methoxyphenyl)-2-phenyl-N-[1-[(2-phenyl-4-pyridinyl)methyl]-4-piperidinyl]-, trihydrochloride (9CI)
MF C36 H36 N4 O . 3 Cl H



● 3 HCl

10537407.ttn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-
MF C41 H44 F2 N4 O6
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn


LS 683 ANSWEERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(4-bromophenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
 [(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-
 MF C41 H45 Br N4 O6
 CI C08



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn


LS 683 ANSWEERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-[4-(methylthio)phenyl]-5-(3,4,5-trimethoxyphenyl)-
 N-[1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl)methyl]-4-piperidinyl]-,
 trihydrochloride (9CI)
 MF C42 H48 N4 O6 S . 3 Cl H



● S HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(3-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-
MF C42 H48 N4 O7
CT C08



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-methoxyphenyl)-N,1-bis[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-, monohydrochloride (9CI)
MF C44 H50 N2 O7 . Cl H



● 9CI

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(2,3-dihydro-1H-inden-5-yl)-2-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C44 H50 N4 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(4-chloro-3,5-dimethoxyphenyl)-N-[1-[[2-(4-chloro-3,5-dimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-N-methyl-
MF C34 H38 Cl2 N4 O4
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-[3-(methylthio)phenyl]-N-((3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl)-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-, dihydrochloride (9CI)
MF C43 H49 N3 O6 S . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-methyl-2-(3,4,5-trimethoxyphenyl)-N-[[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]methyl]-
MF C37 H46 N4 O6
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Carbanic acid, 1-[[[2-(4-chloro-3,5-dimethoxyphenyl)-4-pyridinyl]methyl]-4-
piperidinyl]-, ethyl ester (9CI)
MF C22 H28 Cl N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn

L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[[[2-(3,4,5-trimethoxyphenyl)-4-
pyridinyl]methyl]-, ethyl ester
MF C23 H30 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenamine, 4-butoxy-
MF C10 H15 N O
CI C08



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[4-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]cyclohexyl]-,
trihydrochloride (9CI)
MF C43 H49 N3 O7 . 3 Cl H



● 3 HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[phenyl[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methylamino]-, 1,1-dimethylethyl ester
MF C32 H40 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-methylphenyl)[(5-(3,4,5-trimethoxyphenyl)-3-pyridinyl)methylamino]-, 1,1-dimethylethyl ester
MF C32 H41 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1-Piperidinecarboxylic acid, 4-[(4-butoxyphenyl)][5-(3,4,5-trimethoxyphenyl)-3-pyridinylmethylamino]-, 1,1-dimethylethyl ester
 MF C35 H47 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, 2-(3,5-difluorophenyl)-N-[(1-[(2-(3,5-difluorophenyl)-4-pyridinylmethyl)-4-piperidyl]-N-(4-methoxyphenyl))-trihydrochloride (9CI)
 MF C36 H32 F4 N4 O . 3 Cl H



10537407.tzn


L5 683 ANSWEERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-((4-ethoxyphenyl)-N-(4-methoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-
MF C41 H46 N4 O5
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWEERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-fluorophenyl)-N-((3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl)-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-
MF C42 H46 F N3 O6 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(4-chlorophenyl)-N-[1-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-4-piperidinyl]-2-(3,4,5-trimethoxyphenyl)-,
 dihydrochloride (9CI)
 MF C42 H46 Cl N3 O6 . 2 Cl H
 CT COM



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
 [[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-
 MF C42 H48 N4 O6
 CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-[(4-(trifluoromethoxy)phenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-[(5-(3,4,5-trimethoxyphenyl)-3-pyridinyl)methyl]-4-piperidinyl]-, trihydrochloride (3Cl)
 MF C42 H45 F3 N4 O7 . 3 Cl F
 CI COM



● 3 HCl

10537407.tzn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-(4-ethoxyphenyl)-N,1-bis[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-
 MF C45 H52 N2 O7
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn

LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenesulfonamide, 2-nitro-N-(3S)-3-pyrrolidinyl-N-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
MF C25 H28 N4 O7 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-1,3-benzodioxol-5-yl-2-(3,4,5-trimethoxyphenyl)-N-
[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C42 H46 N4 O8
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[ethyl[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]amino]-, ethyl ester
MF C25 H35 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-1,3-benzodioxol-5-yl-2-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, trihydrochloride (9CI)
MF C42 H46 N4 O8 . 3 Cl H



● 3 HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanol, 5-(3,4,5-trimethoxyphenyl)-
MF C15 H17 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenesulfonamide, 2-nitro-N-[[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C26 H30 N4 O7 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinecarboxylic acid, 2-chloro-, ethyl ester
MF C8 H8 Cl N O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenamine, 4-(methylthio)-
MF C7 H9 N S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[[2-(2-fluorophenyl)-4-pyridinyl]methyl]](4-methoxyphenyl)amino)-, 1,1-dimethylethyl ester
MF C29 H34 F N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(4-chlorophenyl)-N-(4-piperidinyl-5-(3,4,5-trimethoxyphenyl)-, dihydrochloride (9Cl)
MF C26 H30 Cl N3 O3 . 2 Cl H



● 2 HCl


10537407.tzn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(2-methoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-, monohydrochloride (9CI)
MF C28 H34 N2 O4 . Cl H



10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-[1-[(2-(3,4-dimethoxyphenyl)-4-pyridinyl)methyl]-
4-piperidinyl]-N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-
MF C40 H43 F N4 O5
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, 2-(3-fluorophenyl)-N-(4-methoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, trihydrochloride (3Cl)
 MF C39 H41 F N4 O4 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(4-methoxyphenyl)-N-[1-[(2-phenyl-4-pyridinyl)methyl]-4-piperidinyl]-2-(3,4,5-trimethoxyphenyl)-
 MF C39 H42 N4 O4
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, trihydrochloride (9CI)
 MF C41 H44 F2 N4 O6 . 3 Cl E



●3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-[4-(trifluoromethyl)phenyl]-N,1-bis[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-, monohydrochloride (9CI)
 MF C44 H47 F3 N2 O6 . Cl H



● HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-[4-(methylthio)phenyl]-N-[1-[(3',4',5'-
trimethoxy[1,1'-biphenyl]-3-yl)methyl]-4-piperidyl]-2-(3,4,5-
trimethoxyphenyl)-
MF C43 H49 N3 O6 S
CT C08



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(3-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
trihydrochloride (9CI)
MF C42 H48 N4 O7 . 3 Cl H



• 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-
MF C42 H48 N4 O7
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-[3-(methylthiophenyl)-6-(3,4,5-trimethoxyphenyl)-
N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C42 H48 N4 O6 S
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Pyridine, 4-(chloromethyl)-2-(4-chlorophenyl)-
MF Cl2 H9 Cl2 N



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-[3-(methylthio)phenyl]-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-2-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
, dihydrochloride (9CI)
MF C43 H49 N3 O6 S . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWEBS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[[2-(3,4,5-trimethoxyphenyl)-4-
pyridinyl]methyl]amino]methyl-, 1,1-dimethylethyl ester
MF C26 H37 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWEBS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanol, 2-(4-chloro-3,5-dimethoxyphenyl)-
MF C14 H14 Cl N O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn

L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Pyridine, 4-(chloromethyl)-2-(3,4,5-trimethoxyphenyl)-
MF C15 H16 Cl N O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Propyn-1-amine
MF C3 H5 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(2-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[4-
[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]cyclohexyl]-
MF C43 H49 N3 O7
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-phenyl-N-4-piperidinyl-2-(3,4,5-trimethoxyphenyl)-
, dihydrochloride (9CI)
MF C26 H31 N3 O3 . 2 Cl H



• 2 HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-methylphenyl)amino]-, 1,1-dimethylethyl
ester
MF C17 H26 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-butoxyphenyl)amino]-, 1,1-dimethylethyl
ester
MF C20 H32 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-[1-[(2-(3,5-difluorophenyl)-4-pyridinyl)methyl]-4-piperidinyl]-N-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-
MF C39 H40 F2 N4 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-[1-[(2-(4-ethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-N-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-, trihydrochloride (9CI)
MF C41 H46 N4 O5 . 3 Cl H



● 3 HCl

10537407.tzn


L5 683 ANSWEBS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C41 H45 F N4 O6
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWEBS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-chlorophenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C41 H45 Cl N4 O6
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
trihydrochloride (9CI)
MF C42 H48 N4 O6 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(2,3-dimethoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-
N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C43 H50 N4 O8
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-(4-ethoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-
 , dihydrochloride (9CI)
 MF C44 H51 N3 O7 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Benzenesulfonamide, N-methyl-2-nitro-N-[[2-(3,4,5-trimethoxyphenyl)-4-
 pyridinyl]methyl]-
 MF C22 H23 N3 O7 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWEERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(3,5-dimethoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-
N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-
MF C43 H50 N4 O8
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWEERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]amino]-, ethyl ester
MF C23 H31 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-1,3-benzodioxol-5-yl-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
MF C27 H31 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Pyridine, 5-(chloromethyl)-2-(3,4,5-trimethoxyphenyl)-
MF C15 H16 Cl N O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinecarboxylic acid, 2-(3,4,5-trimethoxyphenyl)-
MF C15 H15 N O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinecarboxamide
MF C6 H12 N2 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWEBS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenemethanamine
MF C7 H9 N
CI COM

$\text{H}_2\text{N}-\text{CH}_2-\text{Ph}$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWEBS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(4-ethoxyphenyl)-N-(4-methoxyphenyl)-N-(4-piperidinyl-, dihydrochloride (9CI)
MF C26 H31 N3 O2 . 2 Cl H



● HCl

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-chlorophenyl)[(2-(3,4,5-
trimethoxyphenyl)-4-pyridinyl)methylamino]-, 1,1-dimethylethyl ester
MF C31 H38 Cl N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(2-methoxyphenyl)[(5-(3,4,5-
trimethoxyphenyl)-3-pyridinyl)methylamino]-, 1,1-dimethylethyl ester
MF C32 H41 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(4-fluorophenyl)-N-1-[[2-(3-methoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, trihydrochloride (9Cl)
 MF C39 H41 F N4 O4 . 3 Cl H



●3 HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, 2-(2-fluorophenyl)-N-1-[[2-(2-fluorophenyl)-4-pyridinyl]methyl]-4-piperidinyl]-N-(4-methoxyphenyl)-
 MF C36 H34 F2 N4 O
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-phenyl-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl)methyl]-, dihydrochloride (9CI)
MF C42 H47 N3 O6 . 2 Cl H



● 2 HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(3,4-difluorophenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl)methyl]-4-piperidinyl]- dihydrochloride (9CI)
MF C41 H44 F2 N4 O6
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-[4-(trifluoromethyl)phenyl]-N-[(3',4',5'-
trimethoxy[1,1'-biphenyl]-3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-
pyridinyl)methyl]-
MF C43 H46 F3 N3 O6
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-[4-(methylthio)phenyl]-2-(3,4,5-trimethoxyphenyl)-
N-1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl)methyl]-4-piperidinyl]-,
trihydrochloride (9CI)
MF C42 H48 N4 O6 S . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-(4-butoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-1-[(5-(3,4,5-trimethoxyphenyl)-3-pyridinyl)methyl]-
 MF C46 H55 N3 O7
 CT C04



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10537407.tzn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(4-methoxyphenyl)-N-[1-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-4-piperidinyl]-2-(3,4,5-trimethoxyphenyl)-,
 dihydrochloride (9CI)
 MF C43 H49 N3 O7 . 2 Cl H



10537407.trn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-[3-(methylthio)phenyl]-2-(3,4,5-trimethoxyphenyl)-
N-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-
MF C42 H48 N4 O6 S
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Pyridine, 4-(chloromethyl)-2-(3-methoxyphenyl)-
MF C13 H12 Cl N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, 2-[(4-chloro-3,5-dimethoxyphenyl)-N-[1-[[2-(4-chloro-3,5-dimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-N-phenyl-, trihydrochloride (9CI)
 MF C39 H40 Cl2 N4 O4 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-(phenylmethyl)-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-, trihydrochloride (9CI)
 MF C43 H49 N3 O6 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Boronic acid, (4-chloro-3,5-dimethoxyphenyl)- (9CI)
MF C8 H10 B Cl O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-chlorophenyl)amino]-, 1,1-dimethylethyl
ester
MF C16 H23 Cl N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenesulfonyl chloride, 2-nitro-
MF C6 H4 Cl N O4 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-methyl-2-((3,4,5-trimethoxyphenyl)-N-([1-([2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinylmethyl)-, ethanediolate (1:1)
MF C37 H46 N4 O6 . C2 H2 O4

CM 1




CM 2



10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-fluorophenyl)[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methylamino]-, 1,1-dimethylethyl ester
MF C32 H39 F N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-[4-(methylthio)phenyl]-N-4-piperidyl-5-(3,4,5-
trimethoxyphenyl)-, dihydrochloride (9CI)
MF C27 H33 N3 O3 S . 2 Cl H



● 2 HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(4-ethoxyphenyl)-N-4-piperidinyl-5-(3,4,5-trimethoxyphenyl)-, dihydrochloride (9CI)
MF C28 H35 N3 O4 . 2 Cl H



● 2 HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(3,4-difluorophenyl)-N-1-[(2-(3,4-difluorophenyl)-4-pyridinylmethyl)-4-piperidinyl]-N-(4-methoxyphenyl)-, trihydrochloride (9CI)
MF C36 H32 F4 N4 O . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, 2-(3-methoxyphenyl)-N-(4-methoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-
 MF C40 H44 N4 O5
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(4-fluorophenyl)-N-[1-[[3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-4-piperidinyl]-2-(3,4,5-trimethoxyphenyl)-,
 MF C42 H46 F N3 O6 . 2 Cl H



● 2 HCl


10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-bromophenyl)-N,1-bis[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-, monohydrochloride (9CI)
MF C43 H47 Br N2 O6 . Cl H



10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-methylphenyl)-2-[(3,4,5-trimethoxyphenyl)-N-[1-
[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-
MF C42 H48 N4 O6
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(3-methoxyphenyl)-N1-bis[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-, monohydrochloride (9CI)
MF C44 H50 N2 O7 . Cl H



10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-[(3,4,5-trimethoxyphenyl)-N-[1-
[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-
MF C43 H50 N4 O7
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidine, N-(4-butylphenyl)-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
 MF C46 H55 N3 O6
 CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(phenylmethyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
 MF C42 H48 N4 O6
 CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn

L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-methoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
, dihydrochloride (9CI)
MF C43 H49 N3 O7 . 2 Cl H




● 2 HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-methyl-2-(3,4,5-trimethoxyphenyl)-N-[(3S)-1-[[2-(
3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-3-pyrrolidinyl]-,
tetrahydrochloride (9CI)
MF C35 H42 N4 O6 . 4 Cl H

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



● 4 HCl

10537407.tzn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzoic acid, 3-bromo-, ethyl ester
MF C9 H9 Br O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Ethane, iodo-
MF C2 H5 I
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


15 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-methoxyphenyl)[(2-(3-methoxyphenyl)-4-
pyridinyl)methyl]amino]-, 1,1-dimethylethyl ester
MF C30 H37 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


15 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(4-bromophenyl)-N-(4-piperidinyl)-5-[(3,4,5-
trimethoxyphenyl)-, dihydrochloride (9Cl)
MF C26 H30 Br N3 O3 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(2-methoxyphenyl)amino]-,
1,1-dimethylethyl ester
MF C17 H26 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-N-[[1-[(2-(3-methoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-
MF C40 H44 N4 O5
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(2-fluorophenyl)-N-([2-
(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl)-
trihydrochloride (3Cl)
MF C39 H41 F N4 O4 . 3 Cl H



●●● HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-phenyl-5-(3,4,5-trimethoxyphenyl)-N-[1-([5-(3,4,5-trimethoxyphenyl)-3-pyridinylmethyl]-4-piperidinyl)-
MF C41 H46 N4 O6
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(3,4-difluorophenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, trihydrochloride (3Cl)
 MF C41 H44 F2 N4 O6 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-[4-(trifluoromethyl)phenyl]-N-[1-[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-4-piperidinyl]-2-(3,4,5-trimethoxyphenyl)-, dihydrochloride (3Cl)
 MF C43 H46 F3 N3 O6 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-[4-(trifluoromethoxy)phenyl]-N',1-bis[(3',4',5'-
 trimethoxy[1,1'-biphenyl]-3-yl)methyl]-
 MF C44 H47 F3 N2 O7
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-(4-butoxyphenyl)-N'-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-1-[1,2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-
 , dihydrochloride (9CI)
 MF C46 H55 N3 O7 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN [1,1'-Biphenyl]-3-carboxamide, 3',4',5'-trimethoxy-N-(4-methoxyphenyl)-N-
[1-[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-4-piperidyl]-
MF C44 H48 N2 O8
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-phenyl-2-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidyl]-
MF C41 H46 N4 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-[1-(4-pyridinylmethyl)-4-piperidinyl]-,
tetrahydrochloride (9CI)
MF C17 H22 N4 . 4 Cl H



● 4 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-ethyl-2-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, tetrahydrochloride (9CI)
MF C37 H46 N4 O6 . 4 Cl H



● 4 HCl

10537407.tzn

L5 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(phenylmethyl)-1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-
MF C27 H33 N3 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn

L5 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-methyl-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, (2E)-2-butenedioate
MF C36 H44 N4 O6 . 2 C4 H4 O4

CM 1




CM 2

Double bond geometry as shown.



10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-fluorophenyl)amino]-, 1,1-dimethylethyl
ester
MF C16 H23 F N2 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Indole-1,3(2H)-dione, potassium salt (1:1)
MF C8 H5 N O2 . K
CI COM




● K

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn


L5 683 ANSWEBS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(4-chlorophenyl)-N-(4-methoxyphenyl)-N-4-
piperidinyl-, dihydrochloride (9CI)
MF C24 H26 Cl N3 O . 2 Cl H



● 2 HCl

10537407.ttn


L5 683 ANSWEBS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-fluorophenyl)-N-4-piperidinyl-2-(3,4,5-
trimethoxyphenyl)-, dihydrochloride (9CI)
MF C26 H30 F N3 O3 . 2 Cl H



● 2 HCl

10537407.tzn


L5 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[4-(methylthio)phenyl]]-[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethylamino]-, 1,1-dimethylethyl ester
MF C32 H41 N3 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[4-(ethoxyphenyl)]-[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethylamino]-, 1,1-dimethylethyl ester
MF C33 H43 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWEBS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-[1-[(2-(3,4-difluorophenyl)-4-pyridinyl)methyl]-4-piperidinyl]-N-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-
MF C39 H40 F2 N4 O4
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWEBS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-methoxyphenyl)-N-[1-[(2-(3-methoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-2-(3,4,5-trimethoxyphenyl)-, trihydrochloride (9CI)
MF C40 H44 N4 O5 . 3 Cl H



● 3 HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-fluorophenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C41 H45 F N4 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-bromophenyl)-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-
3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
MF C42 H46 Br N3 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(4-methylphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
 [(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-,
 trihydrochloride (3Cl)
 MF C42 H48 N4 O6 . 3 Cl H
 CF C42 H48 N4 O6 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-(3-methoxyphenyl)-N-[3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-
 MF C43 H49 N3 O7
 CF C43 H49 N3 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(4-ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
 [(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-,
 trihydrochloride (9Cl)
 MF C43 H50 N4 O7 . 3 Cl H
 CI COM



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(4-butylphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
 [(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-
 MF C45 H54 N4 O6
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(phenylmethyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
 [[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
 MF C42 H48 N4 O6
 CT C08



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(4-butylphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
 [[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
 trihydrochloride (9CI)
 MF C45 H54 N4 O6 . 3 Cl H



● 3 HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(3,5-dimethoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
, dihydrochloride (9CI)
MF C44 H51 N3 O8 . 2 Cl H



● 2 HCl

10537407.tzn

L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
trihydrochloride (9CI)
MF C42 H48 N4 O7 . 3 Cl H




● 3 HCl

10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenesulfonamide, N-methyl-2-nitro-N-(3S)-3-pyrrolidinyl-
MF C11 H15 N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinecarboxylic acid, 5-bromo-, ethyl ester
MF C8 H8 Br N O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenamine
MF C6 H7 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-methoxyphenyl)-N-(4-piperidinyl)-,
dihydrochloride (9CI)
MF C24 H27 N3 O . 2 Cl H



● 2 HCl

10537407.tzn


L5 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-bromophenyl)[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]amino]-, 1,1-dimethylethyl ester
MF C31 H38 Br N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(3-methoxyphenyl)-N-4-piperidinyl-5-(3,4,5-trimethoxyphenyl)-, dihydrochloride (9Cl)
MF C27 H33 N3 O4 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-phenyl-5-(3,4,5-trimethoxyphenyl)-N-[1-([2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-, trihydrochloride (9CI)
 MF C41 H46 N4 O6 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-(4-chlorophenyl)-N-([3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl]methyl)-1-([5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl)-
 MF C42 H46 Cl N3 O6
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-[4-(trifluoromethyl)phenyl]-2-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C42 H45 F3 N4 O6
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-[4-(trifluoromethoxy)phenyl]-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-, dihydrochloride (3Cl)
MF C43 H46 F3 N3 O7 . 2 Cl H



● 2 HCl

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(4-butoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
 [[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
 MF C45 H54 N4 O7
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN [1,1'-Biphenyl]-3-carboxamide, 3',4',5'-trimethoxy-N-(4-methoxyphenyl)-N-
 [1-[[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-,
 dihydrochloride (9CI)
 MF C43 H47 N3 O8 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Phenol, 4-[[4-[[[2-(4-hydroxy-3,5-dimethoxyphenyl)-4-
pyridinyl]methyl]methylamino]-1-piperidinyl]methyl]-2,6-
dimethoxy-
MF C34 H40 N4 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-[3-(methylthio)phenyl]-1-[[2-(3,4,5-trimethoxyphenyl)-
4-pyridinyl]methyl]-
MF C27 H33 N3 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-methyl-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
MF C37 H45 N3 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinone, 1-[[2-[3,5-dimethoxy-4-(1-methylethoxy)phenyl]-4-pyridinyl]methyl]-
MF C22 H28 N2 O4
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN [1,1'-Biphenyl]-3-carboxylic acid, 3',4',5'-trimethoxy-, ethyl ester
MF C18 H20 O5




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Pyrrolidinecarboxylic acid, 3-amino-, 1,1-dimethylethyl ester, (3S)-
MF C9 H13 N2 O2
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenamine, 4-(trifluoromethyl)-
MF C7 H6 F3 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[[2-(3,5-difluorophenyl)-4-pyridinyl]methyl][4-methoxyphenyl]amino]-, 1,1-dimethylethyl ester
MF C29 H33 F2 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(3,4-difluorophenyl)[(3',4',5'-
trimethoxy[1,1'-biphenyl]-3-yl)methyl]amino]-, 1,1-dimethylethyl ester
MF C32 H38 F2 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[4-(trifluoromethoxyphenyl)[(3',4',5'-
trimethoxy[1,1'-biphenyl]-3-yl)methyl]amino]-, 1,1-dimethylethyl ester
MF C33 H39 F3 N2 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-methoxyphenyl)[(3',4',5'-
trimethoxy[1,1'-biphenyl]-3-yl)methyl]amino]-, 1,1-dimethylethyl ester
MF C33 H42 N2 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(4-fluorophenyl)-N-[1-[(2-(4-fluorophenyl)-4-
pyridinyl)methyl]-4-piperidinyl]-N-(4-methoxyphenyl)-, trihydrochloride
[9CI]
MF C36 H34 F2 N4 O . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(4-bromophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
 [(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-,
 trihydrochloride (9CI)
 MF C41 H45 Br N4 O6 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-[4-(methylthio)phenyl]-N-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-
 MF C43 H49 N3 O6 S
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
 [[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-,
 trihydrochloride (3Cl)
 MF C42 H48 N4 O7 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(4-ethoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
 [[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-
 MF C43 H50 N4 O7
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-pyridinemethanamine, N-(2,3-dihydro-1H-inden-5-yl)-6-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C44 H50 N4 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C42 H48 N4 O7
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(2,3-dihydro-1H-inden-5-yl)-N-[(3',4',5'-
trimethoxy[1,1'-biphenyl]-2-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-
pyridinyl)methyl]-, dihydrochloride (9CI)
MF C45 H51 N3 O6 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,1'-Biphenyl, 2-(chloromethyl)-3',4',5'-trimethoxy-
MF Cl6 H17 Cl O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanol, 2-[(3,4,5-trimethoxyphenyl)-
MF C15 H17 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Pyridine, 2-[(3,4,5-trimethoxyphenyl)-4-[[4-[(2-(3,4,5-trimethoxyphenyl)-4-
pyridinyl]methoxy]-1-piperidinyl)methyl]-, trihydrochloride (9CI)
MF C35 H41 N3 O7 . 3 Cl H



● 3 HCl

10537407.tnn


LS 693 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Pyridine, 4-(chloromethyl)-2-(3,4-difluorophenyl)-
MF Cl2 H8 Cl F2 N



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 693 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-piperidinyl)-N-(4-(trifluoromethyl)phenyl)-2-
(3,4,5-trimethoxyphenyl)-, dihydrochloride (9CI)
MF C27 H30 F3 N3 O3 . 2 Cl H



● 2 HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(3-methoxyphenyl)[(2-(3,4,5-
trimethoxyphenyl)-4-pyridinyl)methyl]amino]-, 1,1-dimethylethyl ester
MF C32 H41 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(4-chlorophenyl)-N-(4-methoxyphenyl)-N-[1-[(2-(
3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-
MF C39 H41 Cl N4 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, 2-(3,4-dimethoxyphenyl)-N-(4-methoxyphenyl)-N-[1-
 [(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-,
 trihydrochloride (3Cl)
 MF C41 H46 N4 O6 . 3 Cl H



● 3 HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-(4-fluorophenyl)-N,1-bis[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-
 MF C43 H47 F N2 O6
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSRS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-(4-chlorophenyl)-N-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-
 , dihydrochloride (9CI)
 MF C42 H46 Cl N3 O6 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSRS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-(4-methylphenyl)-N,1-bis[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-, monohydrochloride (9CI)
 MF C44 H50 N2 O6 . Cl H



● HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(3,5-dimethoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-4-yl)methyl]-1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-
MF C44 H51 N3 O8
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-1,3-benzodioxol-5-yl-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-4-yl)methyl]-1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-
MF C43 H47 N3 O8
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinone, 1-[[[2-(4-chloro-3,5-dimethoxyphenyl)-4-pyridinyl]methyl]-
MF C19 H21 Cl N2 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinecarboxamide, N-methyl-N,1-bis[[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-, (2Z)-2-butenedioate (1:1)
MF C37 H44 N4 O7 . C4 H4 O4

CM 1




CM 2

Double bond geometry as shown.



10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanol, 2-[3,5-dimethoxy-4-(1-methylethoxy)phenyl]-
MF C17 H21 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-methyl-1-([2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl)-
MF C21 H29 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-(phenylamino)-, 1,1-dimethylethyl ester
MF C16 H24 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenamine, 4-ethoxy-
MF C8 H11 N O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(4-fluorophenyl)-N-(4-methoxyphenyl)-N-4-
piperidinyl-, dihydrochloride (9CI)
MF C24 H26 F N3 O . 2 Cl H



● 2 HCl

10537407.ttn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(3,4-difluorophenyl)-N-4-piperidinyl-2-(3,4,5-
trimethoxyphenyl)-, dihydrochloride (9CI)
MF C26 H29 F2 N3 O3 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-4-piperidinyl-N-(4-(trifluoromethoxy)phenyl)-2-
(3,4,5-trimethoxyphenyl)-, dihydrochloride (9CI)
MF C27 H30 F3 N3 O4 . 2 Cl F



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-methoxyphenyl)-N-4-piperidinyl-2-(3,4,5-
trimethoxyphenyl)-, dihydrochloride (9CI)
MF C27 H33 N3 O4 . 2 Cl F



● 2 HCl

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-[1-([2-(4-fluorophenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-
MF C39 H41 F N4 O4
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-methoxyphenyl)-N-[1-([2-(2-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-2-(3,4,5-trimethoxyphenyl)-, trihydrochloride (9CI)
MF C40 H44 N4 O5 . 3 Cl H



● 3 HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(3,4-difluorophenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
MF C42 H45 F2 N3 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-bromophenyl)-2-[(3,4,5-trimethoxyphenyl)-N-[[
[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-
MF C41 H45 Br N4 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidine, N-[4-(methylthio)phenyl]-N-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-
 , dihydrochloride (9CI)
 MF C43 H49 N3 O6 S . 2 Cl H



● 2 HCl

10537407.ttn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(3-methoxyphenyl)-N-[1-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-4-piperidinyl]-2-(3,4,5-trimethoxyphenyl)-
 MF C43 H49 N3 O7
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(4-ethoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
 [[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
 trihydrochloride (3Cl)
 MF C43 H50 N4 O7 . 3 Cl H



10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(2,3-dihydro-1H-inden-5-yl)-2-(3,4,5-
 trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-
 piperidinyl]-
 MF C44 H50 N4 O6
 Cl COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C42 H48 N4 O7
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-[3-(methylthio)phenyl]-N-(3',4',5'-trimethoxy[1,1'-
biphenyl]-4-yl)methyl)-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
MF C43 H49 N3 O6 S . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(3,5-dimethoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-
 N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-,
 trihydrochloride (9CI)
 MF C43 H50 N4 O8 . 3 Cl H



● 3 HCl

10537407.tzn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, 2-(4-chloro-3,5-dimethoxyphenyl)-N-[1-[[2-(4-chloro-
 3,5-dimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-N-methyl-,
 tetrahydrochloride (9CI)
 MF C34 H38 Cl2 N4 O4 . 4 Cl H




● 4 HCl

10537407.tzn

LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinecarboxamide, N,1-bis[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-, (2Z)-2-butenedioate (1:1)
MF C36 H42 N4 O7 . C4 H4 O4

CM 1



CM 2

Double bond geometry as shown.



10537407.tzn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Boric acid (H3BO3), tris(1-methylethyl) ester
MF C9 H21 B O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-methylphenyl)[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methylamino]-, 1,1-dimethylethyl ester
MF C33 H42 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-butoxyphenyl)[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methylamino]-, 1,1-dimethylethyl ester
MF C36 H48 N2 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-[1-([2-(4-chlorophenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-, trihydrochloride (3Cl)
MF C39 H41 Cl N4 O4 . 3 Cl E



● 3 HCl

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(4-ethoxyphenyl)-N-[1-([2-(4-ethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-methoxyphenyl)-
MF C40 H44 N4 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-(4-fluorophenyl)-N-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-
 , dihydrochloride (9CI)
 MF C42 H46 F N3 O6 . 2 Cl H
 CI



● 2 HCl

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
 [[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
 MF C41 H45 Cl N4 O6
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-methylphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
MF C43 H49 N3 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-[4-(trifluoromethoxyphenyl)-5-(3,4,5-
trimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-
piperidinyl]-, trihydrochloride (9CI)
MF C42 H45 F3 N4 O7 . 3 Cl H



● 3 HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinethanamine, N-1,3-benzodioxol-5-yl-2-(3,4,5-trimethoxyphenyl)-N-
[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C42 H46 N4 O8
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-cyclohexyl-1-[[2-(3,4,5-trimethoxyphenyl)-4-
pyridinyl]methyl]-
MF C26 H37 N3 O3
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn

LS 683 ANSWEBS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-1,3-benzodioxol-5-yl-6-(3,4,5-trimethoxyphenyl)-N-
[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
trihydrochloride (3Cl)
MF C42 H46 N4 O8 . 3 Cl H



● 3 HCl

10537407.ttn


LS 683 ANSWEBS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzene, 5-iodo-1,3-dimethoxy-2-(1-methylethoxy)-
MF Cl1 H15 I O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(3,4,5-trimethoxyphenyl)-N-[[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-
MF C35 H42 N4 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn

L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-oxo-, 1,1-dimethylethyl ester
MF C10 H17 N O3
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenamine, 4-chloro-
MF C6 H5 Cl N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[[2-(3-fluorophenyl)-4-pyridinylmethyl]](4-methoxyphenyl)amino]-, 1,1-dimethylethyl ester
MF C29 H34 F N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-chlorophenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-, monohydrochloride (9CI)
MF C27 H31 Cl N2 O3 . Cl H



• HCl

10537407.tzn


L5 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(2,3-dimethoxyphenyl)[(2-(3,4,5-
trimethoxyphenyl)-4-pyridinyl)methyl]amino]-, 1,1-dimethylethyl ester
MF C33 H43 N3 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidyl]-5-(3,4,5-trimethoxyphenyl)-
MF C39 H40 F2 N4 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(3-fluorophenyl)-N-[1-([2-(3-fluorophenyl)-4-pyridinyl]methyl)-4-piperidyl]-N-(4-methoxyphenyl)-, trihydrochloride
MF C36 H34 F2 N4 O . 3 Cl H



● 3 HCl

10537407.ttn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-methoxyphenyl)-2-phenyl-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C39 H42 N4 O4
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-, trihydrochloride (9CI)
MF C41 H44 F2 N4 O6 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-bromophenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
trihydrochloride (3Cl)
MF C41 H45 Br N4 O6 . 3 Cl H
CI



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-[4-(methylthio)phenyl]-5-(3,4,5-trimethoxyphenyl)-
N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C42 H48 N4 O6 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(3-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-,
trihydrochloride (9CI)
MF C42 H48 N4 O7 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-methoxyphenyl)-N-[3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl]methyl]-1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-
MF C43 H49 N3 O7
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-2-propynyl-2-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-9CI)
MF C39 H44 N4 O6
CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-methyl-2-(3,4,5-trimethoxyphenyl)-N-[(3S)-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-3-pyrrolidinyl]-9CI)
MF C35 H42 N4 O6
CI COM

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn

LS 683 ANSHERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-[3-(methylthio)phenyl]-2-(3,4,5-trimethoxyphenyl)-
 N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-,
 (2E)-2-butenedioate (1:1)
 MF C42 H48 N4 O6 S . C4 H4 O4

CM 1




CM 2

Double bond geometry as shown.



10537407.tzn


LS 683 ANSHERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-methyl-N-(4-piperidinylmethyl)-2-(3,4,5-
 trimethoxyphenyl)-
 MF C22 H31 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinecarboxamide, 1-[(2-(4-chloro-3,5-dimethoxyphenyl)-4-
pyridinyl)methyl]-
MF C20 H24 Cl N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-[3,4,5-trimethoxyphenyl]-
MF C15 H18 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenamine, 3,4-difluoro-
MF C6 H5 F2 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[(4-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]cyclohexyl]-
MF C43 H49 N3 O7
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-phenyl-N-4-piperidinyl-5-(3,4,5-trimethoxyphenyl)-
, dihydrochloride (9CI)
MF C26 H31 N3 O3 . 2 Cl H



● 2 HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-methylphenyl)-N-4-piperidinyl-2-(3,4,5-trimethoxyphenyl)-, dihydrochloride (9CI)
MF C27 H33 N3 O3 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-butoxyphenyl)-N-4-piperidinyl-2-(3,4,5-trimethoxyphenyl)-, dihydrochloride (9CI)
MF C30 H39 N3 O4 . 2 Cl H



• 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(3,5-difluorophenyl)-N-(4-methoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-
MF C39 H40 F2 N4 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(4-ethoxyphenyl)-N-(4-methoxyphenyl)-N-[1-[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-, trihydrochloride (3Cl)
MF C41 H46 N4 O5 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-
MF C41 H45 F N4 O6
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(4-chlorophenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
 [[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-
 MF C41 H45 Cl N4 O6
 CT C08



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
 [[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-,
 trihydrochloride (9CI)
 MF C42 H48 N4 O6 . 3 Cl H



● S HCl

10537407.tzn


L5 683 ANSWEERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-[4-(trifluoromethoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
MF C42 H45 F3 N4 O7
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn

L5 683 ANSWEERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-ethoxyphenyl)-N,1-bis[3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-, monohydrochloride (9CI)
MF C45 H52 N2 O7 . Cl H




● HCl

10537407.tzn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Pyrrolidinecarboxylic acid, 3-[[[(2-nitrophenyl)sulfonyl]([2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]amino]-, 1,1-dimethylethyl ester,
(3S)-
MF C30 H36 N4 O9 S
CI COM


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(3,5-dimethoxyphenyl)-6-(3,4,5-trimethoxyphenyl)-
N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-
MF C43 H50 N4 O8
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-methyl-N-4-piperidyl-2-(3,4,5-trimethoxyphenyl)-
MF C21 H29 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-1,3-benzodioxol-5-yl-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-2-yl)methyl]-1--[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
dihydrochloride (9CI)
MF C43 H47 N3 O8 . 2 Cl H



● 2 HCl

10537407.trn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinecarboxylic acid, 5-(3,4,5-trimethoxyphenyl)-, ethyl ester
MF C17 H19 N O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.trn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, 1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
MF C20 H27 N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinecarboxylic acid, 6-chloro-, ethyl ester
MF C8 H8 Cl N O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenamine, 4-methoxy-
MF C7 H9 N O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWEERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(3,4-dimethoxyphenyl)-N-(4-methoxyphenyl)-N-4-
piperidinyl-, dihydrochloride (9CI)
MF C26 H31 N3 O3 . 2 Cl H



● 2 HCl

10537407.tnn


LS 683 ANSWEERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(4-chlorophenyl)[(5-(3,4,5-
trimethoxyphenyl)-3-pyridinyl)methyl]amino]-, 1,1-dimethylethyl ester
MF C31 H38 Cl N3 O5



***PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[(2-methoxyphenyl)[(3',4',5'-
trimethoxy[1,1'-biphenyl]-3-yl)methyl]amino]-, 1,1-dimethylethyl ester
MF C33 H42 N2 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


L5 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-[1-[(2-(3,4-dimethoxyphenyl)-4-pyridinyl)methyl]-
4-piperidinyl]-N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-,
trihydrochloride (9CI)
MF C40 H43 F N4 O5 . 3 Cl H



● 3 HCl

10537407.ttn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-[1-[(2-(3-fluorophenyl)-4-pyridinyl)methyl]-4-piperidinyl]-N-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-
MF C39 H41 F N4 O4
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(4-methoxyphenyl)-N-[1-[(2-phenyl-4-pyridinyl)methyl]-4-piperidinyl]-2-(3,4,5-trimethoxyphenyl)-, trihydrochloride (9CI)
MF C39 H42 N4 O4 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSHERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-(3,4-difluorophenyl)-N-[1-[(3',4',5'-
trimethoxy[1,1'-biphenyl]-3-yl)methyl]-4-piperidyl]-2-(3,4,5-
trimethoxyphenyl)-
MF C42 H45 F2 N3 O6
CI C08



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSHERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-[4-(trifluoromethyl)phenyl]-N-[(3',4',5'-
trimethoxy[1,1'-biphenyl]-3-yl)methyl]-1-[[15-(3,4,5-trimethoxyphenyl)-3-
pyridinyl)methyl]-
MF C43 H46 F3 N3 O6
CI C08



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


L5 683 ANSERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-[(4-(methylthio)phenyl)-N-[1-[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-4-piperidyl]-2-(3,4,5-trimethoxyphenyl)-, dihydrochloride (9Cl)
 MF C43 H49 N3 O6 S . 2 Cl H



● 2 HCl

10537407.tzn


L5 683 ANSERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Piperidinamine, N-(4-butoxyphenyl)-N,1-bis[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)methyl]-
 MF C47 H56 N2 O7
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]methyl]-4-piperidinyl]-,
trihydrochloride (3Cl)
MF C42 H48 N4 O7 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidamine, N-[3-(methylthio)phenyl]-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
MF C43 H49 N3 O6 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Pyridine, 4-(chloromethyl)-2-(4-fluorophenyl)-
MF Cl2 H9 Cl F N



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-[3-(methylthio)phenyl]-2-(3,4,5-trimethoxyphenyl)-
N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
trihydrochloride (9CI)
MF C42 H48 N4 O6 S . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(phenylmethyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
 [(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-,
 tetrahydrochloride (9CI)
 MF C42 H48 N4 O6 . 4 Cl H



● 4 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinecarboxylic acid, 2-(4-chloro-3,5-dimethoxyphenyl)-
 MF C14 H12 Cl N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanol, 2-(3,4,5-trimethoxyphenyl)-
MF C15 H17 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

LS 683 ANSKERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Pyridine, 4-(chloromethyl)-, hydrochloride (1:1)
MF C6 H6 Cl N . Cl H




● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(2-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-N-[4-
 [[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]cyclohexyl]-,
 trihydrochloride (3Cl)
 MF C43 H49 N3 O7 . 3 Cl H



● 3 HCl

10537407.tnn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1-Piperidinecarboxylic acid, 4-[phenyl[[2-(3,4,5-trimethoxyphenyl)-4-
 pyridinyl]methyl]amino]-, 1,1-dimethylethyl ester
 MF C31 H39 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-[4-(methylthio)phenyl]-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-, monohydrochloride (9CI)
MF C28 H34 N2 O3 S . Cl H



● HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-ethoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-, monohydrochloride (9CI)
MF C29 H36 N2 O4 . Cl H



● HCl

10537407.tzn


LS 683 ANSWEERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, N-[1-([2-(3,5-difluorophenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-, trihydrochloride (3Cl)
MF C39 H40 F2 N4 O4 . 3 Cl H
CI



● 3 HCl

10537407.tzn


LS 683 ANSWEERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyridinemethanamine, 2-(3-methoxyphenyl)-N-(4-methoxyphenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-
MF C38 H40 N4 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWEBS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Pyridinemethanamine, N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
 [(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-,
 trihydrochloride (9CI)
 MF C41 H45 F N4 O6 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWEBS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(4-chlorophenyl)-2-(3,4,5-trimethoxyphenyl)-N-[1-
 [(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-,
 trihydrochloride (9CI)
 MF C41 H45 Cl N4 O6 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(4-methylphenyl)-N-[1-[(3',4',5'-trimethoxy[1,1'-
 biphenyl]-3-yl)methyl]-4-piperidinyl]-2-(3,4,5-trimethoxyphenyl)-
 MF C43 H49 N3 O6
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinemethanamine, N-(2,3-dimethoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-
 N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
 trihydrochloride (9CI)
 MF C43 H50 N4 O8 . 3 Cl H



● 3 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-ethoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-3-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
MF C44 H51 N3 O7
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-butylphenyl)-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-
4-yl)methyl]-1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
MF C46 H55 N3 O6
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(3,5-dimethoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-2-yl)methyl]-1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-
MF C44 H51 N3 O8
CT COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(4-butylphenyl)-N-[(3',4',5'-trimethoxy[1,1'-biphenyl]-
4-yl)methyl]-1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-,
dihydrochloride (9CI)
MF C46 H55 N3 O6 . 2 Cl E



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, N-(3,5-dimethoxyphenyl)-N-[(3',4',5'-trimethoxy[1,1'-
biphenyl]-4-yl)methyl]-1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-
, dihydrochloride (9CI)
MF C44 H51 N3 O8 . 2 Cl H



● 2 HCl

10537407.tzn


LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanol, 6-(3,4,5-trimethoxyphenyl)-
MF C15 H17 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, 1-[[2-[3,4,5-trimethoxyphenyl]-4-pyridinyl]methyl]-,
trihydrochloride (9CI)
MF C20 H27 N3 O3 . 3 Cl H



● 3 HCl

10537407.tnn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzene, 5-iodo-1,2,3-trimethoxy-
MF C9 H11 I O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10537407.ttn

LS 683 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenamine, 2-methoxy-
MF C7 H9 N O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

10537407.ttn

=> FIL STNGUIDE
FILE 'STNGUIDE' ENTERED AT 13:27:03 ON 07 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 29, 2008 (20080229/UP).

| COST IN U.S. DOLLARS | SINCE FILE | | TOTAL |
|----------------------|------------|---------|-------|
| | ENTRY | SESSION | |
| => d cost | 0.00 | 6.00 | |
| CONNECT CHARGES | 0.06 | 1.02 | |
| NETWORK CHARGES | 0.06 | | |
| SEARCH CHARGES | 0.00 | 12.72 | |
| OTHER CHARGES | 0.00 | 11.65 | |
| | ----- | ----- | |
| FULL ESTIMATED COST | 0.06 | | 31.39 |

IN FILE 'STNGUIDE' AT 13:27:07 ON 07 MAR 2008

=>

=>
Executing the logoff script...

=> LOG E

| COST IN U.S. DOLLARS | SINCE FILE | | TOTAL |
|----------------------|------------|---------|-------|
| | ENTRY | SESSION | |
| FULL ESTIMATED COST | 1.50 | | 32.83 |

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:42:12 ON 07 MAR 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSFTACH01625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 MAR 31 IPICODE, IPIPAT, and IPIUID enhanced with new custom
IPC display formats
NEWS 3 MAR 31 CAS REGISTRY enhanced with additional experimental
spectra
NEWS 4 MAR 31 CA/Chplus and CASREACT patent number format for U.S.
applications updated
NEWS 5 MAR 31 LPCI now available as a replacement to LDPCI
NEWS 6 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements

10537407.ttn

NEWS 7 APR 04 STN AnaVist, Version 1, to be discontinued
NEWS 8 APR 15 WPIUS, WPIINEX, and WPIX enhanced with new predefined hit display formats
NEWS 9 APR 28 EMBASE Controlled Term thesaurus enhanced
NEWS 10 APR 28 INRESEARCH relocated with enhancements
NEWS 11 MAY 30 INPAFAMDB now available on STN for patent family searching
NEWS 12 MAY 30 UGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 13 JUN 06 ERFULL enhanced with 246,000 English abstracts
NEWS 14 JUN 06 EMBASE updated with 41,000 documents
NEWS 15 JUN 13 USPATFILL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 16 JUN 19 CAS REGISTRY includes selected substances from web-based collections
NEWS 17 JUN 25 CA/Chplus and USPAT databases updated with IPC reclassification data
NEWS 18 JUN 30 AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 19 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 20 JUN 30 STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 21 JUN 30 STN AnaVist enhanced with database content from ERFULL
NEWS 22 JUL 28 CA/Chplus patent coverage enhanced
NEWS 23 JUL 28 ERFULL enhanced with additional legal status information from the epline Register
NEWS 24 JUL 28 IFICDS, IFIPAT, and IFIUCB relocated with enhancements
NEWS 25 JUL 28 STN Viewer performance improved
NEWS 26 AUG 01 INPADOCDB and INPAFAMDB coverage enhanced
NEWS 27 AUG 13 CA/Chplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 28 AUG 15 CROLD to be discontinued on December 31, 2008
NEWS 29 AUG 15 Chplus currency for Korean patents enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:37:37 ON 23 AUG 2008

=> file req

FILE 'REGISTRY' ENTERED AT 11:37:47 ON 23 AUG 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.

10537407.ttn

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 AUG 2008 HIGHEST RN 1042980-87-9
DICTIONARY FILE UPDATES: 22 AUG 2008 HIGHEST RN 1042980-87-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stnqes/stnqes/properties.html>

=>

Uploading C:\Program Files\Stnqes\Stnqes\10537407-3.str



chain nodes :

13 20 21

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 14 15 16 17 18 19 22 23 24 25 26
27 28 29 30 31 32 33 34 35 36 37 38 39

chain bonds :

6-7 8-13 13-14 17-20 20-21 20-22 21-28 30-34

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 14-15 14-19
15-16 16-17 17-18 18-19 22-23 22-27 23-24 24-25 25-26 26-27 28-29 28-33
29-30 30-31 31-32 32-33 34-35 34-39 35-36 36-37 37-38 38-39

10537407.tzn

exact/norm bonds :

13-14 14-15 14-19 15-16 16-17 17-18 17-20 18-19 20-21 20-22

exact bonds :

6-7 9-13 21-28 30-34

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 22-23 22-27
23-24 24-25 25-26 26-27 28-29 28-33 29-30 30-31 31-32 32-33 34-35 34-39
35-36 36-37 37-38 38-39

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:CLASS 21:CLASS 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
38:Atom 39:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STM Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 11:38:05 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 38 TO ITERATE

100.0% PROCESSED 38 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 391 TO 1129

PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAN L1


=> d scan

10537407.tzn

L2 2 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STM

IN 3-Pyridinemethanamine, N-(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
hydrochloride (1:3)

MF C42 H48 N4 O6 . 3 Cl H




● 3 HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.tnn

L2 2 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinemethanamine, N-(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-,
hydrochloride (1:3)
MF C42 H48 N4 O7 . 3 Cl H



ALL ANSWERS HAVE BEEN SCANNED

10537407.tnn

=> 1
1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l1 full
FULL SEARCH INITIATED 11:38:19 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 643 TO ITERATE

100.0% PROCESSED 643 ITERATIONS 39 ANSWERS
SEARCH TIME: 00.00.01

L3 39 SEA SSS FUL L1

=> file caplus
FILE 'CAPLUS' ENTERED AT 11:38:22 ON 23 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Aug 2008 VOL 149 ISS 9
FILE LAST UPDATED: 22 Aug 2008 (20080822/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l3
L4 10 L3

=> d chib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 10 ANSWERS - CONTINUE? Y/(N):y

10537407.tn

14 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
2007:278041 Document No. 146:323376 Composition containing slightly water-soluble piperidine derivative or its salt with high dissolution and absorbency and manufacture of the composition. Miura, Hiroshi; Kanabako, Makoto (Kowa Spinning Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 2007063163 A 20070315, Bpp. (Japanese). COHEN: JKOXAF. APPLICATION: JP 2005-249233 20050830.

AB The title composition, useful for treatment of asthma, allergy, rheumatoid, atherosclerosis, and so on., contains 4-[N-(4-methoxyphenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridin-3-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl]piperidine or its salt with high dissoln. and absorbency. The composition is manufactured by treating a composition

containing porous SiO₂ and the piperidine derivative or its salt with supercrit.

or subcrit. fluid of CO₂ for improvement of dissoln. and absorbency of the compound. The piperidine derivative and lightwt. SiO₂ (Sylsila 350) were treated

with a CO₂ supercrit. fluid at 60° 18 MPa for 5 h. The resulting piperidine derivative was highly adsorbed by dose to rat and showed high blood content.

IT 501669-92-7


RL: PEP (Physical, engineering or chemical process); PKT (Pharmacokinetics); THU (Therapeutic use); BTOL (Biological study); PROC (Process); USES (Uses)

(manufacture of composition containing slightly water-soluble piperidine derivative or its

salt with high dissoln. and absorbency by treatment with supercrit. or subcrit. CO₂ with porous SiO₂)

RN 501669-92-7 CAPLUS


CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



10537407.tn

14 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
2006:796238 Document No. 145:202968 Agent for prevention/therapy of disease caused by keratinocyte growth. Edano, Toshiyuki; Tabunoki, Yuichiro; Koshi, Tomoyuki (Kowa Co., Ltd., Japan). PCT Int. Appl. WO 2006/082934 A1 20060810, 33pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BE, CA, CH, CN, CO, CR, CU, CE, DE, DK, DM, EE, EG, ES, EQ, FI, GE, GD, GE, GG, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LF, LG, LS, LI, LU, LV, LY, MA, MD, MG, MH, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RU, RW, SC, SD, SE, SG, SK, SL, SM, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA; RW: AT, BE, BF, BG, CF, CG, CH, CI, CM, CN, CU, DE, EE, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NL, PT, SE, SN, TD, TS, TR. (Japanese). COHEN: PIXXIZ. APPLICATION: WO 2006-79301636 20060201. PRIORITY: JP 2005-26178 20050202.

GI



AB An agent for the prevention/therapy of skin disease caused by keratinocyte growth, which comprises, as an active ingredient, a compound represented by the general formula (I): [wherein A represents a group selected from the following formulas: (A1) and (A2), X represents CH or N, Y represents CH₂ or C=O, 2 represents CH or N, R1 represents an alkoxy group, R2 and R3 represent an alkyl group, R4 represents a group selected from an alkyl group and the following group, R5 represents an alkoxy or alkylthio group, m represents an integer of 1 to 3, n represents an integer of 1 or 2 and o represents an integer of 1 or 2], a salt of the compound or a solvated material thereof.


IT 501671-58-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BTOL (Biological study); USES (Uses)

(agent for prevention/therapy of skin disease caused by keratinocyte growth)

RN 501671-58-5 CAPLUS

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)




10537407.tzn

10537407.tzn

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
2005:346861 Document No. 142:404289 Angiogenesis inhibitor. Doi, Takeshi;
Tamura, Masahiro (Kowa Co., Ltd., Japan). PCT Int. Appl. WO 2005/034953 A1
20050421, 29 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA,
BB, BS, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC,
EE, EG, ES, FI, GB, GD, GE, GH, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA,
NB, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SL, ST,
TD, TM, TW, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RM: AT,
BE, BF, BG, CH, CO, CY, CZ, DE, DK, DR, ES, FI, FR, GA, GB, GR, IE,
IT, LU, MC, MG, MP, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). C00DM:
FIX002. APPLICATION: WO 2004/3914956 20041008. PRIORITY: US 2003-310012P
20031010.

G1



AB A preventive/therapeutic agent for diseases attributable to angiogenesis
which contains as an active ingredient a cyclic amine compound represented
by the general formula (I): (Chemical formula I) (I) (wherein R1, R2, and R3
each independently represents hydrogen, halogeno, hydroxy, alkyl,
halogenoalkyl, alkoxy, alkylthio, carboxy, alkoxy carbonyl, or alkanoyl; W1
and W2 each independently represents nitrogen or CH; X represents oxygen,
NR4, COR4, or NR4CO; R4's each represents hydrogen, alkyl, alkenyl,
alkynyl, (un)substituted aryl, (un)substituted heteroaryl, (un)substituted
aralkyl, or (un)substituted heteroaralkyl; and l, m, and n each is 0 or
1), a salt of the compound, or a solvate of either.

IT 850213-84-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THW
(Therapeutic use); BIO (Biological study); PREP (Preparation); USES
(Uses)

methoxyphenylpyridinylaminopiperidine derivs. as angiogenesis
inhibitors for treatment of neovascularization-related diseases)

RN 850213-84-2 CAPLUS

CN 3-Pyridinemethanesulfonamide, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[12-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methoxy]-4-piperidinyl]-
2-hydroxy-1,2,3-propanetricarboxylate (1:1) (CA INDEX NAME)

CM 1

CRM 501669-92-7


CME C42 H48 N4 O7

10537407.ttn

14 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

2004:515485 Document No. 141:71451 Preparation of heterocyclic compounds as erythropoietin production accelerators. Inagawa, Shigehiko; Doi, Takeshi; Tamura, Masahiro; Ohkuchi, Masao (Kowa Co., Ltd., Japan). PCT Int. Appl. WO 2004/052859 A1 2/04/0624, 294 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CY, DE, DK, DM, EC, EG, ES, FI, GB, GD, GE, GH, GR, GU, HK, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, ST, TG, TN, TR, TT, TZ, UA, US, UZ, VG, VN, YU, ZA, ZM, ZW; RM: AI, BE, BF, BG, CF, CG, CH, CI, CK, CZ, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SH, TD, TG, TR. (Japanese). CODEN: PINKOR. APPLICATION: WO 2003-IP15589 20031205. PRIORITY: US 2002-PV431234 20021206.

GT



AB The title compds. I [R1, R2, and R3 each independently represents hydrogen, halogeno, hydroxy, alkyl, halogenoalkyl, alkoxy, alkylthio, carboxy, alkoxy-carbonyl, or alkanoyl; W1 and W2 each independently represents nitrogen or CH; X represents oxygen, NR4, COMR4, or NR4CO; R4 represents hydrogen, alkyl, alkenyl, alkynyl, (un)substituted aryl, (un)substituted heteroaryl, (un)substituted aralkyl, or (un)substituted heteroaralkyl; A is (CH2)a, and a, m, and n each is 0 or 1] are prepared. The erythropoietin production promoting effect of compds. of this invention was demonstrated in an in vitro assay using HepG3 cells.

II 427886-47-3P 501669-92-7P 501670-79-7P
501670-80-0P 501670-95-7P 501670-96-8P
501671-11-0P 501671-12-1P 501671-41-6P
501671-42-7P 501671-51-4P 501671-58-5P
501671-73-4P 501671-74-5P 501672-01-1P
501672-02-2P 501672-16-8P 501672-31-7P
501672-32-8P 501672-47-5P 501672-48-6P
501672-59-9P 501672-60-2P 501673-37-6P
501673-38-7P 501673-39-8P 501673-40-1P
501673-41-2P 501673-42-3P 501673-43-4P
501673-44-5P 501673-45-6P 501673-46-7P
501673-47-8P 709669-59-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

[preparation of heterocyclic compds. as erythropoietin production accelerators]

RN 427886-47-3 CAPLUS

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)


10537407.ttn



● 3 HCL


RN 501669-92-7 CAPLUS

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501670-79-7 CAPLUS

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCL

RN 501670-80-0 CAPLUS

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]- (CA INDEX NAME)


10537407.tzn

INDEX NAME)



RN 501670-95-7 CAPLUS


CN 3-Pyridinemethanamine, N-[(4-butoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 501670-96-8 CAPLUS


CN 3-Pyridinemethanamine, N-[(4-butoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-hydrochloride (1:3) (CA INDEX NAME)



RN 501671-11-0 CAPLUS

CN 3-Pyridinemethanamine, N-[(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-hydrochloride (1:3) (CA INDEX NAME)


10537407.tzn



● 3 HCl


RN 501671-12-1 CAPLUS

CN 3-Pyridinemethanamine, N-[(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-hydrochloride (1:3) (CA INDEX NAME)



RN 501671-41-6 CAPLUS

CN 3-Pyridinemethanamine, N-[(4-(trifluoromethoxy)phenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501671-42-7 CAPLUS

CN 3-Pyridinemethanamine, N-[(4-(trifluoromethoxy)phenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-hydrochloride (1:3) (CA INDEX NAME)


10537407.tzn

piperidinyl]- (CA INDEX NAME)



RN 501671-57-4 CAPLUS


CN 3-Pyridinemethanamine, N-[4-(methoxythio)phenyl]-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 501671-58-5 CAPLUS


CN 3-Pyridinemethanamine, N-[4-(methoxythio)phenyl]-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501671-73-4 CAPLUS

CN 3-Pyridinemethanamine, N-(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)


10537407.tzn



●3 HCl


RN 501671-74-5 CAPLUS

CN 3-Pyridinemethanamine, N-(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501672-01-1 CAPLUS

CN 3-Pyridinemethanamine, N-(4-bromophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




●3 HCl

RN 501672-02-2 CAPLUS

CN 3-Pyridinemethanamine, N-(4-bromophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)


10537407.ttn

INDEX NAME




RN 501672-16-8 CAPLUS

CN 3-Pyridinemethanamine, N-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-{3,4,5-trimethoxyphenyl}-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



RN 501672-31-7 CAPLUS

CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-{3,4,5-trimethoxyphenyl}-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501672-32-8 CAPLUS


CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-{3,4,5-trimethoxyphenyl}-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)

10537407.ttn



RN 501672-47-5 CAPLUS


CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-{3,4,5-trimethoxyphenyl}-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 501672-48-6 CAPLUS


CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-{3,4,5-trimethoxyphenyl}-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



RN 501672-59-9 CAPLUS

CN 3-Pyridinemethanamine, N-phenyl-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-{3,4,5-trimethoxyphenyl}-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)


10537407.tzn



● 3 HCl


RN 501672-60-2 CAPLUS

CN 3-Pyridinemethanamine, N-phenyl-5-(3,4,5-trimethoxyphenyl)-N-[1-([2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]- (CA INDEX NAME)



RN 501673-37-6 CAPLUS

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501673-38-7 CAPLUS


CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)

10537407.tzn



RN 501673-39-8 CAPLUS


CN 3-Pyridinemethanamine, N-[1-([2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 501673-40-1 CAPLUS


CN 3-Pyridinemethanamine, N-[1-([2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 501673-41-2 CAPLUS

CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)


10537407.tzn



● 3 HCl


RN 501673-42-3 CAPLUS

CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 501673-43-4 CAPLUS

CN 3-Pyridinemethanamine, N-[1-([2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501673-44-5 CAPLUS


CN 3-Pyridinemethanamine, N-[1-([2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)

10537407.tzn



RN 501673-45-6 CAPLUS


CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 501673-46-7 CAPLUS


CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 501673-47-8 CAPLUS


CN 3-Pyridinemethanamine, N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-methylthiophenyl)-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)

10537407.tzn



RN 703669-59-0 CAPLUS

CN 3-Pyridinemethanamine, N-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

10537407.tzn

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

2004:41159 Document No. 140:93930 Preparation of cyclic amines as cell adhesion and cell infiltration inhibitors. Kodama, Tatsuhiko; Tamura, Masahiro; Oda, Toshiaki; Yamazaki, Yukiyo; Nishikawa, Masahiro; Takemura, Shunji; Dei, Takeshi; Kyotani, Yoshinori; Chkuchi, Masao (Kowa Co., Ltd., Japan). U.S. Pat. Appl. Publ. US 2004/0010147 A1 2004/01/15, 148 pp., Cont.-in-part of U.S. Ser. No. 107,108. (English). COUN: USXKCO. APPLICATION: US 2002-191534 2002/07/10. PRIORITY: US 2001-941684 2001/08/30; US 2001-969328 2001/10/26; US 2002-107180 2002/03/28.

G1

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title comds. I [R1-R3 = H, halo, alkoxy, etc.; W1, W2 = H, CH; X = O, NR4, CONR4, NR4CO; R4 = H, alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, etc.; and l, m, and n each = 0-1] were prepared. For example, (3S)-11.48Cl was prepared in 68% yield by base-catalyzed condensation of (3S)-3-methylamino-1-[[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl]pyrrolidine with 4-chloromethyl-2-(3,4,5-trimethoxyphenyl)pyridine and acidulation with HCl. Selective invention comds. showed IC50 values of 0.04 μM to 0.3 μM for inhibition of cell adhesion. I and their pharmaceutical comds. (2 examples given) are useful as antiallergic, antirheumatic, antiasthmatic agents, etc.

IT 427886-47-3P 501669-92-7P 501670-73-7P

501670-80-0P 501670-95-7P 501670-96-8P

501671-11-0P 501671-12-1P 501671-25-6P

501671-26-7P 501671-41-6P 501671-42-7P

501671-57-4P 501671-58-5P 501671-73-4P

501671-74-5P 501672-01-1P 501672-02-2P

501672-15-7P 501672-16-8P 501672-31-7P

501672-32-8P 501672-47-5P 501672-48-6P

501672-59-9P 501672-60-2P 501673-37-6P

501673-38-7P 501673-39-8P 501673-40-1P

501673-41-2P 501673-42-3P 501673-43-4P

501673-44-5P 501673-45-6P 501673-46-7P

501673-47-8P

RL: PMC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


(Uses)

(preparation of cyclic amines as cell adhesion and infiltration inhibitors)

RN 427886-47-3 CAPLUS


CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)

10537407.tzn




● 3 HCl

RN 501669-92-7 CAPLUS
CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-hydrochloride (1:3) (CA INDEX NAME)



RN 501670-79-7 CAPLUS
CN 3-Pyridinemethanamine, N-(4-ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl


RN 501670-80-0 CAPLUS
CN 3-Pyridinemethanamine, N-(4-ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-hydrochloride (1:3) (CA INDEX NAME)

10537407.tzn

INDEX NAME)




RN 501670-95-7 CAPLUS
CN 3-Pyridinemethanamine, N-(4-butoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501670-96-8 CAPLUS
CN 3-Pyridinemethanamine, N-(4-butoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-hydrochloride (1:3) (CA INDEX NAME)




RN 501671-11-0 CAPLUS
CN 3-Pyridinemethanamine, N-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-hydrochloride (1:3) (CA INDEX NAME)

10537407.tn




● 3 HCl

RN 501671-12-1 CAPLUS
CN 3-Pyridinemethanamine, N-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



RN 501671-23-5 CAPLUS
CN 3-Pyridinemethanamine, N-(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl


RN 501671-26-7 CAPLUS
CN 3-Pyridinemethanamine, N-(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)

10537407.tn

INDEX NAME)




RN 501671-41-6 CAPLUS
CN 3-Pyridinemethanamine, N-[4-(trifluoromethoxy)phenyl]-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501671-42-7 CAPLUS
CN 3-Pyridinemethanamine, N-[4-(trifluoromethoxy)phenyl]-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




RN 501671-57-4 CAPLUS
CN 3-Pyridinemethanamine, N-[4-(methylthio)phenyl]-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)

10537407.tnn




● 3 HCl

RN 501671-59-5 CAPLUS
CN 3-Pyridinemethanamine, N-[4-(methylthio)phenyl]-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501671-73-4 CAPLUS
CN 3-Pyridinemethanamine, N-(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl


RN 501671-74-5 CAPLUS
CN 3-Pyridinemethanamine, N-(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]- (CA INDEX NAME)

10537407.tnn

INDEX NAME)




RN 501672-01-1 CAPLUS
CN 3-Pyridinemethanamine, N-(4-bromophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501672-02-2 CAPLUS
CN 3-Pyridinemethanamine, N-(4-bromophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 501672-15-7 CAPLUS
CN 3-Pyridinemethanamine, N-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)

10537407.tzn




● 3 HCl

RN 501672-16-8 CAPLUS
CN 3-Pyridinemethanamine, N-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501672-31-7 CAPLUS
CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl


RN 501672-32-8 CAPLUS
CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]- (CA INDEX NAME)

10537407.tzn

INDEX NAME)




RN 501672-47-5 CAPLUS
CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501672-48-6 CAPLUS
CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501672-59-9 CAPLUS
CN 3-Pyridinemethanamine, N-phenyl-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)


10537407.tzn



● 3 HCl


RN 501672-60-2 CAPLUS

CN 3-Pyridinemethanamine, N-phenyl-5-(3,4,5-trimethoxyphenyl)-N-[1-([2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]- (CA INDEX NAME)



RN 501673-37-6 CAPLUS

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501673-38-7 CAPLUS


CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)

10537407.tzn



RN 501673-39-8 CAPLUS


CN 3-Pyridinemethanamine, N-[1-([2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 501673-40-1 CAPLUS


CN 3-Pyridinemethanamine, N-[1-([2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 501673-41-2 CAPLUS

CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)


10537407.tzn



● 3 HCl


RN 501673-42-3 CAPLUS

CN 3-Pyridinemethanamine, N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 501673-43-4 CAPLUS

CN 3-Pyridinemethanamine, N-[1-([2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501673-44-5 CAPLUS


CN 3-Pyridinemethanamine, N-[1-([2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)

10537407.tzn



RN 501673-45-6 CAPLUS


CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 501673-46-7 CAPLUS


CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 501673-47-8 CAPLUS

CN 3-Pyridinemethanamine, N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-[4-(methylthio)phenyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



10537407.tzn



10537407.tzn

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
2003:836851 Document No. 139:323438 Preparation of pyridylmethyl substituted
piperidin-4-amines as HDAC inhibitors for treating cancer. Nataka,
Chikage; Kodama, Tetsuhiko; Doi, Takeshi; Tamura, Masahiro; Oda, Toshiaki;
Yamazaki, Yukiyo; Mishikawa, Masahiro; Takemura, Shunji; Ohkuchi, Masao
(Kowa Co., Ltd., Japan). PCT Int. Appl. WO 2003086397 A1 20031023, 232
pp. DESIGNATED STATES: W: AE, AG, AL, AN, AU, BA, BG, BR, BY,
BZ, CA, CH, CN, CU, CR, CZ, DE, DK, DM, DO, EC, EE, ES, FI, GB,
GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LS,
LR, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PA,
PE, PG, PH, PK, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, TH, TR, TT, TZ, UA, UG,
US, UZ, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM,
CY, DE, DG, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT,
SE, SN, TD, TG. (English). CODES: PIXX02. APPLICATION: WO
2003-086602 20030411. PRIORITY: US 2002-071675P 20020412; US 2002-412571P
20020323.

GI



AB The present invention is directed to a method for treating cancer, a
method for inhibiting histone deacetylase, and a method for facilitating
gene therapy, comprising administering an effective amount of the title
cyclic amine I (R1-R3 = H, halo, OR, alkyl, haloalkyl, alkoxy, alkylthio,
CO2R, alkoxybenzoyl, alkanyl; R1, R2 = N or CH; X = O, NR4, COR4, or
NR4O; R4 = H, alkyl, alkenyl, alkynyl, (un)substituted (hetero)aryl or
(hetero)alkyl; l, m, n = 0-1) or salt thereof. Preparation of the compds. I
is described. Thus, reacting 4-(p-anisidino)-1-[(2-(3,4,5-
trimethoxyphenyl)pyridin-4-yl)methyl] piperidine with 4-chloromethyl-2-
(3,4,5-trimethoxyphenyl)pyridine (pregns. given) afforded 40A II.38C1
which exhibited strong growth inhibitory effect on typical cultured human
cancer cells.

10537407.ttn


IT 427886-47-3P 501669-92-7P 501670-79-7P
501670-80-0P 501670-95-7P 501670-96-8P
501671-11-0P 501671-12-1P 501671-25-6P
501671-26-7P 501671-41-6P 501671-42-7P
501671-57-4P 501671-58-5P 501671-73-4P
501671-74-5P 501672-01-1P 501672-02-2P
501672-15-7P 501672-16-8P 501672-31-7P
501672-32-8P 501672-47-5P 501672-48-6P
501672-59-9P 501672-60-2P 501673-37-6P
501673-38-7P 501673-39-8P 501673-40-1P
501673-41-2P 501673-42-3P 501673-43-4P
501673-44-5P 501673-45-6P 501673-46-7P
501673-47-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PREP (Preparation); USGS (Uses)

(preparation of pyridylmethyl substituted piperidin-4-amines as BDMC inhibitors for treating cancer)

RI 427886-47-3 CAPLUS


CI 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RI 501669-92-7 CAPLUS

CI 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)




RI 501670-79-7 CAPLUS

CI 3-Pyridinemethanamine, N-(4-ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-

10537407.ttn


[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RI 501670-80-0 CAPLUS

CI 3-Pyridinemethanamine, N-(4-ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RI 501670-95-7 CAPLUS

CI 3-Pyridinemethanamine, N-(4-butoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

10537407.tnn


RN 501670-96-8 CAPLUS

CN 3-Pyridinemethanamine, N-(4-butoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA
INDEX NAME)



RN 501671-11-0 CAPLUS


CN 3-Pyridinemethanamine, N-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 501671-12-1 CAPLUS

CN 3-Pyridinemethanamine, N-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA
INDEX NAME)




RN 501671-25-6 CAPLUS

CN 3-Pyridinemethanamine, N-(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-

10537407.tnn


[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 501671-26-7 CAPLUS

CN 3-Pyridinemethanamine, N-(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA
INDEX NAME)



RN 501671-41-6 CAPLUS

CN 3-Pyridinemethanamine, N-[4-(trifluoromethoxy)phenyl]-5-(3,4,5-
trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-
piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

10537407.tzn


RN 501671-42-7 CAPLUS

CN 3-Pyridinemethanamine, N-[4-(trifluoromethoxy)phenyl]-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501671-57-4 CAPLUS


CN 3-Pyridinemethanamine, N-[4-(methylthio)phenyl]-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 501671-58-5 CAPLUS

CN 3-Pyridinemethanamine, N-[4-(methylthio)phenyl]-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 501671-73-4 CAPLUS

CN 3-Pyridinemethanamine, N-(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-

10537407.tzn


[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 501671-74-5 CAPLUS

CN 3-Pyridinemethanamine, N-(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501672-01-1 CAPLUS

CN 3-Pyridinemethanamine, N-(4-bromophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

10537407.tnn


RN 501672-02-2 CAPLUS

CN 3-Pyridinemethanamine, N-(4-bromophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA
INDEX NAME)



RN 501672-15-7 CAPLUS


CN 3-Pyridinemethanamine, N-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 501672-16-8 CAPLUS

CN 3-Pyridinemethanamine, N-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA
INDEX NAME)




RN 501672-31-7 CAPLUS

CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-

10537407.tnn


[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 501672-32-8 CAPLUS

CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-
[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA
INDEX NAME)



RN 501672-47-5 CAPLUS

CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

10537407.ttn


RN 501672-48-6 CAPLUS

CN 3-Pyridinethanamine, N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501672-59-9 CAPLUS


CN 3-Pyridinethanamine, N-phenyl-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 501672-60-2 CAPLUS

CN 3-Pyridinethanamine, N-phenyl-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 501673-37-6 CAPLUS

CN 3-Pyridinethanamine, N-(4-methoxyphenyl)-N-[1-[[2-(3-methoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)

10537407.ttn


hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 501673-38-7 CAPLUS

CN 3-Pyridinethanamine, N-(4-methoxyphenyl)-N-[1-[[2-(3-methoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 501673-39-8 CAPLUS

CN 3-Pyridinethanamine, N-[1-[[2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501673-40-1 CAPLUS


10537407.tzn

CN 3-Pyridinemethanamine, N-[1-[[2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 501673-41-2 CAPLUS


CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-N-[1-[[2-(3-methoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 501673-42-3 CAPLUS

CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-N-[1-[[2-(3-methoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 501673-43-4 CAPLUS

CN 3-Pyridinemethanamine, N-[1-[[2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-,

10537407.tzn


hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 501673-44-5 CAPLUS

CN 3-Pyridinemethanamine, N-[1-[[2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 501673-45-6 CAPLUS

CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-N-[1-[[2-(3-methoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501673-46-7 CAPLUS


10537407.tzn

CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-N-[1-[(2-(3-methoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 501673-47-8 CAPLUS

CN 3-Pyridinemethanamine, N-[1-[(2-(3-methoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-N-[4-(methylthio)phenyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



10537407.tzn

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN 2003:622567 Document No. 139:179974 Preparation of cyclic amines as cell adhesion and infiltration inhibitors. Kodama, Tatsuhiko; Tamura, Masahiro; Oda, Toshiaki; Yamazaki, Yukiyo; Kishikawa, Masahiro; Takemura, Shunji; Doi, Takeshi; Kyotani, Yoshinori; Ohuchi, Masao (Kowa Co., Ltd., Japan). U.S. US 6605620 B1 20030812, 149 pp., Cont.-in-part of U.S. Ser. No. 983,928. (English). CODEX USXMAN. APPLICATION: US 2002-107180 20020328. PRIORITY: US 2001-941684 20010830; US 2001-983928 20011026.

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I (R1, R2, and R3 = independently H, alkoxy; W1 and W2 = independently N or CH; X = O, NR4, CONR4, or NR4O; R4 = H, alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, etc.; l, m, n = 0 or 1) and their salts and hydrates were prepared as cell adhesion and cell infiltration inhibitors. For example, II*46CL was prepared in 68% yield by base-catalyzed condensation of (3S)-3-methylamino-1-[(2-(3,4,5-trimethoxyphenyl)pyridin-4-yl)methyl]pyrrolidine with 4-chloromethyl-2-[3,4,5-trimethoxyphenyl]pyridine and acidulation with HCl. Selective invention compds. showed IC50 values of 0.04 µM to 0.3 µM for inhibition of cell adhesion. I and their pharmaceutical compds. (2 examples given) are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents (no data).

IT 427886-47-3P 501669-92-7P 501670-79-7P
501670-80-0P 501670-95-7P 501670-96-8P
501671-11-0P 501671-12-1P 501671-25-6P
501671-26-7P 501671-41-6P 501671-42-7P
501671-57-4P 501671-58-5P 501671-73-4P
501671-74-5P 501672-01-1P 501672-02-2P
501672-15-7P 501672-16-8P 501672-31-7P
501672-32-8P 501672-47-5P 501672-48-6P
501672-59-9P 501672-60-2P


RL: PMC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(cell adhesion and infiltration inhibitor; preparation of cyclic amines as cell adhesion and infiltration inhibitors via condensation)

RN 427886-47-3 CAPLUS


CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)

10537407.tnn




● 3 HCl

RN 501669-92-7 CAPLUS
CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-hydrochloride (1:3) (CA INDEX NAME)



RN 501670-79-7 CAPLUS
CN 3-Pyridinemethanamine, N-(4-ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl


RN 501670-80-0 CAPLUS
CN 3-Pyridinemethanamine, N-(4-ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-hydrochloride (1:3) (CA INDEX NAME)

10537407.tnn

INDEX NAME)




RN 501670-95-7 CAPLUS
CN 3-Pyridinemethanamine, N-(4-butoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501670-96-8 CAPLUS
CN 3-Pyridinemethanamine, N-(4-butoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-hydrochloride (1:3) (CA INDEX NAME)




RN 501671-11-0 CAPLUS
CN 3-Pyridinemethanamine, N-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-hydrochloride (1:3) (CA INDEX NAME)

10537407.tn




● 3 HCl

RN 501671-12-1 CAPLUS
CN 3-Pyridinemethanamine, N-[(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-{3,4,5-trimethoxyphenyl}-4-pyridinyl)methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501671-23-5 CAPLUS
CN 3-Pyridinemethanamine, N-[(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-{3,4,5-trimethoxyphenyl}-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl


RN 501671-26-7 CAPLUS
CN 3-Pyridinemethanamine, N-[(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-{3,4,5-trimethoxyphenyl}-4-pyridinyl)methyl]-4-piperidinyl]- (CA INDEX NAME)

10537407.tn

INDEX NAME)




RN 501671-41-6 CAPLUS
CN 3-Pyridinemethanamine, N-[(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-{3,4,5-trimethoxyphenyl}-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501671-42-7 CAPLUS
CN 3-Pyridinemethanamine, N-[(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-{3,4,5-trimethoxyphenyl}-4-pyridinyl)methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 501671-57-4 CAPLUS
CN 3-Pyridinemethanamine, N-[(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-{3,4,5-trimethoxyphenyl}-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)

10537407.ttn




● 3 HCl

RN 501671-59-5 CAPLUS
CN 3-Pyridinemethanamine, N-[4-(methylthio)phenyl]-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501671-73-4 CAPLUS
CN 3-Pyridinemethanamine, N-(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl


RN 501671-74-5 CAPLUS
CN 3-Pyridinemethanamine, N-(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]- (CA INDEX NAME)

10537407.ttn

INDEX NAME)




RN 501672-01-1 CAPLUS
CN 3-Pyridinemethanamine, N-(4-bromophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501672-02-2 CAPLUS
CN 3-Pyridinemethanamine, N-(4-bromophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 501672-15-7 CAPLUS
CN 3-Pyridinemethanamine, N-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)

10537407.tzn




● 3 HCl

RN 501672-16-8 CAPLUS
CN 3-Pyridinemethanamine, N-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501672-31-7 CAPLUS
CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl


RN 501672-32-8 CAPLUS
CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]- (CA INDEX NAME)

10537407.tzn

INDEX NAME)




RN 501672-47-5 CAPLUS
CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501672-48-6 CAPLUS
CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501672-59-9 CAPLUS
CN 3-Pyridinemethanamine, N-phenyl-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)


10537407.tzn



● 3 HCl

RN 501672-60-2 CAPLUS

CN 3-Pyridinemethanamine, N-phenyl-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)




10537407.tzn

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

2003:202625 Document No. 138:238016 Preparation of cyclic amine compounds as cell adhesion inhibitors. Kodama, Tatsuhiko; Tamura, Masahiro; Oda, Toshaki; Yamazaki, Yukiyo; Nishikawa, Masahiro; Takemura, Shunji; Doi, Takeshi; Eiyotani, Yoshinori; Ohkuchi, Masao (Kowa Co., Ltd., Japan). PCT Int. Appl. WO 2003/020703 A1 20030315, 291 pp. DESIGNATED STATES: W, AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CU, CR, CY, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, HA, HR, HU, IL, IN, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NC, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AL, BY, BG, BE, BR, RU, TC, TM; RY: RM; AB, BE, BF, BJ, CF, CG, CH, CI, CM, CL, CS, DE, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NI, PT, SE, SN, TD, TG, TR. (Japanese). COHEN: FIDOC2. APPLICATION: WO 2002-78450 20020328. PRIORITY: US 2001-941684 20010830; US 2001-963928 20011026; US 2002-107180 20020328; US 2002-191534 20020710.

GI



I

AB The title comps. I [R1, R2, and R3 each independently represents hydrogen, alkoxy, etc.; W1 and W2 are the same or different and each represents nitrogen or CH; X represents oxygen, NR4, CONR4, or NR4CO; R4 represents hydrogen, alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, etc.; and l, m, and n each is 0 or 1] are prepared. I are useful as antiallergic, antirheumatic, antiasthmatic agents, etc. In an in vitro test for cell adhesion inhibition, comps. of this invention showed IC50 values of 0.04 μM to 0.3 μM. Formulations are given.

II 427886-47-3P 501669-92-7P 501670-79-7P
501670-80-4P 501670-95-7P 501670-96-8P
501671-11-4P 501671-12-1P 501671-25-6P
501671-26-7P 501671-41-6P 501671-42-7P
501671-57-4P 501671-58-5P 501671-73-4P
501671-74-5P 501672-01-1P 501672-02-2P
501672-15-7P 501672-16-8P 501672-31-7P
501672-32-8P 501672-47-5P 501672-48-6P
501672-59-9P 501672-60-2P 501673-37-6P
501673-38-7P 501673-39-8P 501673-40-1P
501673-41-2P 501673-42-3P 501673-43-4P
501673-44-5P 501673-45-6P 501673-46-7P
501673-47-8P


10537407.trn

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cyclic amine compds. as cell adhesion inhibitors)

RN 427886-47-3 CAPLUS


CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 501669-92-7 CAPLUS


CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501670-79-7 CAPLUS

CN 3-Pyridinemethanamine, N-(4-ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)


10537407.trn



● 3 HCl


RN 501670-80-0 CAPLUS

CN 3-Pyridinemethanamine, N-(4-ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501670-95-7 CAPLUS

CN 3-Pyridinemethanamine, N-(4-butoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501670-96-8 CAPLUS

CN 3-Pyridinemethanamine, N-(4-butoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]- (CA INDEX NAME)


10537407.tzn

INDEX NAME)



RN 501671-11-0 CAPLUS


CN 3-Pyridinemethanamine, N-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 501671-12-1 CAPLUS


CN 3-Pyridinemethanamine, N-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



RN 501671-25-6 CAPLUS

CN 3-Pyridinemethanamine, N-(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)


10537407.tzn



● 3 HCl


RN 501671-26-7 CAPLUS

CN 3-Pyridinemethanamine, N-(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



RN 501671-41-6 CAPLUS

CN 3-Pyridinemethanamine, N-[4-(trifluoromethoxy)phenyl]-5-(3,4,5-trimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501671-42-7 CAPLUS

CN 3-Pyridinemethanamine, N-[4-(trifluoromethoxy)phenyl]-5-(3,4,5-trimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)


10537407.tzn

piperidinyl]- (CA INDEX NAME)



RN 501671-57-4 CAPLUS


CN 3-Pyridinemethanamine, N-[4-(methoxythio)phenyl]-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 501671-58-5 CAPLUS


CN 3-Pyridinemethanamine, N-[4-(methoxythio)phenyl]-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501671-73-4 CAPLUS

CN 3-Pyridinemethanamine, N-(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)


10537407.tzn



●3 HCl


RN 501671-74-5 CAPLUS

CN 3-Pyridinemethanamine, N-(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501672-01-1 CAPLUS

CN 3-Pyridinemethanamine, N-(4-bromophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




●3 HCl

RN 501672-02-2 CAPLUS

CN 3-Pyridinemethanamine, N-(4-bromophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)


10537407.tzn

INDEX NAME



RN 501672-15-7 CAPLUS


CN 3-Pyridinemethanamine, N-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 501672-16-8 CAPLUS


CN 3-Pyridinemethanamine, N-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



RN 501672-31-7 CAPLUS

CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)


10537407.tzn



● 3 HCl


RN 501672-32-8 CAPLUS

CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



RN 501672-47-5 CAPLUS

CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501672-48-6 CAPLUS

CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)


10537407.ttn

INDEX NAME



RN 501672-59-9 CAPLUS


CN 3-Pyridinemethanamine, N-phenyl-5-(3,4,5-trimethoxyphenyl)-N-[1-([2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 501672-60-2 CAPLUS


CN 3-Pyridinemethanamine, N-phenyl-5-(3,4,5-trimethoxyphenyl)-N-[1-([2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]- (CA INDEX NAME)



RN 501673-37-6 CAPLUS

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)


10537407.ttn



● 3 HCl


RN 501673-38-7 CAPLUS

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 501673-39-8 CAPLUS

CN 3-Pyridinemethanamine, N-[1-([2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl


RN 501673-40-1 CAPLUS

CN 3-Pyridinemethanamine, N-[1-([2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)

10537407.tzn




RN 501673-41-2 CAPLUS
CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501673-42-3 CAPLUS
CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 501673-43-4 CAPLUS
CN 3-Pyridinemethanamine, N-[1-([2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)

10537407.tzn




● 3 HCl

RN 501673-44-5 CAPLUS
CN 3-Pyridinemethanamine, N-[1-([2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 501673-45-6 CAPLUS
CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 501673-46-7 CAPLUS
CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)

10537407.tzn



RN 501673-47-8 CAPLUS

CN 3-Pyridinemethanamine, N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-([4-(methylthio)phenyl]-5-(3,4,5-trimethoxyphenyl))- (CA INDEX NAME)




10537407.tzn

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

2002:974250 Document No. 138:55868 Preparation of piperidinylmethylpyridines as inhibitors of cell adhesion and cell infiltration.. Kodama, Tatsuhiko; Tamura, Masahiro; Oda, Toshiaki; Yamazaki, Yukioyoshi; Nishikawa, Masahiro; Takemura, Shunji; Doi, Takeshi; Kyotani, Yoshinori; Ohkuchi, Masao (Kowa Co., Ltd., Japan). U.S. US 6498169 B1 20021224, 64 pp., Cont.-in-part of U.S. 6,395,753. (English). CUDEN: USXAM. APPLICATION: US 2001-983928 20011026. PRIORITY: US 2001-941684 20010830.

GI



AB Title compds. [I; R1, R2, R3 = H, alkoxy; W1, W2 = N, CH; X = O, NR4, CONR4, NR4CO; R4 = H, alkyl, aryl, heteroaryl, aralkyl, heteroalkyl; m, n = 0, 1], were prepared Thus, (3S)-3-[N-methyl-N-(2-nitrobenzene)sulfonylamino]pyrrolidine (preparation given) and 4-chloromethyl-2-(3,4,5-trimethoxyphenyl)pyridine (preparation given) were coupled to give (3S)-3-[N-methyl-N-(2-nitrobenzene)sulfonylamino]-1-([2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl)pyrrolidine (II). II inhibited binding of U937 cells to human umbilical venous endothelial cells (HUVEC) cultures with IC50 = 0.03 μM. II drug formulations are given. I have inhibitory effects on both cell adhesion and cell infiltration and are useful as antiasthmatic agents, antiallergic agents, antirheumatic agents, antiarteriosclerotic agents, antiinflammatory agents, anti-Sjogren's syndrome agents or the like.

IT 427886-47-3E, 4-[N-(4-Methoxyphenyl)-N-([5-(3,4,5-trimethoxyphenyl)pyridin-3-yl]methyl)amino]-1-([2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl)piperidine Trihydrochloride 501663-92-7P


RL: PMC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOU (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperidinylmethylpyridines as inhibitors of cell adhesion and cell infiltration)

RN 427886-47-3 CAPLUS

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-([2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)


10537407.tzn



● 3 HCl

RN 501669-92-7 CAPLUS

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]- (CA INDEX NAME)



10537407.tzn

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
2002:403898 Document No. 136:386028 Preparation of 1-[(pyridin-4-yl)methyl]-4-piperidinamines as cell adhesion inhibitors for treatment of inflammatory diseases. Kodama, Tatsuhiko; Tamura, Masahiro; Oda, Toshaki; Yamazaki, Yukiyo; Kishikawa, Masahiro; Takemura, Shunji; Doi, Takeshi; Kyotani, Yoshinori; Ohkuchi, Masao (Kowa Co., Ltd., Japan). U.S. 6395753 B1 20020528, 40 pp. (English). CODEN: USKXAM. APPLICATION: US 2001-941684 20010830.

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [wherein, R1, R2, and R3 = independently H, halo, GE, (halo)alkyl, alkoxy, alkylthio, carboxy, alkoxy-carboxyl, or alkanyl; W1 and W2 = independently N or CH; X = O, NR4, COR4, or NR4O; R4 = independently H, alkyl, alkenyl, alkynyl, or (un)substituted (hetero)aryl or (hetero)alkyl; and m, n, and p = independently 0 or 1; or salts or hydrates thereof] were prepared as cell adhesion and cell infiltration inhibitors. For example, 1-[(2-(3,4,5-trimethoxyphenyl)pyridin-4-yl)methyl]-4-piperidone (preparation given) was reacted with p-anisidine in toluene and the resulting oil treated with NaBH4 and EtOH to give the piperidinamine (55%). N-alkylation with 3-chloromethyl-5-(3,4,5-trimethoxyphenyl)pyridine (preparation given) in the presence of Et3N and KI in AcCN, followed by conversion to the salt, afforded II●3HCl (54). The latter inhibited U937 cell adhesion in TNF-α stimulated human umbilical venous endothelial cells with IC50 of 0.03 μM. Capsule, tablet, and injection formulations containing II are provided. I are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents, and the like (no data).

IT (27886-47-3P, 4-[N-(4-Methoxyphenyl)-N-[(5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)methyl]amino]-1-[(2-(3,4,5-trimethoxyphenyl)pyridin-4-yl)methyl]piperidine trihydrochloride
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOU (Biological study); PREP (Preparation); USES (Uses)
(cell adhesion inhibitor; preparation of (pyridinylmethyl)piperidinamines as cell adhesion inhibitors for treatment of inflammatory diseases)

RN 427886-47-3 CAPLUS

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[(2-(3,4,5-trimethoxyphenyl)-4-pyridinyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)

10537407.tzn



● 3 HCl

10537407.tzn

=> file uspatfull

FILE 'USPATFULL' ENTERED AT 11:39:15 ON 23 AUG 2008

CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 21 Aug 2008 (20080821/PD)

FILE LAST UPDATED: 21 Aug 2008 (20080821/ED)

HIGHEST GRANTED PATENT NUMBER: US7415732

HIGHEST APPLICATION PUBLICATION NUMBER: US20080201812

CA INDEXING IS CURRENT THROUGH 21 Aug 2008 (20080821/UPCA)

ISSUE CLASS FIELDS (/I/NCI) CURRENT THROUGH: 21 Aug 2008 (20080821/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2008

USPRO MANUAL OF CLASSIFICATIONS THESANVRUS ISSUE DATE: Jun 2008

USPATFULL now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

=> s 13

15

8 13

=> d chlb abs hitstr 1-

YOU HAVE REQUESTED DATA FROM 8 ANSWERS - CONTINUE? Y/(N):y

10537407.ttn

15 ANSWER 1 OF 8 USPTFULL ON STM

2007:49252 Angiogenesis inhibitor.

Doi, Takeshi, Higashiyama-shi, JAPAN

Tamura, Masahiro, Machida-shi, JAPAN

Kowa Co., Ltd., Wagoya-shi, JAPAN (non-U.S. corporation)

US 20070043078 A1 20070222

APPLICATION: US 2004-574972 A1 20041008 (10)

NO 2004-WP14956 20041008 20060407 FCT 371 date

PRIORITY: US 2003-51012P 20031010 (60)

DOCUMENT TYPE: Utility; APPLICATION

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a prophylactic or therapeutic agent against a disease or pathological condition caused by angiogenesis, comprising, as an active ingredient, a cyclic amine compound represented by the general formula (1): #6STR1#

wherein R.sup.1, R.sup.2, and R.sup.3 each independently represent a hydrogen atom, a halogen atom, a hydroxy group, an alkyl group, a halogen-substituted alkyl group, an alkoxy group, an alkythio group, a carbonyl group, an alkoxy carbonyl group, or an alkanyl group; W.sup.1 and W.sup.2 each independently represent N or CH; X represents O, NR.sup.4, CONR.sup.4, or NR.sup.4CO; R.sup.4 represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted heteroaralkyl group; and l, m, and n each represent a number of 0 or 1, or a salt thereof, or a solvate thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 850213-84-2P

(methoxyphenylpyridinylaminopiperidine derivs. as angiogenesis inhibitors for treatment of neovascularization-related diseases)


RN 850213-84-2 USPTFULL

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (CA INDEX NAME)

CN 1

CRN 501659-92-7

CMP C42 H48 N4 O7




CN 2

CRN 77-92-9

CMP C6 H8 O7

10537407.ttn




IT 501669-92-7

(methoxyphenylpyridinylaminopiperidine derivs. as angiogenesis inhibitors for treatment of neovascularization-related diseases)

RN 501669-92-7 USPTFULL

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)




IT 427886-47-3

(methoxyphenylpyridinylaminopiperidine derivs. as angiogenesis inhibitors for treatment of neovascularization-related diseases)

RN 427886-47-3 USPTFULL

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

10537407.tzn

15 ANSWER 2 OF 8 USPATFULL on STM

2006:47512 Erythropoietin production accelerator.

Imagawa, Shigehiko, Tsukuba-Shi, JAPAN

DoI, Takeshi, Tokyo, JAPAN

Tamura, Masahiro, Tokyo, JAPAN

Ohkuchi, Masao, Tokorozawa-shi, JAPAN

Kowa Co., Ltd., Aichi, JAPAN (non-U.S. corporation)

US 2006/0041986 A1 20060223

APPLICATION: US 2003-537407 A1 20031205 (10)

NO 2003-JP15589 20031205 20050602 FCT 371 date

PRIORITY: US 2002-431234P 20021206 (60)

DOCUMENT TYPE: Utility APPLICATION.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a preventive or therapeutic agent for pathological conditions caused by reduced production of erythropoietin, or for anemia, or for chronic anemia, renal anemia, aplastic anemia, or pure red cell aplasia, the agent comprising, as an active ingredient, a cyclic amine compound represented by the following formula (1):
#STR1# wherein,

R.sup.1, R.sup.2 and R.sup.3 each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxy-carbonyl or alkanoyl group;

N.sup.1 and N.sup.2 each independently represent N or CH;

X represents O, NR.sup.4, CONR.sup.4 or NR.sup.4CO;

R.sup.4 each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

II 427886-47-3P 501669-92-7P 501670-79-7P

501670-80-0P 501670-95-7P 501670-96-8P

501671-11-0P 501671-12-1P 501671-41-6P

501671-42-7P 501671-57-4P 501671-58-5P

501671-73-4P 501671-74-5P 501672-01-1P

501672-02-2P 501672-16-8P 501672-31-7P

501672-32-8P 501672-47-5P 501672-48-6P

501672-59-9P 501672-60-2P 501673-37-6P

501673-38-7P 501673-39-8P 501673-40-1P

501673-41-2P 501673-42-3P 501673-43-4P

501673-44-5P 501673-45-6P 501673-46-7P


501673-47-8P 709669-59-0P

(preparation of heterocyclic compds. as erythropoietin production accelerators)

RN 427886-47-3 USPATFULL

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)


10537407.tzn



● 3 HCL


RN 501669-92-7 USPATFULL

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501670-79-7 USPATFULL

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCL

RN 501670-80-0 USPATFULL

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)


10537407.tzn

INDEX NAME)



RN 501670-95-7 USPATFULL


CN 3-Pyridinemethanamine, N-(4-butoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 501670-96-8 USPATFULL


CN 3-Pyridinemethanamine, N-(4-butoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501671-11-0 USPATFULL

CN 3-Pyridinemethanamine, N-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)


10537407.tzn



●3 HCl


RN 501671-12-1 USPATFULL

CN 3-Pyridinemethanamine, N-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501671-41-6 USPATFULL

CN 3-Pyridinemethanamine, N-[4-(trifluoromethoxy)phenyl]-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




●3 HCl

RN 501671-42-7 USPATFULL

CN 3-Pyridinemethanamine, N-[4-(trifluoromethoxy)phenyl]-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)


10537407.tzn

4-piperidinyl]- (CA INDEX NAME)



RN 501671-57-4 USPATFULL


CN 3-Pyridinemethanamine, N-[4-(methylthio)phenyl]-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 501671-58-5 USPATFULL


CN 3-Pyridinemethanamine, N-[4-(methylthio)phenyl]-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



RN 501671-73-4 USPATFULL

CN 3-Pyridinemethanamine, N-(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)


10537407.tzn



● 3 HCl


RN 501671-74-5 USPATFULL

CN 3-Pyridinemethanamine, N-(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



RN 501672-01-1 USPATFULL

CN 3-Pyridinemethanamine, N-(4-bromophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501672-02-2 USPATFULL


CN 3-Pyridinemethanamine, N-(4-bromophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)

10537407.tzn


INDEX NAME)



RN 501672-16-8 USPATFULL
CN 3-Pyridinemethanamine, N-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 501672-31-7 USPATFULL
CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501672-32-8 USPATFULL
CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)

10537407.tzn




RN 501672-47-5 USPATFULL
CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501672-48-6 USPATFULL
CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501672-59-9 USPATFULL
CN 3-Pyridinemethanamine, N-phenyl-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)


10537407.tzn



● 3 HCl


RN 501672-60-2 USPATFULL

CN 3-Pyridinemethanamine, N-phenyl-5-(3,4,5-trimethoxyphenyl)-N-[1-([2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]- (CA INDEX NAME)



RN 501673-37-6 USPATFULL

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501673-38-7 USPATFULL


CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)

10537407.tzn



RN 501673-39-8 USPATFULL


CN 3-Pyridinemethanamine, N-[1-([2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 501673-40-1 USPATFULL


CN 3-Pyridinemethanamine, N-[1-([2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 501673-41-2 USPATFULL


CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)

10537407.ttn




● 3 HCl

RN 501673-42-3 USPATFULL
CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 501673-43-4 USPATFULL
CN 3-Pyridinemethanamine, N-[1-([2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501673-44-5 USPATFULL
CN 3-Pyridinemethanamine, N-[1-([2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)

10537407.ttn




RN 501673-45-6 USPATFULL
CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501673-46-7 USPATFULL
CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 501673-47-8 USPATFULL
CN 3-Pyridinemethanamine, N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-[4-(methylthio)phenyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)

10537407.tzn



RN 709669-59-0 USPATFULL

CN 3-Pyridinemethanamine, N-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

10537407.tzn

L5 ANSWER 3 OF 8 USPATFULL on SIN

2005:203339 Medicine for treating cancer.

Mateki, Chikage, Yokohama-shi Kanagawa, JAPAN

Kodama, Tatsuhiko, Tokyo, JAPAN

Doi, Takeshi, Tokyo, JAPAN

Tamura, Masahiro, Tokyo, JAPAN

Oga, Toshiaki, Tokyo, JAPAN

Yamazaki, Takiyoshi, Tokyo, JAPAN

Nishikawa, Masahiro, Tokyo, JAPAN

Takemura, Shunji, Tokyo, JAPAN

Ohkuchi, Masao, Saitama, JAPAN

KOWA CO., LTD, Aichi, JAPAN, 460-8625 (non-U.S. corporation)

US 20050176744 A1 20050811

APPLICATION: US 2003-510759 AL 20030411 (10)

WO 2003-IP4402 20030411

PRIORITY: US 2002-371675P 20020412 (60)

US 2003-412571P 20020923 (60)

DOCUMENT TYPE: Utility; APPLICATION.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ABSTRACT The present invention is directed to a method for treating cancer, a method for inhibiting histone deacetylase, and a method for facilitating gene therapy, comprising administering an effective amount of a cyclic amine compound represented by the following formula (1): (wherein R1, R2, and R3 each independently represent a hydrogen atom, a halogen atom, a hydroxy group, an alkyl group, a halogen-substituted alkyl group, an alkoxy group, an alkylthio group, a carboxyl group, an alkoxy carbonyl group, or an alkanyl group; W1 and W2, which are identical to or different from each other, represent N or CH; X represents O, NR4, CONR4, or NR4CO; R4 represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted alkaryl group, or a substituted or unsubstituted heteroalkaryl group; and l, m, and n each represent a number of 0 or 1), a salt thereof, or a hydrate thereof.208 ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 427886-47-3P 501669-92-7P 501670-73-7P

501670-80-0P 501670-95-7P 501670-96-8P

501671-11-0P 501671-12-1P 501671-25-6P

501671-26-7P 501671-41-6P 501671-42-7P

501671-57-4P 501671-58-5P 501671-73-4P

501671-74-3P 501672-01-1P 501672-02-2P

501672-15-7P 501672-16-8P 501672-31-7P

501672-32-8P 501672-47-5P 501672-48-6P

501672-59-9P 501672-60-2P 501673-37-6P

501673-38-7P 501673-39-8P 501673-40-1P

501673-41-2P 501673-42-3P 501673-43-4P

501673-44-5P 501673-45-6P 501673-46-7P

501673-47-8P


(preparation of pyridylmethyl substituted piperidin-4-amines as HDAC

inhibitors for treating cancer)

RN 427886-47-3 USPATFULL


CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)

10537407.ttn




● 3 HCl

RN 501669-92-7 USPATFULL
CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501670-79-7 USPATFULL
CN 3-Pyridinemethanamine, N-(4-ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl


RN 501670-80-0 USPATFULL
CN 3-Pyridinemethanamine, N-(4-ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]- (CA INDEX NAME)

10537407.ttn

INDEX NAME)




RN 501670-95-7 USPATFULL
CN 3-Pyridinemethanamine, N-(4-butoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501670-96-8 USPATFULL
CN 3-Pyridinemethanamine, N-(4-butoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]- (CA INDEX NAME)




RN 501671-11-0 USPATFULL
CN 3-Pyridinemethanamine, N-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)

10537407.tzn




● 3 HCl

RN 501671-12-1 USPATFULL
CN 3-Pyridinemethanamine, N-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA
INDEX NAME)



RN 501671-25-6 USPATFULL
CN 3-Pyridinemethanamine, N-(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl


RN 501671-26-7 USPATFULL
CN 3-Pyridinemethanamine, N-(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA

10537407.tzn

INDEX NAME)




RN 501671-41-6 USPATFULL
CN 3-Pyridinemethanamine, N-[4-(trifluoromethoxy)phenyl]-5-(3,4,5-
trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501671-42-7 USPATFULL
CN 3-Pyridinemethanamine, N-[4-(trifluoromethoxy)phenyl]-5-(3,4,5-
trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
4-piperidinyl]- (CA INDEX NAME)




RN 501671-57-4 USPATFULL
CN 3-Pyridinemethanamine, N-[4-(methylthio)phenyl]-5-(3,4,5-trimethoxyphenyl)-
N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
hydrochloride (1:3) (CA INDEX NAME)

10537407.tzn




● 3 HCl

RN 501671-59-5 USPATFULL
CN 3-Pyridinemethanamine, N-([4-(methylthio)phenyl]-5-(3,4,5-trimethoxyphenyl)-
N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-
(CA INDEX NAME)



RN 501671-73-4 USPATFULL
CN 3-Pyridinemethanamine, N-(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-,
hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl


RN 501671-74-5 USPATFULL
CN 3-Pyridinemethanamine, N-(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]- (CA

10537407.tzn

INDEX NAME)




RN 501672-01-1 USPATFULL
CN 3-Pyridinemethanamine, N-(4-bromophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-,
hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501672-02-2 USPATFULL
CN 3-Pyridinemethanamine, N-(4-bromophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]- (CA
INDEX NAME)




RN 501672-15-7 USPATFULL
CN 3-Pyridinemethanamine, N-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinylmethyl]-4-piperidinyl]-,
hydrochloride (1:3) (CA INDEX NAME)

10537407.tzn




● 3 HCl

RN 501672-16-8 USPATFULL
CN 3-Pyridinemethanamine, N-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501672-31-7 USPATFULL
CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl


RN 501672-32-8 USPATFULL
CN 3-Pyridinemethanamine, N-(4-difluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)

10537407.tzn

INDEX NAME)




RN 501672-47-5 USPATFULL
CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501672-48-6 USPATFULL
CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501672-59-9 USPATFULL
CN 3-Pyridinemethanamine, N-phenyl-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)


10537407.tzn



● 3 HCl


RN 501672-60-2 USPATFULL

CN 3-Pyridinemethanamine, N-phenyl-5-(3,4,5-trimethoxyphenyl)-N-[1-([2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]- (CA INDEX NAME)



RN 501673-37-6 USPATFULL

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501673-38-7 USPATFULL


CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)

10537407.tzn



RN 501673-39-8 USPATFULL


CN 3-Pyridinemethanamine, N-[1-([2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 501673-40-1 USPATFULL


CN 3-Pyridinemethanamine, N-[1-([2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 501673-41-2 USPATFULL


CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)

10537407.ttn




● 3 HCl

RN 501673-42-3 USPATFULL
CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 501673-43-4 USPATFULL
CN 3-Pyridinemethanamine, N-[1-([2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501673-44-5 USPATFULL
CN 3-Pyridinemethanamine, N-[1-([2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)

10537407.ttn




RN 501673-45-6 USPATFULL
CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501673-46-7 USPATFULL
CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 501673-47-8 USPATFULL
CN 3-Pyridinemethanamine, N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-[4-(methylthio)phenyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)

10537407.tnn



10537407.tnn

15 ANSWER 4 OF 8 USPTAFULL on SIN

2004:13624 Cyclic amine compounds and pharmaceutical composition containing the same.

Kodama, Tatsuhiko, Tokyo, JAPAN
 Tamura, Masahiro, Tokyo, JAPAN
 Oda, Toshiaki, Tokyo, JAPAN
 Yamazaki, Takiyoshi, Tokyo, JAPAN
 Nishikawa, Masahiro, Tokyo, JAPAN
 Takemura, Shunji, Tokyo, JAPAN
 Doi, Takeshi, Tokyo, JAPAN
 Kyotani, Yoshinori, Tokyo, JAPAN
 Okuchi, Masao, Tokorozawa-shi, JAPAN
 KOWA CO., LTD., Nagoya-shi, JAPAN (non-U.S. corporation)
 US 2004/001417 A1 2004/0115
 APPLICATION: US 2002-191534 A1 2002/0710 (10)
 DOCUMENT TYPE: Utility APPLICATION

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AE A cyclic amine compound represented by the following general formula
 (1): ##STR1##

wherein,

R.sub.1, R.sub.2 and R.sub.3 each independently represent a hydrogen atom or an alkoxy group;

W.sub.1 and W.sub.2 each independently represent N or CH;

X represents O, NR.sub.4, CONR.sub.4 or NR.sub.4CO;

R.sub.4 represents a hydrogen atom, or an alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; and

l, m and n each represents a number of 0 or 1,

a salt thereof and a hydrate thereof are provided.

These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 427886-47-3P 501669-92-7P 501670-79-7P

501670-80-0P 501670-95-7P 501670-96-8P

501671-11-0P 501671-12-1P 501671-25-6P

501671-26-7P 501671-41-6P 501671-42-7P

501671-57-0P 501671-58-5P 501671-73-4P

501671-74-8P 501672-01-1P 501672-02-2P

501672-15-7P 501672-16-8P 501672-31-7P

501672-32-8P 501672-47-5P 501672-48-6P

501672-59-9P 501672-60-2P 501673-37-6P

501673-38-7P 501673-39-8P 501673-40-1P

501673-41-2P 501673-42-3P 501673-43-4P

501673-44-5P 501673-45-6P 501673-46-7P


501673-47-8P

(preparation of cyclic amines as cell adhesion and infiltration inhibitors)

RM 427886-47-3 USPTAFULL


CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)

10537407.tzn




● 3 HCl

RN 501669-92-7 USPATFULL
CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501670-79-7 USPATFULL
CN 3-Pyridinemethanamine, N-(4-ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl


RN 501670-80-0 USPATFULL
CN 3-Pyridinemethanamine, N-(4-ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-

10537407.tzn

[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 501670-95-7 USPATFULL
CN 3-Pyridinemethanamine, N-(4-butoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501670-96-8 USPATFULL
CN 3-Pyridinemethanamine, N-(4-butoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 501671-11-0 USPATFULL
CN 3-Pyridinemethanamine, N-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)

10537407.trn




● 3 HCl

RN 501671-12-1 USPATFULL
CN 3-Pyridinemethanamine, N-[(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501671-25-6 USPATFULL
CN 3-Pyridinemethanamine, N-[(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl


RN 501671-26-7 USPATFULL
CN 3-Pyridinemethanamine, N-[(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-

10537407.trn

[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 501671-41-6 USPATFULL
CN 3-Pyridinemethanamine, N-[(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501671-42-7 USPATFULL
CN 3-Pyridinemethanamine, N-[(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 501671-57-4 USPATFULL
CN 3-Pyridinemethanamine, N-[(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)

10537407.tzn




● 3 HCl

RN 501671-58-5 USPATFULL
CN 3-Pyridinemethanamine, N-[(4-methylthio)phenyl]-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



RN 501671-73-4 USPATFULL
CN 3-Pyridinemethanamine, N-(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl


RN 501671-74-5 USPATFULL
CN 3-Pyridinemethanamine, N-(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-

10537407.tzn

[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 501672-01-1 USPATFULL
CN 3-Pyridinemethanamine, N-(4-bromophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501672-02-2 USPATFULL
CN 3-Pyridinemethanamine, N-(4-bromophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 501672-15-7 USPATFULL
CN 3-Pyridinemethanamine, N-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)

10537407.tnn




● 3 HCl

RN 501672-16-8 USPATFULL
CN 3-Pyridinemethanamine, N-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 501672-11-7 USPATFULL
CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● 3 HCl


RN 501672-32-8 USPATFULL
CN 3-Pyridinemethanamine, N-(3,4,5-trimethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:1) (CA INDEX NAME)

10537407.tnn

[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 501672-47-5 USPATFULL
CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● 3 HCl

RN 501672-48-6 USPATFULL
CN 3-Pyridinemethanamine, N-(3,4,5-trimethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




RN 501672-59-9 USPATFULL
CN 3-Pyridinemethanamine, N-phenyl-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:1) (CA INDEX NAME)

10537407.tzn




● 3 HCl

RN 501672-60-2 USPATFULL
CN 3-Pyridinemethanamine, N-phenyl-5-(3,4,5-trimethoxyphenyl)-N-[1-([2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]- (CA INDEX NAME)



RN 501673-37-6 USPATFULL
CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl


RN 501673-38-7 USPATFULL
CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)

10537407.tzn

NAME)




RN 501673-39-8 USPATFULL
CN 3-Pyridinemethanamine, N-[1-([2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501673-40-1 USPATFULL
CN 3-Pyridinemethanamine, N-[1-([2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 501673-41-2 USPATFULL
CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-N-[1-([2-(3-methoxyphenyl)-4-pyridinyl]methyl)-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)

10537407.ttn




● 3 HCl

RN 501673-42-3 USPATFULL
CN 3-Pyridinemethanamine, N-[1-[[2-(3-methoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 501673-43-4 USPATFULL
CN 3-Pyridinemethanamine, N-[1-[[2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl


RN 501673-44-5 USPATFULL
CN 3-Pyridinemethanamine, N-[1-[[2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)

10537407.ttn

(NAME)




RN 501673-45-6 USPATFULL
CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-N-[1-[[2-(3-methoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501673-46-7 USPATFULL
CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-N-[1-[[2-(3-methoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 501673-47-8 USPATFULL
CN 3-Pyridinemethanamine, N-[1-[[2-(3-methoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-N-(4-methylthio)phenyl)-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)

10537407.tzn



10537407.tzn

15 ANSWER 5 OF 8 USPATFULL on STN

2003:216182 Cyclic amine compounds and pharmaceutical composition containing the same.

Kodama, Tatsuhiko, Tokyo, JAPAN
 Tamura, Masahiro, Tokyo, JAPAN
 Oga, Toshiaki, Tokyo, JAPAN
 Yamazaki, Takiyoshi, Tokyo, JAPAN
 Nishikawa, Masahiro, Tokyo, JAPAN
 Takemura, Shunji, Tokyo, JAPAN
 Doi, Takeshi, Tokyo, JAPAN
 Kyotani, Yoshinori, Tokyo, JAPAN
 Ohkuchi, Masao, Tokyo, JAPAN
 Kowa Co., Ltd., Tokyo, JAPAN (non-U.S. corporation)
 US 4605420 B1 20030812
 APPLICATION: US 2002-107190 20020328 (10)
 DOCUMENT TYPE: Utility; GRANTED.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A cyclic amine compound by the following general formula (1): ##STR1##

wherein,

R.sup.1, R.sup.2 and R.sup.3 each independently represent a hydrogen atom or an alkoxy group

W.sup.1 and W.sup.2 each independently represent N or CH₂

X represents O, NR.sup.4, CONR.sup.4 or NR.sup.4CO;

R.sup.4 represents a hydrogen atom, or an alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; and

l, m and n each represents a number of 0 or 1, a salt thereof and a hydrate thereof are provided. These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 427886-47-3P 501669-92-7P 501670-73-7P

501670-80-0P 501670-95-7P 501670-96-8P

501671-11-0P 501671-12-1P 501671-25-6P

501671-26-7P 501671-41-6P 501671-42-7P

501671-57-4P 501671-58-5P 501671-73-4P

501671-74-3P 501672-01-1P 501672-02-2P

501672-15-7P 501672-16-8P 501672-31-7P

501672-32-8P 501672-47-5P 501672-48-6P


501672-59-9P 501672-60-2P

(cell adhesion and infiltration inhibitor; preparation of cyclic amines as cell adhesion and infiltration inhibitors via condensation)

BN 427886-47-3 USPATFULL


CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)

10537407.tnn




● 3 HCl

RN 501669-92-7 USPATFULL
CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501670-79-7 USPATFULL
CN 3-Pyridinemethanamine, N-(4-ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl


RN 501670-80-0 USPATFULL
CN 3-Pyridinemethanamine, N-(4-ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)

10537407.tnn

INDEX NAME)




RN 501670-95-7 USPATFULL
CN 3-Pyridinemethanamine, N-(4-butoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501670-96-8 USPATFULL
CN 3-Pyridinemethanamine, N-(4-butoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 501671-11-0 USPATFULL
CN 3-Pyridinemethanamine, N-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)

10537407.tzn




● 3 HCl

RN 501671-12-1 USPATFULL
CN 3-Pyridinemethanamine, N-(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501671-25-6 USPATFULL
CN 3-Pyridinemethanamine, N-(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl


RN 501671-26-7 USPATFULL
CN 3-Pyridinemethanamine, N-(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)

10537407.tzn

INDEX NAME)




RN 501671-41-6 USPATFULL
CN 3-Pyridinemethanamine, N-[4-(trifluoromethoxy)phenyl]-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501671-42-7 USPATFULL
CN 3-Pyridinemethanamine, N-[4-(trifluoromethoxy)phenyl]-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 501671-57-4 USPATFULL
CN 3-Pyridinemethanamine, N-[4-(methylthio)phenyl]-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)

10537407.tzn




● 3 HCl

RN 501671-59-5 USPATFULL
CN 3-Pyridinemethanamine, N-([4-(methylthio)phenyl]-5-(3,4,5-trimethoxyphenyl)-
N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-
(CA INDEX NAME)



RN 501671-73-4 USPATFULL
CN 3-Pyridinemethanamine, N-(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl


RN 501671-74-5 USPATFULL
CN 3-Pyridinemethanamine, N-(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA

10537407.tzn

INDEX NAME)




RN 501672-01-1 USPATFULL
CN 3-Pyridinemethanamine, N-(4-bromophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501672-02-2 USPATFULL
CN 3-Pyridinemethanamine, N-(4-bromophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA
INDEX NAME)




RN 501672-15-7 USPATFULL
CN 3-Pyridinemethanamine, N-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
hydrochloride (1:3) (CA INDEX NAME)

10537407.tzn




● 3 HCl

RN 501672-16-8 USPATFULL
CN 3-Pyridinemethanamine, N-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501672-31-7 USPATFULL
CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl


RN 501672-32-8 USPATFULL
CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)

10537407.tzn

INDEX NAME)




RN 501672-47-5 USPATFULL
CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 501672-48-6 USPATFULL
CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501672-59-9 USPATFULL
CN 3-Pyridinemethanamine, N-phenyl-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)


10537407.tzn



● 3 HCl

RN 501672-60-2 USPATFULL

CN 3-Pyridinemethanamine, N-phenyl-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



10537407.tzn

15 ANSWER 6 OF 8 USPATFULL on SIN

2002:340330 Cyclic amine compounds and pharmaceutical composition containing the same.

Kodama, Tatsuhiko, Tokyo, JAPAN
 Tamura, Masahiro, Higashimurayama, JAPAN
 Oda, Toshitaki, Higashimurayama, JAPAN
 Yamazaki, Takiyoshi, Higashimurayama, JAPAN
 Nishikawa, Masahiro, Higashimurayama, JAPAN
 Takemura, Shunji, Bachiyoji, JAPAN
 Doi, Takeshi, Higashimurayama, JAPAN
 Kyotani, Yoshinori, Higashiyama, JAPAN
 Ohkuchi, Masao, Tokorozawa, JAPAN
 Kowa Co., Ltd., Nagoya, JAPAN (non-U.S. corporation)
 US 6498169 B1 20021224
 APPLICATION: US 2001-983928 20011026 (3)
 DOCUMENT TYPE: Utility; GRANTED.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AE A cyclic amine compound represented by the following general formula (I): ##STR1##

wherein,

R.sup.1, R.sup.2 and R.sup.3 each independently represent a hydrogen atom or an alkoxy group;

W.sup.1 and W.sup.2 each independently represent N or CH;

X represents O, NR.sup.4, CONR.sup.4 or NR.sup.4CO;

R.sup.4 each independently represents a hydrogen atom, or an alkyl, aryl, heteroaryl, aralkyl, or heteroalkyl group; and

l, m and n each represents a number of 0 to 1, a salt thereof and a hydrate thereof are provided.

These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 427886-47-3E, 4-[N-(4-Methoxyphenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridin-3-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl]piperidine Trihydrochloride (preparation of piperidinylmethylpyridines as inhibitors of cell adhesion and cell infiltration)

RN 427886-47-3 USPATFULL

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)

10537407.tzn



●3 HCl

10537407.tzn

15 ANSWER 7 OF 8 USPATFULL ON SIN

2002:252223 Adaptive electronic control suspension system and a control method of the system.

Kim, Nak-Hwan, Koyang-shi, KOREA, REPUBLIC OF

US 20020138186 A1 20020926

APPLICATION: US 2002-107108 A1 20020328 (10)

PRIORITY: KR 1997-77574 19971230

DOCUMENT TYPE: Utility; APPLICATION.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB According to the controller for an adaptive electronic suspension system and the control method of the system, it becomes possible to improve the driving performance and steering stability by controlling the damping force of the variable damper considering vehicle speed, steering angle, opening amount of throttle valve, up/down acceleration, brake operation, axle acceleration etc., wherein the controller for an adaptive electronic suspension system includes a vehicle speed sensor, a steering angle sensor, a throttle position sensor, an up/down acceleration sensor, a brake switch, an axle acceleration sensor and an electronic controller for controlling to convert damping force of dampers of four wheels into "hard mode", "medium mode" and "soft mode" by checking up driving state of the vehicle according to detecting signals output from the sensors and driving front and rear actuators to change passages by rotation of control rods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 427886-47-3P 501669-92-7P 501670-79-7P

501670-80-4P 501670-95-7P 501670-96-8P

501671-11-4P 501671-12-1P 501671-25-6P

501671-26-7P 501671-41-4P 501671-42-7P

501671-57-4P 501671-58-5P 501671-73-4P

501671-74-5P 501672-01-1P 501672-02-2P

501672-15-7P 501672-16-8P 501672-31-7P

501672-32-8P 501672-47-5P 501672-48-6P

501672-59-9P 501672-60-2P 501673-37-6P

501673-38-7P 501673-39-8P 501673-40-1P

501673-41-2P 501673-42-3P 501673-43-4P


501673-44-5P 501673-45-6P 501673-46-7P

501673-47-8P

(preparation of cyclic amines as cell adhesion and infiltration inhibitors)

RN 427886-47-3 USPATFULL

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




●3 HCl

10537407.tzn


RN 501669-92-7 USPATFULL

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA
INDEX NAME)



RN 501670-79-7 USPATFULL


CN 3-Pyridinemethanamine, N-(4-ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 501670-83-0 USPATFULL


CN 3-Pyridinemethanamine, N-(4-ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA
INDEX NAME)



RN 501670-95-7 USPATFULL

10537407.tzn


CN 3-Pyridinemethanamine, N-(4-butoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 501670-96-8 USPATFULL

CN 3-Pyridinemethanamine, N-(4-butoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA
INDEX NAME)



RN 501671-11-0 USPATFULL

CN 3-Pyridinemethanamine, N-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

10537407.tzn


RN 501671-12-1 USPATFULL

CN 3-Pyridinemethanamine, N-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA
INDEX NAME)



RN 501671-25-6 USPATFULL


CN 3-Pyridinemethanamine, N-(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 501671-26-7 USPATFULL


CN 3-Pyridinemethanamine, N-(2-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-
[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA
INDEX NAME)



RN 501671-41-6 USPATFULL

10537407.tzn


CN 3-Pyridinemethanamine, N-[4-(trifluoromethoxyphenyl)-5-(3,4,5-
trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 501671-42-7 USPATFULL

CN 3-Pyridinemethanamine, N-[4-(trifluoromethoxyphenyl)-5-(3,4,5-
trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-
4-piperidinyl]- (CA INDEX NAME)



RN 501671-57-4 USPATFULL

CN 3-Pyridinemethanamine, N-[4-(methylthio)phenyl]-5-(3,4,5-trimethoxyphenyl)-
N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-,
hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

10537407.tzn


RN 501671-58-5 USPATFULL

CN 3-Pyridinemethanamine, N-[4-(methylthio)phenyl]-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501671-73-4 USPATFULL


CN 3-Pyridinemethanamine, N-(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 501671-74-5 USPATFULL


CN 3-Pyridinemethanamine, N-(4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501672-01-1 USPATFULL

10537407.tzn


CN 3-Pyridinemethanamine, N-(4-bromophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 501672-02-2 USPATFULL

CN 3-Pyridinemethanamine, N-(4-bromophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501672-15-7 USPATFULL

CN 3-Pyridinemethanamine, N-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

10537407.trn


RN 501672-16-8 USPATFULL

CN 3-Pyridinemethanamine, N-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501672-31-7 USPATFULL


CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 501672-32-8 USPATFULL


CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501672-47-5 USPATFULL

10537407.trn


CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 501672-48-6 USPATFULL

CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501672-59-9 USPATFULL

CN 3-Pyridinemethanamine, N-phenyl-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

10537407.ttn


RN 501672-60-2 USPATFULL

CN 3-Pyridinemethanamine, N-phenyl-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 501673-37-6 USPATFULL


CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-N-[1-[[2-(3-methoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 501673-38-7 USPATFULL

CN 3-Pyridinemethanamine, N-(4-methoxyphenyl)-N-[1-[[2-(3-methoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 501673-39-8 USPATFULL

CN 3-Pyridinemethanamine, N-[1-[[2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl]-

10537407.ttn


4-piperidinyl]-N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 501673-40-1 USPATFULL

CN 3-Pyridinemethanamine, N-[1-[[2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 501673-41-2 USPATFULL

CN 3-Pyridinemethanamine, N-(4-fluorophenyl)-N-[1-[[2-(3-methoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

10537407.tzn


RN 501673-42-3 USPATFULL

CN 3-Pyridinemethanamine, N-[1-[[2-(3-methoxyphenyl)-4-pyridinyl]methyl]-4-fluorophenyl]-N-[1-[[2-(3-methoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 501673-43-4 USPATFULL


CN 3-Pyridinemethanamine, N-[1-[[2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 501673-44-5 USPATFULL

CN 3-Pyridinemethanamine, N-[1-[[2-(3,4-dimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-N-(4-fluorophenyl)-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 501673-45-6 USPATFULL

CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-N-[1-[[2-(3-methoxyphenyl)-4-

10537407.tzn


pyridinyl]methyl]-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 501673-46-7 USPATFULL

CN 3-Pyridinemethanamine, N-(3,4-difluorophenyl)-N-[1-[[2-(3-methoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 501673-47-8 USPATFULL

CN 3-Pyridinemethanamine, N-[1-[[2-(3-methoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-N-[4-(methylthio)phenyl]-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



10537407.tzn

15 ANSWER 8 OF 8 USPATFULL on STM

2002:122651: Cyclic amine compounds and pharmaceutical composition containing the same.

Kodama, Tatsuhiko, Tokyo, JAPAN
Tamura, Masahiro, Higashimurayama, JAPAN
Oga, Toshiaki, Higashimurayama, JAPAN
Yamazaki, Takiyoshi, Higashimurayama, JAPAN
Nishikawa, Masahiro, Higashimurayama, JAPAN
Takemura, Shunji, Hachioji, JAPAN
Doi, Takeshi, Higashimurayama, JAPAN
Kyotani, Yoshinori, Higashimurayama, JAPAN
Ohkuchi, Masao, Tokorozawa, JAPAN
Kowa Co., Ltd., Nagoya, JAPAN (non-U.S. corporation)
US 6395753 B1 20020323
APPLICATION NO: US 2001-941694 20010930 (9)
DOCUMENT TYPE: Utility; GRANTED.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A cyclic amine compound represented by the following general formula
(1): ##STR1##

wherein,

R.sup.1, R.sup.2 and R.sup.3 each independently represent a hydrogen atom or an alkoxy group;

W.sup.1 and W.sup.2 each independently represent N or CH;

X represents O, NR.sup.4, CONR.sup.4 or NR.sup.4CO;

R.sup.4 each independently represents a hydrogen atom, or an alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; and

l, m and n each represents a number of 0 or 1,

a salt thereof and a hydrate thereof are provided.

These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 427886-47-39, 4-[N-(4-Methoxyphenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridin-3-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl]piperidine trihydrochloride
(cell adhesion inhibitor preparation of (pyridyl)methyl]piperidinamines as cell adhesion inhibitors for treatment of inflammatory diseases)

BN 427886-47-3 USPATFULL

CN 3-(pyridin-2-ylmethoxy)amine, N-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-N-[1-[[2-(3,4,5-trimethoxyphenyl)-4-pyridinyl]methyl]-4-piperidinyl]-hydrochloride (1:3) (CA INDEX NAME)

10537407.tzn



● 3 HCl

10537407.ttn

=> FIL STINGUIDE

FILE 'STINGUIDE' ENTERED AT 11:47:39 ON 23 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELEASED: Aug 8, 2008 (20080808/UP).

=> FIL HCAPLUS

Connection closed by remote host

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSFTADK01625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 MAR 31 IFCDB, IPIFAT, and IFIUDB enhanced with new custom
IPC display formats
NEWS 3 MAR 31 CAS REGISTRY enhanced with additional experimental
spectra
NEWS 4 MAR 31 CA/Caplus and CASREACT patent number format for U.S.
applications updated
NEWS 5 MAR 31 LPCI now available as a replacement to LDCPI
NEWS 6 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 7 APR 04 STN AnaVist, Version 1, to be discontinued
NEWS 8 APR 15 WFIDS, WFINDEX, and WFEX enhanced with new
predefined hit display formats
NEWS 9 APR 28 EMBASE Controlled Term thesaurus enhanced
NEWS 10 APR 28 INSRESEARCH reloaded with enhancements
NEWS 11 MAY 30 INPAFAMDB now available on STN for patent family
searching
NEWS 12 MAY 30 DGENE, PCTGEN, and USGENS enhanced with new homology
sequence search option
NEWS 13 JUN 06 EFPULL enhanced with 240,000 English abstracts
NEWS 14 JUN 06 KURASAT updated with 41,000 documents
NEWS 15 JUN 13 USPATFULL and USPAT2 updated with 11-character
patent numbers for U.S. applications
NEWS 16 JUN 19 CAS REGISTRY includes selected substances from
web-based collections
NEWS 17 JUN 25 CA/Caplus and USPAT databases updated with IPC
reclassification data
NEWS 18 JUN 30 AEROSPACE enhanced with more than 1 million U.S.
patent records
NEWS 19 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional
options to display authors and affiliated
organizations
NEWS 20 JUN 30 STN on the Web enhanced with new STN AnaVist
Assistant and BLAST plug-in
NEWS 21 JUN 30 STN AnaVist enhanced with database content from EFPULL

10537407.ttn

NEWS 22 JUL 28 CA/Caplus patent coverage enhanced
NEWS 23 JUL 28 EFPULL enhanced with additional legal status
information from the spoline Register
NEWS 24 JUL 28 IFCDB, IPIFAT, and IFIUDB reloaded with enhancements
NEWS 25 JUL 28 STN Viewer performance improved
NEWS 26 AUG 01 INPAFAMDB and INPAFAMDB coverage enhanced
NEWS 27 AUG 13 CA/Caplus enhanced with printed Chemical Abstracts
page images from 1967-1998
NEWS 28 AUG 15 CMLD to be discontinued on December 31, 2008
NEWS 29 AUG 15 Caplus currency for Korean patents enhanced
NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V6.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Icons
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 13:08:58 ON 23 AUG 2008

=> file hcaplus

FILE 'HCAPLUS' ENTERED AT 13:09:13 ON 23 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 23 Aug 2008 VOL 149 I35 9
FILE LAST UPDATED: 22 Aug 2008 (20080822/ED)

HCaplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s chronic anemia or renal anemia or aplastic anemia or red cell aplasia

10537407.ttn

244472 CHRONIC
9 CHRONICS
244477 CHRONIC
(CHRONIC OR CHRONICS)
42334 ANEMIA
1962 ANEMIAS
42725 ANEMIA
(ANEMIA OR ANEMIAS)
289 CHRONIC ANEMIA
(CHRONIC(W)ANEMIA)
168261 RENAL
12 RENALS
168266 RENAL
(RENAL OR RENALS)
42334 ANEMIA
1962 ANEMIAS
42725 ANEMIA
(ANEMIA OR ANEMIAS)
466 RENAL ANEMIA
(RENAL(W)ANEMIA)
2619 APLASTIC
42334 ANEMIA
1962 ANEMIAS
42725 ANEMIA
(ANEMIA OR ANEMIAS)
1936 APLASTIC ANEMIA
(APLASTIC(W)ANEMIA)
446717 RED
551 REDS
446995 RED
(RED OR REDS)
2442644 CELL
2105858 CELLS
3193629 CELL
(CELL OR CELLS)
1320 APLASTIA
15 APLASTIAS
1334 APLASTIA
(APLASTIA OR APLASTIAS)
227 RED CELL APLASTIA
(RED(W)CELL(W)APLASTIA)
L1 2879 CHRONIC ANEMIA OR RENAL ANEMIA OR APLASTIC ANEMIA OR RED CELL
APLASTIA

=> s l1 and review/dt

2176269 REVIEW/DT

L2 584 L1 AND REVIEW/DT

=> d scan ti

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Application pathway of erythropoietin

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Evaluation of therapeutic effect prediction indicators in
immunosuppressive therapy of aplastic anemia

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 New insights into molecular pathogenesis of bone marrow failure in
paroxysmal nocturnal hemoglobinuria

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Effects of erythropoietin treatment for renal anemia
on function of endocrine systems

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Hematopoietic stem-cell transplantation for acquired aplastic
anemia

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Hematopoietic stem cell transplantation therapy for severe
aplastic anemia

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Erythropoietin-associated PRCA: still an unsolved mystery

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.tnn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Practical considerations for carbamazepine use in bipolar disorder

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.tnn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Diagnosis and treatment of aplastic anemia

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ten

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Erythropoietin in heart failure

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ten

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Extended-release carbamazepine capsules: in bipolar disorder

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Pathogenesis and therapy of acquired pure red cell
aplasia

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Antibody-mediated side effects of recombinant proteins

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.tnn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI When biotech proteins go off-patent

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.tnn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Behavioural effects of the newer antiepileptic drugs: an update

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Pure red cell aplasia - a rare disease with
multiple causes

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI The role of lymphoid cells in the pathogenesis of PNH

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.tnn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Oxidative stress in chronic renal failure as cardiovascular risk factor

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.tnn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Adjunctive therapy in anaemia management

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.trn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI High-dose cyclophosphamide for aplastic anemia and
autoimmunity

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.trn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Erythropoietin gene regulation and oxygen sensing mechanism

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.tzn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Apoptotic mechanisms in the control of normal and pathological
erythropoiesis

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.tzn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Novel erythropoiesis stimulating protein

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.trn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Cyclophosphamide and other new agents for the treatment of severe
aplastic anemia

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.trn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Megakaryocytic growth factors: is there a new approach for management of
thrombocytopenia in patients with malignancies?

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.tnn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Telomere, telomerase, and hematopoietic disorders

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.tnn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Somatic mutation and clonal selection in the pathogenesis and in the control of paroxysmal nocturnal hemoglobinuria

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.trn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN

TI Congenital dyserythropoietic anemia type II: molecular basis and clinical aspects

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.trn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN

TI Anemia of chronic disorders

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.tnn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Critical issues in benzene toxicity and metabolism: the effect of
interactions with other organic chemicals on risk assessment

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.tnn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Tetracyclines, chloramphenicol, erythromycin, clindamycin, and
metronidazole

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Aplastic anemia caused by drugs and chemical industry
agents

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Pure red cell aplasia

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Chloramphenicol. Relation between its toxic and therapeutic action
mechanisms

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Telomeres and aging

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Anemia of chronic kidney disease

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Anemia as a risk factor for chronic kidney disease

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.trn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Allogeneic stem cell transplantation for aplastic anemia

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.trn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Expression of iron metabolism related protein, hepcidin and renal anemia

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Adequate correction of anemia for patient under dialysis

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Pathogenesis of renal anemia

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.trn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Anemia in infectious diseases

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.trn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Pathogenesis of CKD: relations to anemia, renal function and cardiac
function

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.trn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Erythropoietin-induced, antibody-mediated pure red cell
aplasia

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.trn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Erythropoietin in heart failure and other cardiovascular diseases:
Hematopoietic and pleiotropic effects

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.tzn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Heterozygous telomerase deficiency in mouse and man: When less is
definitely not more

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.tzn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy
(TREAT): Evolving the management of cardiovascular risk in patients with
chronic kidney disease

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.trn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Angiotensin converting enzyme inhibition for cardiac hypertrophy in
patients with end-stage renal disease: what is the evidence?

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.trn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Differentiating factors between erythropoiesis-stimulating agents: a guide
to selection for anemia of chronic kidney disease

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Oxidative stress in cardiorenal anemia syndrome: Correlations and
therapeutic possibilities

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Thrombopoietin is essential for the maintenance of normal hematopoiesis in
humans: development of aplastic anemia in patients
with congenital amegakaryocytic thrombocytopenia

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.tnn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Molecular mechanism of hematopoietic stem cell disorders

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.tnn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Human parvovirus B19

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI The rationale for early management of chronic renal insufficiency

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.trn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Relevance of clonogenic assays in hematotoxicology

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.trn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Therapeutic safety monitoring: what to look for and when to look for it

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.trn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Biopharmaceutical drug development: a case history. Filgrastim (NEUPROGEN,
GRAN)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.trn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Interleukin-3 in hematology and oncology: current state of knowledge and
future directions

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Pathogenesis of aplastic anemia and immunity

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Research progress of CD34 antigen and clinical application

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L2 584 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Hypothalamo-hypophyseal axis in hemodialysis patients

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

10537407.ttn

=> d his

(FILE 'HOME' ENTERED AT 13:08:58 ON 23 AUG 2008)

FILE 'HCAPLUS' ENTERED AT 13:09:13 ON 23 AUG 2008

L1 2879 S CHRONIC ANEMIA OR RENAL ANEMIA OR APLASTIC ANEMIA OR RED CELL
L2 584 S L1 AND REVIEW/DT

=> s pathogenesis/ti and L2

3 PATHOGENESIS/TI
L3 0 PATHOGENESIS/TI AND L2

=> s pathogenesis/ti and L2

18036 PATHOGENESIS/TI
L4 22 PATHOGENESIS/TI AND L2

=> d scan

10537407.tzn

L4 22 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
CC 15-0 (Immunochimistry)
TI Effect of T cells on pathogenesis of aplastic
anemia
ST review aplastic anemia T cell
IT Anemia
(aplastic; effect of T cells on pathogenesis of aplastic
anemia)
IT T cell
(effect of T cells on pathogenesis of aplastic anemia
)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.tzn

L4 22 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
CC 15-0 (Immunochimistry)
TI Advance study on pathogenesis of aplastic
anemia
ST review aplastic anemia immune
IT Anemia
Hematopoiesis
(advance study on pathogenesis of aplastic anemia)
IT Genetics
(immunogenetics; advance study on pathogenesis of aplastic
anemia)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L4 22 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STM
CC 14-0 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 3
TI Molecular pathogenesis of Fanconi anemia: recent progress
ST review genetic Fanconi anemia
IT Anemia (disease)
IT Genetics
Human
(altered genetics of Fanconi anemia progress)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

10537407.ttn

=> d his

(FILE 'HOME' ENTERED AT 13:08:58 ON 23 AUG 2008)

FILE 'HCAPLUS' ENTERED AT 13:09:13 ON 23 AUG 2008

L1 2879 S CHRONIC ANEMIA OR RENAL ANEMIA OR APLASTIC ANEMIA OR RED CELL
L2 584 S L1 AND REVIEW/DT
L3 0 S PATHOGENESIS/TI AND L2
L4 22 S PATHOGENESIS/TI AND L2

=> s l2 and induced/ti
447636 INDUCED/TI
1 INDUCEDS/TI
447637 INDUCED/TI
((INDUCED OR INDUCEDS)/TI)
L5 20 L2 AND INDUCED/TI

=> s multiple causes/ti
91591 MULTIPLE/TI
104 MULTIPLE/TI
91693 MULTIPLE/TI
((MULTIPLE OR MULTIPLES)/TI)
17013 CAUSES/TI
L6 24 MULTIPLE CAUSES/TI
((MULTIPLE(W)CAUSES)/TI)

=> s l6 and l2
L7 1 L6 AND L2

=> d cblb abs l-
YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y

10537407.tzn

L7 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN
2003:807996 Document No. 140:108949 Pure red cell
aplasia - a rare disease with multiple causes.
Djaldeiti, M.; Blay, A.; Bergman, M.; Salman, H.; Bessler, H. (Research
Laboratory Unit, Rabin Med. Center, Petah Tiqva, Israel). Biomedicine &
Pharmacotherapy, 57(8), 326-332 (English) 2003. CODEN: BIPHEK. ISSN:
0753-3322. Publisher: Editions Scientifiques et Medicales Elsevier.

AB A review. Pure red cell aplasia (PRCA) is a
relatively rare disease although multiple factors are implied in the
pathogenesis of its development. A slow progressive normocytic-
normochromic anemia and reticulocytopenia, without leukopenia and
thrombocytopenia in a patient who, except pallor, does not show abnormal
findings on phys. examination, should arise the suspicion that he has PRCA.
Search for underlying diseases or infections and intake of drugs may help
for the establishment of the diagnosis of acquired PRCA. Lack of
erythroblasts in the bone marrow with normal development of the other
hemopoietic series, as well as high level of serum erythropoietin are
important clues for the diagnosis. Elimination of potentially causative
factors, administration of immunosuppressive agents and/or recombinant
erythropoietin, preferably epoetin beta, may induce remission and complete
recovery.

10537407.tzn

=> d 15 cblb abs 1-
YOU HAVE REQUESTED DATA FROM 20 ANSWERS - CONTINUE? Y/(N):y

- 15 ANSWER 1 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN
2008:180081 Document No. 149:76647 Progress of immune-induced bone marrow failure syndrome in children. Yu, Hui; Qu, Yi-ning; Jin, Run-ming (Department of Pediatrics, Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Peop. Rep. China). Shiyong Erke Linchuang Zazhi, 22(15), 1197-1200 (Chinese) 2007. CODEN: SELZSJ. ISSN: 1003-515X. Publisher: Shiyong Erke Linchuang Zazhi Bianjibu.
- AB A review. The bone marrow failure refers to that because many pathol. factors make the bone marrow's hemopoiesis function inhibited, and which accordingly leads to the decrease of the complete blood cells or some in the peripheral blood. The bone marrow failure syndrome is constituted by a series of diseases whose main causes include the decrease of the bone marrow hyperplasia and (or) invalid hemopoiesis, insufficient of the hemopoiesis raw materials, the abnormal clone cell "berching" and so on. These diseases can be genetic or acquired, the later mainly includes the acquired aplastic anemia (AAA), the myelodysplastic syndrome (MDS), paroxysmal nocturnal hemoglobinuria (PNH) and so on. More and more researches show that more than 70 % acquired bone marrow failure syndromes are related to the immune factors. In this paper, these diseases were mainly reviewed with 24 refs.

- 15 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN
2008:163172 Document No. 148:321621 Pured red cell aplasia induced by erythropoiesis-stimulating agents. Pollock, Carol; Johnson, David Wayne; Hoerl, Walter H.; Rossert, Jerome; Casadevall, Nicole; Schellekens, Huub; Delage, Robert; De Francisco, Angel; Macdougall, Iain; Thorpe, Robin; Toffelmire, Edwin (Department of Medicine, Royal North Shore Hospital, University of Sydney, St. Leonards, NSW, Australia). Clinical Journal of the American Society of Nephrology, 3(1), 193-199 (English) 2008. CODEN: CJAS77. ISSN: 1555-9041. Publisher: American Society of Nephrology.
- AB A review. Pure red cell aplasia in patients who are treated for anemia of chronic kidney disease with erythropoiesis-stimulating agents such as epoetin was first reported in 1998. Although the incidence of pure red cell aplasia peaked in 2002, it remains important for nephrologists to know how to investigate a suspected case of pure red cell aplasia and how to identify other causes of hyporesponsiveness to erythropoiesis-stimulating agents, which account for the vast majority of such cases. The authors reviewed the current status of information in the literature and draw on their personal experiences with patients regarding the diagnosis and management of epoetin-induced pure red cell aplasia. The mechanism for development of epoetin-induced pure red cell aplasia remains unconfirmed. It generally occurs after the production of neutralizing anti-erythropoietin antibodies. Elucidation of a suspected pure red cell aplasia case requires a systematic approach, beginning with simple measurements such as blood cell counts, because most cases of erythropoiesis-stimulating agent hyporesponsiveness are attributable to other causes. If these criteria indicate that the patient's response to erythropoiesis-stimulating agent therapy is very poor, then bone marrow examination and measurement of anti-erythropoietin antibodies is justified. If pure red cell aplasia is confirmed, then cessation of erythropoiesis-stimulating agent therapy and initiation of immunosuppressive therapy are recommended. Continued study of epoetin-induced pure red cell aplasia is needed to help nephrologists prevent or manage future cases and will have implications for the use of other protein-based therapeutic agents.

10537407.tzn

L5 ANSWER 3 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN
2008:144039 Document No. 148:345293 Drug-induced and
antibody-mediated pure red cell aplasia: a
review of literature and current knowledge. Smalling, Ralph; Foote,
MaryAnn; Molineux, Graham; Swanson, Steven J.; Elliott, Steve (Amgen Inc.,
Thousand Oaks, CA, 91320-1799, USA). Biotechnology Annual Review, 10,
237-250 (English) 2004. CODEN: BAREFD. ISSN: 1387-2656. Publisher:
Elsevier B.V..

AB A review. Anti-erythropoietin (EPO)-induced pure red
cell aplasia (PRCA) is an uncommon, potentially
life-threatening condition in which the bone marrow stops manufacturing red
blood cells. In the past few years, reports of drug-induced, anti-EPO
antibody-mediated PRCA have increased substantially, with most cases
attributed to the use of one erythropoiesis-stimulating protein, Eprex. A
literature review was undertaken to document the reports of drug-induced
PRCA, with all drugs and drug regimens. The sudden increase in reports of
antibody-mediated PRCA is discussed.

10537407.tzn

L5 ANSWER 4 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN
2007:1381659 Document No. 148:182255 Epoetin-induced pure
red cell aplasia: diagnosis and treatment.
Macdougall, Iain C. (Department of Renal Medicine, King's College
Hospital, London, UK). Current Opinion in Nephrology & Hypertension,
16(6), 585-588 (English) 2007. CODEN: CHNYEM. ISSN: 1062-4821.
Publisher: Lippincott Williams & Wilkins.

AB Purpose of review: Antibody-mediated pure red cell
aplasia is now recognized as a rare complication of
erythropoiesis-stimulating agent therapy. The incidence of this adverse
effect peaked in 2002, but new cases still appear sporadically. The aim
of this review is to discuss the latest opinions regarding the detection
and management of this condition. Recent findings: The diagnosis of
classical erythropoiesis-stimulating agent induced pure red
cell aplasia is made by a constellation of clin.
features, including severe transfusion-dependent anemia,
reticulocytopenia, low or absent erythroblasts in the bone marrow, and the
presence of circulating antierythropoietin antibodies. Recently, some
cases have been reported in which the bone marrow findings show red cell
hypoplasia rather than aplasia; this may represent earlier presentations
of the same condition. Summary: Management of pure red
cell aplasia as a complication of erythropoiesis-
stimulating agent therapy consists of stopping the drug and implementing
an immunosuppressive regimen to reduce or abolish erythropoietin antibody
production. A recent animal study suggested that a possible alternative
strategy may be to administer a novel peptide-based erythropoietin
receptor agonist called Hematide that does not cross react with
antierythropoietin antibodies, and will allow ongoing stimulation of
erythropoiesis; this is the subject of a current clin. trial.

10537407.ttn

- 15 ANSWER 5 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN
2007:639503 Document No. 147:111556 Anemia induced by cadmium
intoxication. Horiguchi, Hyogo (Center for Community Medicine, Yichi
Medical University, Tochigi, 329-0498, Japan). Nippon Eiseigaku Zasshi,
62(3), 889-904 (Japanese) 2007. CODEN: NEZAAQ. ISSN: 0021-5082.
Publisher: Nippon Eisei Gakkai.
- AB A review. Anemia is commonly induced by chronic cadmium (Cd)
intoxication. Three main factors are involved in the development of
Cd-induced anemia: hemolytic, iron-deficiency, and renal. Intravascular
hemolysis can occur at the early stage of Cd exposure owing to the direct
damaging effect on erythrocytes. In addition, Cd that accumulates in
erythrocytes affects membrane cytoskeletons and decreases cell
deformability, and these cells are then trapped and destroyed in the
spleen. Iron deficiency can be detected in animals after an oral exposure
to Cd, which competes with iron for absorption in the intestines, leading
to anemia. However, an increase in body iron content along with anemia is
often observed in cases of parenteral exposure or itai-itai disease.
Therefore, it is estimated that Cd disrupts the efficient usage of iron in Hb
biosynthesis in the body. Renal anemia is observed
during the very last phase of chronic, severe Cd intoxication, such as
itai-itai disease, showing a decrease in the formation of erythropoietin
from renal tubular cells. Because the renal anemia is
based on the same pathophysiol. as Cd-induced osteomalacia, which is
derived from the disturbance of mineral metabolism due to renal tubular
dysfunction, it is reasonable to include renal anemia
in the criteria for the diagnosis of itai-itai disease. Hemodilution
could also contribute to the development of Cd-induced anemia. Bone
marrow hypoplasia or the inhibition of heme synthesis might only be
involved in Cd-induced anemia in severe cases of Cd intoxication.

10537407.ttn

- 15 ANSWER 6 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN
2006:1294777 Document No. 146:633870 Drug-induced aplastic
anemia. Nakao, Shinji (Dep. of Hematology and Respiratory
Diseases, Kanazawa Univ., Japan). Ketsueki Funtan, 16(10), 1645-1651
(Japanese) 2006. CODEN: KEFJAN. ISSN: 1344-6940. Publisher: Iyaku
Jinarusha.
- AB A review with refs.

15 ANSWER 7 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN

2006:105132 Document No. 144:246338 In vitro and animal models of drug-induced blood dyscrasias. Ip, Julia; Utrecht, Jack P. (Faculty of Pharmacy, University of Toronto, Toronto, ON, M5S 2S2, Can.). Environmental Toxicology and Pharmacology, 21(2), 135-140 (English) 2006. CODEN: ETOPFR. ISSN: 1382-5689. Publisher: Elsevier B.V..

AB A review. Drug-induced blood dyscrasias can be either acute and predictable or delayed and unpredictable (idiosyncratic). The predictable toxicity is relatively easy to reproduce with in vitro models, although they may not work for drugs that require bioactivation. It is very unlikely that idiosyncratic blood dyscrasias can be modeled in vitro, although some drugs (or their reactive metabolites) that cause idiosyncratic reaction are toxic to bone marrow cells in vitro. Although the mechanisms of idiosyncratic reactions are poorly understood, there is evidence that most are due to reactive metabolites and some are immune-mediated. Therefore, screening drugs for their bioactivation by myeloperoxidase, the major oxidative enzyme in bone marrow, may provide some measure of the risk that a drug will cause blood dyscrasias. Several examples of drug-induced idiosyncratic agranulocytosis, aplastic anemia, and thrombocytopenia are presented, but better in vivo models are clearly needed to gain a clearer understanding of these adverse reactions.

15 ANSWER 8 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN

2006:165317 Document No. 145:145391 Erythropoietin-induced, antibody-mediated pure red cell aplasia.

Rosser, Jerome; Maroni, Brad; Aljama, Pedro; Casadevall, Nicole; Cooper, Max; Delage, Robert; Eckardt, Kai-Uwe; de Francisco, Angel Martin Luis; Forl, Walter; Jekmann, Wolfgang; Johnson, David; Locatelli, Francesco; MacDougall, Iain; Missenson, Allen R.; Pollock, Carol; Schellekens, Huub; Thorpe, Robin; Toffelmire, Edwin (The Pure Red Cell Aplasia Global Scientific Advisory Board (GSAB), Hôpital Européen Georges Pompidou, Paris, 75015, Fr.). European Journal of Clinical Investigation, 35(Suppl. 3), 95-99 (English) 2005. CODEN: EJCIB9. ISSN: 0014-2972. Publisher: Blackwell Publishing Ltd..

AB A review. Pure red cell aplasia (PRCA) is a rare hematol. condition that is characterized by severe aregenerative anemia due to an almost complete cessation of red blood cell production. While antibody-mediated PRCA was extremely rare before 1998, the incidence of this disorder increased sharply after 1998 in patients receiving s.c. epoetin alfa produced by Ortho-Biotech and marketed outside the USA. The diagnosis of antibody-mediated PRCA relies mostly on the results of bone marrow biopsy or aspirate, which shows an absence of erythroid precursors and/or red cell maturation arrest while counts of white cell and platelet precursors are normal, and on the identification of circulating anti-erythropoietin antibodies. Retrospective anal. of PRCA cases has shown that immunosuppressive therapy can induce a disappearance of anti-erythropoietin antibodies in most patients.

- 15 ANSWER 9 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN
2005:287560 Document No. 143:38452 Epoetin-induced autoimmune pure red cell aplasia. Casadevall, Nicole; Eckardt, Kai-Uwe; Rossert, Jerome (Department of Hematology, Hotel Dieu and INSERM U362, Paris, Fr.). Journal of the American Society of Nephrology, 16(Suppl. 1), 867-869 (English) 2005. CODEN: JASN00. ISSN: 1046-6673. Publisher: American Society of Nephrology.
- AB A review. During the first 10 yr of therapy with recombinant human erythropoietin (EPO), only three cases of antibody-associated pure red cell aplasia have been described in patients who were treated with EPO, whereas several millions of patients have received this treatment. Thus, the possibility for epoetin to induce the formation of anti-EPO antibodies was considered extremely low. However, since 1996, a significant increase in the number of cases of EPO-induced pure red cell aplasia has been found in patients with chronic kidney disease with a peak in 2001 and 2002. The incidence rate seems now to be back to the baseline level. The change in formulation of epoetin α sold outside the United States seems to be the cause of these antibodies.

- 15 ANSWER 10 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN
2005:255826 Document No. 142:457177 Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. Evans, Andrew M.; Bennett, Charles L.; Luminari, Stefano (Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, 60611, USA). Best Practice & Research, Clinical Hematology, 18(3), 481-489 (English) 2005. CODEN: BPRCA5. Publisher: Elsevier B.V..
- AB A review. In 2002, investigators from France reported 13 patients in whom pure red cell aplasia developed during treatment with recombinant human erythropoietin (epoetin). We reviewed 208 cases of this syndrome reported worldwide. Adverse event reports describing suspected and confirmed cases of epoetin-associated PRCA in web-sites maintained by the manufacturers and distributors of epoetin products and other publicly available sources were reviewed. Cases were reported from countries in Europe, North America, Asia, Australia and the United States (US). For >95% of the cases, EPREX had been administered s.c. to persons with chronic kidney disease (CKD) and anemia for a mean of nine months prior to diagnosis of PRCA. For 80% of persons with the syndrome, reversal of antibody production and recovery of reticulocytes occurred with discontinuation of Epoetin and treatment with immunosuppressive agents. Patients with anemia of CKD who developed neutralizing anti-erythropoietin antibodies and pure red cell aplasia during treatment with Epoetin have been identified in a number of countries. In non-US countries, switching renal dialysis patients from s.c. to i.v. administration of epoetin α and improved handling of the drug appear to have been successful strategies for reducing the occurrence of this toxicity. The decrease in cases occurred coincident with these varied changes, although it is difficult to prove causality. PRCA is a rare, but important side effect of Epoetin therapy.

15 ANSWER 11 of 20 HCAPLUS COPYRIGHT 2008 ACS on STN

2000:390772 Document No. 133:129955 Effect of G-CSF and GM-CSF in chemotherapy induced neutropenia. Link, H. (Department of Internal Medicine I, Westpfalz-Klinikum, Kaiserslautern, D-67653, Germany). Antibiotiques, 2(1), 11-22 (English) 2000. CODEN: ANTRVQ. ISSN: 1294-5501. Publisher: Masson Editeur.

AB A review with 157 refs. Neutropenia and associated infections are major risk factors for morbidity and mortality in chemotherapy. Stimulation of neutrophil production with recombinant human granulocyte-stimulating factor (G-CSF) or granulocyte-macrophage stimulating factor (GM-CSF) may reduce the duration and degree of neutropenia and thus improve the outcome of patients. G-CSF and GM-CSF can mobilize hematopoietic stem and progenitor cells from the bone marrow into the blood. The stem cells thus become accessible for collection by leukapheresis, storage and transplantation. Numerous studies have been performed since the development of both hematopoietic growth factors. The indications for the use of hematopoietic growth factors can be defined as follows: after myeloblastic therapy and autologous or allogeneic bone marrow or stem cell transplantation; mobilization of hematopoietic progenitor cells from bone marrow into the peripheral blood (allogeneic and autologous transplantation); severe chronic neutropenia (NP); idiopathic NP; congenital metabolic disorders with NP with severe combined immunodeficiency; congenital or cyclic NP without chromosomal aberrations; NP in M.Gaucher; initial prophylaxis following intensive myelotoxic cytotoxic chemotherapy, with an expected duration of neutropenia (< 500 neutrophils/ mm^3) of at least 7 days, with risk of febrile neutropenia > 40%; aplastic anemia; acute agranulocytosis; HIV infection; drug-induced neutropenia, for example zidovudine (AZT) or ganciclovir. The following indications are possible, but not unanimously accepted: initial prophylaxis following moderately myelotoxic cytotoxic chemotherapy with an expected duration of neutropenia (< 500 neutrophils/ mm^3) of 5-7 days and presence of risk factors, with risk of febrile neutropenia > 40%; Secondary prophylaxis following cytostatic chemotherapy if neutropenia (< 500/ mm^3) occurred for more than 5 days in the first cycle; Treatment of chemotherapy induced febrile neutropenia without and with microbiol. or clin. documented infections: however only few data support this latter application.

15 ANSWER 12 of 20 HCAPLUS COPYRIGHT 2008 ACS on STN

2000:390925 Document No. 132:318100 Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings. Dunn, Christopher J.; Goa, Karen L. (Adis International Limited, Auckland, N. Z.). Drugs, 59(3), 681-717 (English) 2000. CODEN: DRUGAY. ISSN: 0012-6667. Publisher: Adis International Ltd..

AB A review with 158 refs. Lenograstim is the glycosylated recombinant form of human granulocyte colony stimulating factor. The drug is used to reduce the risk of life-threatening infection in patients with neutropenia, particularly after cytotoxic chemotherapy. Lenograstim accelerates neutrophil recovery significantly after chemotherapy, with beneficial effects on clin. end-points such as incidence of laboratory-confirmed infection and length of hospital stay. Chemotherapy dose intensity has also been increased in patients receiving lenograstim, notably those with breast or small cell lung cancer, although improvements in tumor response and survival have not been demonstrated. Lenograstim also assists neutrophil recovery in patients undergoing bone marrow transplantation, and stimulates the production of peripheral blood stem cells (PBSCs) for autologous transfusion after aggressive chemotherapy. Lenograstim also mobilizes CD34+ cells more efficiently in unit dose terms than filgrastim and has been used successfully to mobilize PBSCs from healthy donors for allogeneic transplantation. Randomized trials have shown increases in rates of disease remission after lenograstim therapy in patients with acute myeloid leukemia, with no evidence of stimulation of malignant blasts. The drug has also shown potential in the mobilization of nonmalignant PBSCs for autotransplantation in patients with chronic myeloid leukemia. Other studies show efficacy of lenograstim in patients with acute lymphoblastic leukemia, aplastic anemia, in children with severe chronic neutropenia and in the reversal of neutropenia related to antiviral therapy in patients with AIDS, although data are not extensive. Cost analyses of lenograstim have been carried out from a hospital perspective, although results have been inconclusive. Cost-effectiveness or cost-benefit data are lacking at present. Lenograstim is well tolerated, with bone pain and injection site reactions being reported most frequently in clin. trials. Conclusions: Lenograstim has been confirmed as a valuable adjunct to minimize the hematol. toxicity of myelosuppressive chemotherapy in patients with malignant disease. The drug also enhances neutrophil recovery in patients undergoing stem cell rescue, and assists PBSC mobilization. Data indicate clin. benefit with lenograstim in myeloid disorders, with no evidence of malignant blast cell proliferation. Further studies are required to assess more fully the pharmacoeconomic implications of the use of lenograstim and other recombinant growth factors, to provide more data on the efficacy of the drug in the management of disease-related neutropenia, and to clarify fully its position relative to filgrastim.

10537407.tzn

- LS ANSWER 13 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN
1999:252266 Document No. 131:69315 Overview of benzene-induced
aplastic anemia. Smith, Martyn T. (School of Public
Health Division of Environmental Health Sciences, University of
California, Berkeley, CA, 947207360, USA). European Journal of
Haematology, Supplementum, 60, 107-110 (English) 1996. CODEN: EJRSEW.
ISSN: 0902-4506. Publisher: Munksgaard International Publishers Ltd..
- AB A review and discussion with 46 refs. The scientific literature is
replete with reports of cases of benzene-induced toxicity to the
hematopoietic system. These mainly involve aplastic
anemia, the first cases of which were reported in 1897. At high
levels of benzene exposure (air concentration > 100 p.p.m.), the incidence of
aplastic anemia is approx. 1/100 individuals exposed,
but this drops precipitously at lower levels of exposure (10-20 p.p.m.) to
around 1/10,000. Factors that affect susceptibility may include high
liver cytochrome P 450 2E1 activity and low folic acid intake. The
mechanism of benzene-induced aplastic anemia remains
unclear, but is likely to involve: (a) metabolism of benzene in the liver; (b)
transport of metabolites to the marrow and their secondary activation to
toxic quinones and free radicals by peroxidase enzymes; (c) induction of
apoptosis, DNA damage and altered differentiation in early progenitor
cells; and (d) depletion of the stem cell pool.

10537407.tzn

- LS ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN
1996:587654 Document No. 125:237317 Original Reference No. 125:44045a,44048a
Aminopyrine-induced blood dyscrasias - still a problem in many
parts of the world. Chan, Thomas Y. K.; Chan, Anthony W. K. (Prince Wales
Hospital, Chinese University Hong Kong, Shatin, Hong Kong).
Pharmacoeconomics and Drug Safety, 5(4), 215-219 (English) 1996.
CODEN: POSADA. ISSN: 1053-8569. Publisher: Wiley.
- AB A review with 42 refs. The aminopyrines were introduced a century ago as
analgesics and antipyretics, but it was not until the 1930s that
agranulocytosis, their major adverse reaction, was recognized. In
patients receiving aminopyrines, although agranulocytosis is the most
frequent blood dyscrasia, aplastic anemia has also
been reported. For these reasons, these drugs have been banned or
withdrawn from the market in most industrialized countries. However,
aminopyrines are still available in many parts of the world, including the
Far East, Africa and Latin and South America and can be found as
adulterants in some "herbal" patent preps. Their continuing availability
in the Far East may have contributed in part to the higher incidence of
aplastic anemia, compared with the West.

10537407.tnn

LS ANSWER 15 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN
1988:621670 Document No. 109:221670 Original Reference No. 109:36491a,36492a
Drug-induced aplastic anemia. Nomura, Takeo
(Nippon Med. Coll., Japan). Tokishikoroji Foramu, 11(3), 231-9 (Japanese)
1988. CODEN: TUPROD5. ISSN: 0287-8712.
AB A review with 21 refs.

10537407.tnn

LS ANSWER 16 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN
1986:61382 Document No. 104:61382 Original Reference No. 104:9665a,9668a
Drug-induced aplastic anaemia and agranulocytosis. Incidence
and mechanisms. Vincent, Paul C. (Kanematsu Lab., R. Prince Alfred Hosp.,
Sydney, 2050, Australia). Drugs, 31(1), 52-63 (English) 1986. CODEN:
DRUGAY. ISSN: 0012-6667.
AB A review with approx. 85 refs. A discussion is given on drug-induced
aplastic anemia and agranulocytosis resulting from
adverse interactions between the drug and the heropoietic pathway.

10537407.ttn

- LS ANSWER 17 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN
1979:114647 Document No. 90:114647 Original Reference No. 90:17971a,17974a
Drug-induced bone marrow aplasia. Yunis, Adel A. (Fac. Med.,
Univ. Sao Paulo, Sao Paulo, Brazil). Revista Brasileira de Pesquisas
Medicas e Biologicas, 11(4-5), 287-96 (English) 1978. CODEN: RBPMB2.
ISSN: 0034-7310.
- AB A review with 38 refs. emphasizing mechanisms of action of drugs
suppressing bone marrow function.

10537407.ttn

- LS ANSWER 18 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN
1973:23800 Document No. 78:23800 Original Reference No. 78:3701a,3704a
Organotropic damage of therapy. Drug-induced damage of bone
marrow. Remmele, W. (Pathol. Inst., Klin. Landeshauptstadt Wiesbaden,
Wiesbaden, Fed. Rep. Ger.). Verhandlungen der Deutschen Gesellschaft fuer
Pathologie, 56, 291-310 (German) 1972. CODEN: VDGPAN. ISSN: 0070-6113.
- AB A review with 47 refs. of blood and bone marrow damage induced by therapy
with chloramphenicol [I] [56-75-7] and other drugs. Types of damage
discussed were aplastic anemia, other types of anemia,
agranulocytosis, and thrombocytopenia.

10537407.ttn

LS ANSWER 19 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN
1971:85330 Document No. 74:85330 Original Reference No. 74:13831a,13834a
Drug-induced leukopenia and aplastic anemia.
Pisciotta, Anthony V. (Marquette Sch. Med., Milwaukee County Gen. Hosp.,
Milwaukee, WI, USA). Clinical Pharmacology & Therapeutics (St. Louis, MO,
United States), 12(1), 13-43 (English) 1971. CODEN: CLPTAT. ISSN:
0009-9236.

AB A review of presently available basic and clin. information related to the
mechanisms of unpredicted hematopoietic damage attributed to drugs. 322
refs.

10537407.ttn

LS ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN
1970:119619 Document No. 72:119619 Original Reference No. 72:21507a,21510a
Drug-induced bone marrow injury. Yunis, Adel A. (Univ. of
Miami, Miami, FL, USA). Advances in Internal Medicine, 15, 357-76
(English) 1969. CODEN: AIDMAL. ISSN: 0065-2822.

AB A discussion is given of the mechanisms of toxicity in agranulocytosis and
aplastic anemia on therapy by androgens,
glucocorticoids, and the anabolic agent oxymetholone. Important toxic
agents are chloramphenicol, sulfonamides, phenylbutazone,
diphenylhydantoin, methylphenylethylhydantoin, chlorpromazine,
propylthiouracil, methimazole, and chlordan. 101 refs.

10537407.tzn

=> d his

(FILE 'HMSX' ENTERED AT 13:08:59 ON 23 AUG 2008)

FILE 'HCAFLUS' ENTERED AT 13:09:13 ON 23 AUG 2008

11 2879 S CHRONIC ANEMIA OR RENAL ANEMIA OR APLASTIC ANEMIA OR RED CELL
12 594 S L1 AND REVIEW/UT
13 0 S PATHOGENESIS/TI AND L2
14 22 S PATHOGENESIS/TI AND L2
15 20 S L2 AND INDUCED/TI
16 24 S MULTIPLE CAUSES/TI
17 1 S L6 AND L2

=> d chlb abs 14 1-

YOU HAVE REQUESTED DATA FROM 22 ANSWERS - CONTINUE? Y/(N):y

10537407.tzn

L4 ANSWER 1 OF 22 HCAFLUS COPYRIGHT 2008 ACS ON STM

2008:103507 Document No. 149:149936 Pathogenesis, diagnosis and treatment of pure red cell aplasia after solid organ transplantation. Li, Donglin; Liang, Tingbo (The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang Province, 310003, Peop. Rep. China). Zhonghua Yixue Zazhi (Beijing, China), 86(42), 3020-3022 (Chinese) 2006. CODEN: CHHTAT. ISSN: 0376-2491. Publisher: Zhonghua Yixuehui Zazhishe.

AB A review. The pathogenesis, diagnosis and treatment of pure red cell aplasia (PRCA) after solid organ transplantation were summarized with several subsections as follow, pathogenesis of PRCA after solid organ transplantation, clin. manifestation and diagnosis of PRCA after solid organ transplantation, treatment and prevention for PRCA after solid organ transplantation, and conclusions and prospect in the future.

10537407.tzn

- 14 ANSWER 2 OF 22 HCAPLUS COPYRIGHT 2008 ACS on STN
2008:103360 Document No. 149:149935 Effect of T cells on
pathogenesis of aplastic anemia. Zhang,
Qiang; Zhai, Zhimin (Department of Clinical Laboratory Medicine and
Diagnostics, Bengbu Medical College, Bengbu, Anhui Province, 233003, Peop.
Rep. China). Linchuang Shixue Yu Jianshan, 8(4), 344-347 (Chinese) 2006.
CODEN: LSTJAH. ISSN: 1671-2587. Publisher: Linchuang Shixue Yu Jianshan
Zazhishu.
- AB A review. The effect of T cells on the pathogenesis of aplastic
anemia (AA) was summarized with several subsections as follow,
relationship of AA with the amount and phenotypic abnormality of T cells,
functional disorder of T cells and AA, relationship of AA with cloning and
amplification, and apoptosis of T cells and AA.

10537407.tzn

- 14 ANSWER 3 OF 22 HCAPLUS COPYRIGHT 2008 ACS on STN
2007:1461240 Document No. 148:375794 Progress in pathogenesis of
aplastic anemia. Tan, Jinghua (Tongji Hospital, Tongji
University, Shanghai, 200065, Peop. Rep. China). Zhongguo Xueshe Xueye Yu
Zhongliu Zazhi, 11(5), 278-281 (Chinese) 2006. CODEN: ZKXYAD. ISSN:
1673-5323. Publisher: Zhongguo Xueshe Xueye Yu Zhongliu Zazhishu.
- AB A review. Immunity mediated pathogenesis, genetic basis, apoptotic
increase of hematopoietic cells and glutathione S-transferase (GST) in
aplastic anemia are reviewed in this article.

10537407.ttn

L4 ANSWER 4 OF 22 HCAPLUS COPYRIGHT 2008 ACS on STN
2007:975626 Document No. 148:211296 New insights into molecular
pathogenesis of bone marrow failure in paroxysmal nocturnal
hemoglobinuria. Kawaguchi, Tatsuya; Nakakuma, Hideki (Departments of
Hematology and Infectious Diseases, Kumamoto University Graduate School of
Medical Sciences, Kumamoto, Japan). International Journal of Hematology,
86(1), 27-32 (English) 2007. CODEN: IJHEEY. ISSN: 0925-5710. Publisher:
Carden Jennings Publishing.

AB A review. Paroxysmal nocturnal hemoglobinuria (PNH) is caused by the
clonal expansion of hematopoietic stem cells with mutations of the
phosphatidylinositol glycan-class A gene (PIGA). PNH clones then fail to
generate glycosylphosphatidylinositol (GPI) or to express a series of
GPI-linked membrane proteins including complement-regulatory proteins,
resulting in complement-mediated intravascular hemolysis and thrombosis.
Bone marrow failure is another characteristic feature of PNH. It is
currently considered that immune-mediated injury of hematopoietic cells is
implicated in PNH marrow failure as well as in aplastic
anemia, a well-known PNH-related disorder. There is increasing
evidence that the autoimmune attack allows PNH clones to selectively
survive in the injured marrow, leading to clin. manifestations
characteristic of PNH. As candidate mols. that trigger the immune attack
on marrow cells, stress-inducible membrane proteins and Wilms' tumor
protein WT1 have been proposed. Among the stress-inducible proteins,
GPI-linked proteins, such as cytomegalovirus glycoprotein UL16-binding
protein, are distinct candidates that not only induce immune attack, but
also allow PNH clones to survive the attack. Here, we overview the
current understanding of the mol. pathogenesis of bone marrow failure in
PNH.

10537407.ttn

L4 ANSWER 5 OF 22 HCAPLUS COPYRIGHT 2008 ACS on STN
2006:1129970 Document No. 147:7816 Advance study on pathogenesis
of aplastic anemia. Meng, Fankai; Sun, Hanying; Liu,
Wenli; Zhou, Jianfeng (Tongji Medical College, Huazhong University of
Science and Technology, Wuhan, Hubei Province, 430030, Peop. Rep. China).
Zhonghua Weike Jazhi (Beijing, China), 44(10), 789-790 (Chinese) 2005.
CODEN: CHENAR. ISSN: 0578-1425. Publisher: Zhonghua Yixuehui Zazhishe.

AB A review. The pathogenesis of aplastic anemia (AA)
was explored with subdivision headings: (1) abnormal situations of cell
immune; (2) disorder of lymph factors secretion; (3) abnormal of AA
immunogenetics; (4) humoral immune of AA; and (5) mechanism of
hematopoiesis inhibition in AA.

- 14 ANSWER 6 OF 22 HCAPLUS COPYRIGHT 2008 ACS on STN
2006:1089558 Document No. 146:225693 Pathogenesis of renal anemia. Wangaku, Masami; Eckardt, Kai-Uwe [Division of Nephrology and Endocrinology, University of Tokyo School of Medicine, Tokyo, Japan]. *Seminars in Nephrology*, 26(4), 261-268 (English) 2006. CODEN: SNEPDU. ISSN: 0270-9295. Publisher: Elsevier.
- AB A review. Anemia is a common complication of chronic kidney disease. Although mechanisms involved in the pathogenesis of renal anemia include chronic inflammation, iron deficiency, and shortened half-life of erythrocytes, the primary cause is deficiency of erythropoietin (EPO). Serum EPO levels in patients with chronic kidney disease are usually within the normal range and thus fail to show an appropriate increase with decreasing Hb levels, as found in renal anemia. Studies elucidating the regulation of EPO expression led to the identification of the hypoxia inducible factor-hypoxia responsive element system. However, despite much progress in understanding the molecular mechanisms through which cells can sense oxygen availability and translate this information into altered gene expression, the reason why EPO production is inappropriately low in diseased kidneys remains incompletely understood. Both alterations in the function of EPO-producing cells and perturbations of the oxygen-sensing mechanism in the kidney may contribute. As with other anemias, the consequences of renal anemia are a moderate decrease in tissue oxygen tensions and counterregulatory mechanisms that maintain total oxygen consumption, including a persistent increase in cardiac output.

- 14 ANSWER 7 OF 22 HCAPLUS COPYRIGHT 2008 ACS on STN
2006:1083658 Document No. 146:248422 Heterogeneity in the molecular pathogenesis of paroxysmal nocturnal hemoglobinuria (PNH) syndromes and expansion mechanism of a PNH clone. Shichishima, Tsutomu; Noji, Hideyoshi [First Department of Internal Medicine, Fukushima Medical University, Fukushima, Japan]. *International Journal of Hematology*, 94(2), 97-103 (English) 2006. CODEN: IJHEJY. ISSN: 0925-5710. Publisher: Carden Jennings Publishing.
- AB A review. Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematol. disorder that is manifested by complement-mediated hemolysis, venous thrombosis, and bone marrow failure and is one disorder of acquired bone marrow failure syndromes that include as aplastic anemia and myelodysplastic syndrome. Nowadays, acquired PNH should be understood as one of the disorders of PNH syndromes. These syndromes include congenital PNH (such as inherited complete CD59 deficiency and PNH with PIG-M mutations), because complement-mediated hemolysis and thrombosis are observed in association with defects of various factors associated with the complement regulatory pathway, including biosynthesis of the glycosylphosphatidylinositol (GPI) anchor. At present, how a "true" PNH clone in acquired PNH expands in the bone marrow remains unclear. Although several candidate genes, including the Wilms tumor gene, the early growth response gene, anti-apoptotic genes, and the high mobility group AT-hook 2 gene, that target corresponding proteins (excluding GPI-related proteins) have been reported, the evidence is insufficient to completely explain the diversity of the clin. and basic pathophysiol. in acquired PNH. However, the hypothesis of expansion of a PNH clone due to the WT1 gene may explain various features of PNH.

- 14 ANSWER 8 OF 22 HCAPLUS COPYRIGHT 2008 ACS on STN
2006:524310 Document No. 144:485701 Molecular pathogenesis of
Fanconi anemia: recent progress. Taniguchi, Toshiyasu; D'Andrea, Alan D.
(Division of Human Biology and the Division of Public Health Sciences,
Fred Hutchinson Cancer Research Center, Seattle, WA, USA). Blood,
107(11), 4223-4233 (English) 2006. CODEN: BLOOD. ISSN: 0006-4971.
Publisher: American Society of Hematology.
- AB A review. A rare genetic disease, Fanconi anemia (FA), now attracts
broader attention from cancer biologists and basic researchers in the DNA
repair and ubiquitin biol. fields as well as from hematologists. FA is a
chromosome instability syndrome characterized by childhood-onset
aplastic anemia, cancer or leukemia susceptibility, and
cellular hypersensitivity to DNA crosslinking agents. Identification of
11 genes for FA has led to progress in the mol. understanding of this
disease. FA proteins, including a ubiquitin ligase (FANCD1), a
monoubiquitinated protein (FANCD2), a helicase (FANCF/BACH/BRIP1), and a
breast/ovarian cancer susceptibility protein (FANCD3/BRCA2), appear to
cooperate in a pathway leading to the recognition and repair of damaged
DNA. Mol. interactions among FA proteins and responsible proteins for
other chromosome instability syndromes (BLM, NBS1, MRE11, ATM, and ATR)
have also been found. Furthermore, inactivation of FA genes has been
observed in a wide variety of human cancers in the general population. These
findings have broad implications for predicting the sensitivity and
resistance of tumors to widely used anticancer DNA crosslinking agents
(cisplatin, mitomycin C, and melphalan). Here, we summarize recent
progress in the mol. biol. of FA and discuss roles of the FA proteins in
DNA repair and cancer biol.

- 14 ANSWER 9 OF 22 HCAPLUS COPYRIGHT 2008 ACS on STN
2006:513920 Document No. 145:393329 Recent advances in the
pathogenesis and management of anemia of chronic disease.
Katsidromi, Sirini; Christakis, John (Department of Hematology,
"Papageorgiou" General Hospital, "Theagenion" Cancer Center, Thessaloniki,
Greece). Haema, 9(1), 43-53 (English) 2006. CODEN: HAGABR. ISSN:
1109-2682. Publisher: Epsilon.
- AB A review. Anemia of chronic disease (ACD) is defined as the anemia
accompanying chronic inflammation, cancer or autoimmune diseases but also,
the anemia observed in the context of acute infection or inflammation. It
accounts for more than 50% of anemias in hospitalized patients presenting
as a hypoproliferative, normocytic or slightly microcytic anemia, with
hypoferremia, decreased transferrin saturation, normal or increased serum
ferritin levels and adequate iron stores in the reticuloendothelial
system. Anemia of chronic disease is characterized by inadequate production
of erythropoietin, inhibition of the proliferation of erythroid progenitor
cells in the bone marrow, disturbances in iron distribution and decreased
red cell survival. A complex network of pro-inflammatory cytokines, such
as IL1, IL6 and TNF- α , which act alone or synergistically, play a
major pathogenic role. Their action is exercised either directly on
erythroid progenitors, causing inhibition of red cell proliferation or
through the enhancement of the apoptotic machinery. Furthermore,
cytokines affect iron homeostasis, causing withdrawal of the metal from
the circulation and storage in the reticuloendothelial cells. Addnl.
recent studies have revealed that hepcidin, a 25 amino acid liver derived
peptide, has a key role in the pathogenesis of ACD. Hepcidin is an acute
phase reactant whose overprod. causes decreased iron absorption in the
gut and accumulation of iron into the macrophages leading thus to
hypoferremia and iron-restricted erythropoiesis. Diagnosis of ACD is
based mainly on changes in iron, as well as erythrocyte parameters. The
main goal in the management of ACD is improvement or cure of the
underlying disease. Outside cancer setting this is mostly the case.
However, if management of the primary disease is not effective, as in
cancer patients, red cell transfusions and/or r-huEPO are required to
treat anemia. Evaluation of iron status before and during r-huEPO therapy
is critical for optimizing treatment. Recently, r-huEPO has been
successfully used in chronic anemia not related to
malignancy, as in intensive care units, in chronic heart failure and in
autoimmune disorders.

10537407.ttn

L4 ANSWER 10 OF 22 HCAPLUS COPYRIGHT 2008 ACS on STN
2006:453663 Document No. 145:416896 Pathogenesis of CKD: relations
to anemia, renal function and cardiac function. Eto, Nobuaki; Nangaku,
Masao (School of Medicine, Affiliated Hospital, The University of Tokyo,
Japan). Ketsuatsu, 13(4), 385-390 (Japanese) 2006. CODEN: KETSAB. ISSN:
1340-4598. Publisher: Senten Igakusha.

AB A review discussing (1) anemia and chronic kidney disease (CKD), (2)
anemia and cardiovascular disease, (3) CKD and cardiovascular disease and
(4) erythropoietin for the treatment of CKD.

10537407.ttn

L4 ANSWER 11 OF 22 HCAPLUS COPYRIGHT 2008 ACS on STN
2006:50536 Document No. 145:121402 Pathogenesis of
aplastic anemia. Teramura, Masanao (Department of
Hematology, Tokyo Women's Medical University, Tokyo, 162-8666, Japan).
Ketsueki, Shuyoka, 51(4), 335-341 (Japanese) 2005. CODEN: KETSBI. ISSN:
0915-8529. Publisher: Kagaku Hyoronsha.

AB A review focuses on gene expression profiles in pathogenesis of
aplastic anemia.

10537407.ttn

- 14 ANSWER 12 OF 22 HCAPLUS COPYRIGHT 2008 ACS ON STN
2005:1232245 Document No. 144:230153 Molecular pathogenesis of
Fanconi anemia. Collins, Natalie; Kupfer, Gary M. (Department of
Microbiology, University of Virginia Health System, University of
Virginia, Charlottesville, VA, USA). International Journal of Hematology,
82(3), 174-183 (English) 2005. CODEN: IJHEHY. ISSN: 0925-5710.
Publisher: Corden Jennings Publishing.
- AB A review. Fanconi anemia (FA) is a rare inherited disorder characterized
clin. by aplastic anemia, developmental defects, and a
susceptibility to cancer. Eleven complementation groups have been
identified (FA-A, -B, -C, -D1, -D2, -E, -F, -G, -I, -J, and -L), and the
genes responsible for 9 groups (FANCA, B, C, D1, D2, E, F, G, and I) have
been cloned. The proteins involved in FA act coordinately in the cellular
response to DNA cross-links in a pathway that has been shown to interact
phys. or functionally with a variety of other proteins involved in DNA
repair or cell cycle control, notably BRCA1, Rad51, ATM, ATR, and Mre11.
Considerable advances in the identification and description of proteins
involved in FA have been recorded, but the precise biochem. function of
the FA pathway remains elusive. As research continues to improve our
understanding of FA, insight will be gained into what is a pivotal process
in cancer biol.

10537407.ttn

- 14 ANSWER 13 OF 22 HCAPLUS COPYRIGHT 2008 ACS ON STN
2005:500337 Document No. 143:344613 Pathogenesis and therapy of
acquired pure red cell aplasia. Jing,
Liping; Shao, Zonghong (Institute of Hematology; Blood Disease Hospital,
CAMS and FJMC, Tianjin, 300020, Peop. Rep. China). Zhonghua Xueyexue
Zazhi, 25(8), 510-512 (Chinese) 2004. CODEN: ZHXC07. ISSN: 0253-2727.
Publisher: Zhongguo Yixue Kexueyuan Xueyexue Yanjiusuo.
- AB A review. It summarizes current knowledge on the pathogenesis and therapy
of acquired pure red cell aplasia (PRCA).

14 ANSWER 14 OF 22 HCAPLUS COPYRIGHT 2008 ACS ON STN

2003:425663 Document No. 139:67398 The role of lymphoid cells in the pathogenesis of PNH. Iuzzato, Lucio; Karadimitris, Anastasios; Araten, David; Notaro, Rosario (Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy). Paroxysmal Nocturnal Hemoglobinuria and Related Disorders: Molecular Aspects of Pathogenesis, [International Symposium on PNH and Related Disorders: Molecular Aspects of Pathogenesis], Tokyo, Japan, Aug. 28-29, 2001, Meeting Date 2001, 105-116. Editor(s): Omine, Mitsuhiro; Kinoshita, Taroh. Springer-Verlag Tokyo: Tokyo, Japan. ISBN: 4-431-76329-2 (English) 2003. CODEN: 690XSV.

AB A review. Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disorder of the hematopoietic stem cell (HSC), characterized by blood cells deficient in the glycosylphosphatidylinositol (GPI)-anchored proteins. The GPI-deficient blood cells result from a somatic mutation of the X-linked PIG-A gene in one or more HSC of the PNH patients, in whom the HSC carrying the mutated PIG-A gene expand to the extent that in many cases GPI-deficient cells eventually comprise most of hematopoiesis. In PNH patients the expansion of the GPI-deficient hematopoiesis is almost invariably associated with features of bone marrow failure. This fact, together with other clin. and exptl. evidence, suggests that the expansion of PIG-A mutant clones is due to a concomitant selective process against the normal HSC carrying the wild type PIG-A, rather than to an intrinsic growth advantage of the mutated HSC. The close association between PNH and idiopathic aplastic anemia, and the recent finding of increased frequency of expanded T cell clones in patients with PNH, support a pathogenetic model based on autoreactive T cells that cause the selective depletion of normal HSC, whereas PNH HSC escape this T-cell-mediated attack, survive and expand. However, the mechanism responsible for the bone marrow failure and the target of the autoimmune T cells remains still unknown. Here, we review the most recent findings and possible mechanisms.

14 ANSWER 15 OF 22 HCAPLUS COPYRIGHT 2008 ACS ON STN

2002:298026 Document No. 137:183127 Molecular pathogenesis of Fanconi anemia. Taniguchi, Toshiyasu; D'Andrea, Alan D. (Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA). International Journal of Hematology, 75(2), 123-129 (English) 2002. CODEN: IJHEEY. ISSN: 0925-5710. Publisher: Carlen Jernings Publishing.

AB A review. Fanconi anemia (FA) is a rare autosomal recessive chromosomal breakage disorder characterized by the childhood onset of aplastic anemia, developmental defects, cancer susceptibility, and cellular hypersensitivity to DNA-crosslinking agents. FA patients can be divided into at least 8 complementation groups (FA-A, FA-B, FA-C, FA-D1, FA-D2, FA-E, FA-F, and FA-G). FA proteins encoded by 6 cloned FA genes (FANCA, FANCB, FANCD1, FANCD2, FANCF, and FANCG) cooperate in a common pathway, culminating in the monoubiquitination of FANCD2 protein and colocalization of FANCD2 and BRCA1 proteins in nuclear foci. These BRCA1 foci have been implicated in the process of homologous recombination-mediated DNA repair. In this review, we will summarize the current progress in the field of FA research and highlight some of the potential functions of the FA pathway in DNA-damage response.

10537407.tzn

- 14 ANSWER 16 OF 22 HCAPLUS COPYRIGHT 2008 ACS ON STN
2000:112778 Document No. 133:38262 Hematopoietic growth factors in the pathogenesis and for the treatment of aplastic anemia. Marsh, Judith C. W. (Department of Haematology, St. George's Hospital Medical School, London, SW17 0RE, UK). Seminars in Hematology, 37(1), 81-90 (English) 2000. CODEN: SEHEA3. ISSN: 0037-1963. Publisher: W. B. Saunders Co..
- AB A review with 86 refs. The production and release of hematopoietic growth factors from bone marrow stromas established in vitro from patients with aplastic anemia is normal or increased. Addition of hematopoietic growth factors to aplastic anemia bone marrow cells results in only modest increases in colony growth, with the exception of granulocyte colony-stimulating factor (G-CSF), which corrects their impaired cloning efficiency to normal. Most clin. data on the use of hematopoietic growth factors in aplastic anemia have derived from uncontrolled and small single-arm studies or case reports. Sustained trilineage hematol. responses have not been observed when hematopoietic growth factors have been used alone or in combination. Serious side effects have been reported for most of the hematopoietic growth factors in patients with aplastic anemia, with the exception of G-CSF. There is a major concern that they may further increase the risk of clonal disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Hematopoietic growth factors should not be used alone in newly diagnosed patients as specific treatment for aplastic anemia, and their use in combination with immunosuppressive therapy should be confined to multicenter, prospective randomized studies.

10537407.tzn

- 14 ANSWER 17 OF 22 HCAPLUS COPYRIGHT 2008 ACS ON STN
1999:101706 Document No. 130:336467 Pathogenesis of aplastic anemia and immunity. Nakao, Shinji (Japan). Saishin Naikagaku Taikou, Puroguresu Shirizu, Volume 3, 113-123. Editor(s): Kanazawa, Ichiro. Nakayama Shoten: Tokyo, Japan. (Japanese) 1997. CODEN: 67FXAF.
- AB A review with 27 refs. discusses clin. symptoms and immunol. mechanism of aplastic anemia, the difficulty in understanding immunol. mechanism, etiol. of aplastic anemia and HLA class II, proliferation of antigen-specific T cells in aplastic anemia bone marrow, isolation of hematopoiesis-cytotoxic T cell clones in bone marrow of patients with aplastic anemia, and immunol. mechanism of aplastic anemia and occurrence of paroxysmal nocturnal hemoglobinuria.

10537407.tzn

- 14 ANSWER 18 OF 22 HCAPLUS COPYRIGHT 2008 ACS ON STN
1998:290761 Document No. 129:66090 Original Reference No. 129:13681a,13684a
Somatic mutation and clonal selection in the pathogenesis and in
the control of paroxysmal nocturnal hemoglobinuria. Bessler, Monica;
Hillmen, Peter (Division of Hematology, Departments of Internal Medicine
and Molecular Biology and Pharmacology, Washington University School of
Medicine, St. Louis, MO, 63110-1093, USA). Seminars in Hematology, 35(2),
149-167 (English) 1998. CODEN: SHEMA3. ISSN: 0037-1963. Publisher: W.
B. Saunders Co..
- AB A review, with 158 refs. Patients with paroxysmal nocturnal
hemoglobinuria (PNH) have a somatic mutation of the X-linked PIG-A gene
which occurs in a hematopoietic stem cell. This results in a proportion
of blood cells being deficient in all glycosyl phosphatidylinositol (GPI)
anchored proteins. These GPI-deficient cells explain many of the clin.
symptoms of PNH, but not the mechanism that enables the PNH clone to
expand. In vitro bone marrow culture studies, mol. anal. of the genetic
lesions, and data derived from mice with PNH blood cells demonstrate that
PIG-A inactivation alone does not confer a proliferative advantage to the
hematopoietic stem cell. Thus, a second factor is needed to cause the
disease. Clin. observations show a close relationship between PNH and
aplastic anemia (AA), and it appears that the cause of
the failure of normal hematopoiesis in AA enables the PNH clone to
proliferate. Correction of the genetic defect in PNH cells by gene
therapy may at first sight be an attractive proposition but the corrected "PNH"
cells may then be exposed to the insult causing bone marrow failure. This
underscores the importance of a more complete understanding of the
pathogenesis of the disease as a scientific foundation for gene therapy.

10537407.tzn

- 14 ANSWER 19 OF 22 HCAPLUS COPYRIGHT 2008 ACS ON STN
1998:2432 Document No. 128:70203 Original Reference No. 128:13555a,13559a
Pathogenesis, diagnosis, and treatment of renal
anemia. Urabe, Akio (Dep. Blood Med., Kanto Teishin Hospital,
Japan). Jissen Rinsho Maika Sirizu, 5(Hinketsu: Wadai no Shikkan), 29-32
(Japanese) 1995. CODEN: JRNST4. Publisher: Medikaru AI Shuppan.
- AB A review, with 5 refs., of the pathogenesis, diagnosis, and treatment with
erythropoietin of renal anemia.

10537407.ttn

- L4 ANSWER 20 OF 22 HCAPLUS COPYRIGHT 2008 ACS on STN
1993:845 Document No. 118:845 Original Reference No. 118:181a,182a Effects
of activin A/EDF on pathogenesis of renal
anemia. Shinohara, Masayuki; Kosaka, Masaaki (Sch. Med., Univ.
Tokushima, Tokushima, 770, Japan). Jikken Igaku, 10(15), 1993-8
(Japanese) 1992. CODEN: JIIGEF. ISSN: 0289-5514.
- AB A review, with 29 refs., on the hypoprodn. of erythropoietin (EPO),
decreased secretion of burst promoting activity (BPA) from the monocytes
and T-lymphocytes, and suppression of erythropoiesis and hemolysis in the
pathogenesis of renal anemia, and the effects of EDF
on impaired erythropoiesis in the anemic patients.

10537407.ttn

- L4 ANSWER 21 OF 22 HCAPLUS COPYRIGHT 2008 ACS on STN
1992:503407 Document No. 117:103407 Original Reference No. 117:17757a,17760a
The role of leukocyte-generated reactive metabolites in the
pathogenesis of idiosyncratic drug reactions. Uetrecht, J. P.
(Fac. Pharm., Univ. Toronto, Toronto, ON, M5S 3S2, Can.). Drug Metabolism
Reviews, 24(3), 249-266 (English) 1992. CODEN: DMTRAR. ISSN: 0360-2532.
- AB A review with 357 refs., including discussions on the involvement of the
immune system in idiosyncratic drug reactions, involvement of reactive
metabolites in idiosyncratic drug reactions, formation of reactive
metabolites by leukocytes, agranulocytosis and aplastic
anemia, drug-induced lupus, and generalized idiosyncratic drug
reactions.

10537407.ttn

14 ANSWER 22 OF 22 HCAPLUS COPYRIGHT 2008 ACS on STN
1988:4311 Document No. 108:6311 Original Reference No. 108:843a,846a
Interferons and other lymphokines in bone marrow suppression in vitro and
in vivo: implications for the pathogenesis of aplastic
anemia. Young, Neal Stuart (Clin. Hematol. Branch, Natl. Heart,
Lung Blood Inst., Bethesda, MD, 20892, USA). Colloque INSERM, 162(Inhib.
Hematopoiesis), 279-88 (English) 1987. CODEN: CITHDE. ISSN: 0768-3154.
AB A review with 49 refs. of lymphokines, (especially interferon) mediation of
suppression of hematopoiesis. These lymphokines may play a role in
aplastic anemia.

10537407.ttn

=> s renal anemia
168261 RENAL
12 RENALS
168266 RENAL
(RENAL OR RENALS)
42334 ANEMIA
1962 ANEMIAS
42725 ANEMIA
(ANEMIA OR ANEMIAS)
L8 466 RENAL ANEMIA
(RENAL (W) ANEMIA)

=> s 18 and review/dt
2176269 REVIEW/DT
L9 151 L8 AND REVIEW/DT

=> s 19 and treatment/ti
467279 TREATMENT/TI
20806 TREATMENTS/TI
487848 TREATMENT/TI
(TREATMENT OR TREATMENTS)/TI
L10 25 L9 AND TREATMENT/TI

=> d scan ti

10537407.tnn

L10 25 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STM
T1 Brain dysfunction in elderly hemodialysis patients: effects of rHuEPO
treatment

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.tnn

L10 25 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STM
T1 Iron therapy during erythropoietin treatment in haemodialysis
patients

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ten

L10 25 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Clinical guide for the treatment of anemia for patient under
dialysis

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ten

L10 25 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 The importance of early treatment of the anaemia of chronic
kidney disease

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.trn

L10 25 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Recombinant human epoetin beta in the treatment of renal
anemia

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.trn

L10 25 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 L-carnitine treatment of anemia

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L10 25 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Treatment of renal anemia by erythropoietin
substitution: The effects on the cardiovascular system

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L10 25 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Exploring dosing frequency and administration routes in the
treatment of anaemia in CKD patients

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L10 25 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Cytokine for the treatment of anemia and its problems

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.ttn

L10 25 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Treatment of renal anemia

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.tzn

L10 25 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Early epoetin treatment in patients with renal insufficiency

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.tzn

L10 25 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Effect of treatment of renal anemia with
recombinant human erythropoietin on central nervous system

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.trn

L10 25 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Present and future strategies in the treatment of renal anaemia

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10537407.trn

L10 25 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
T1 Recombinant human epoetin beta in the treatment of renal
anaemia

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

10537407.tzn

=> d cblb abs 1-
YOU HAVE REQUESTED DATA FROM 25 ANSWERS - CONTINUE? Y/(N):y

10537407.tzn

L10 ANSWER 1 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STM
2008:235601 Document No. 148:276869 Recombinant human epoetin beta in the treatment of renal anemia. Del Vecchio, Lucia; Cavalli, Andrea; Pozzoni, Pietro; Locatelli, Francesco (Department of Nephrology, Manzoni Hospital, Lecco, 23900, Italy). Therapy, 5(1), 91-98 (English) 2008. CODEN: THERCR. ISSN: 1475-0708. Publisher: Future Medicine Ltd..

AB A review. Anemia has obtained increasing relevance and attention in patients with chronic kidney disease as an independent cardiovascular risk factor, since a number of studies have clearly described a relationship between anemia and mortality in this population. This may be a consequence of the impact of anemia on cardiac function leading to the development of left ventricular hypertrophy. The availability of recombinant human erythropoietin has deeply changed the management of anemia in chronic kidney disease patients, representing the most important improvement in the management of this condition after the discovery of dialysis. Epoetin beta is one of the erythropoiesis-stimulating agents now available on the market. Different studies have shown that this drug, when administered once-weekly to hemodialysis patients, is as effective as three-times weekly administration; the less frequent administration schedule reduces nursing times and treatment costs. This is expected to potentially enhance patient compliance, helping more patients to achieve their target Hb levels.

10537407.ttn

L10 ANSWER 2 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN

2007:364936 Document No. 147:419000 Recombinant human epoetin beta in the treatment of renal anemia. Locatelli,

Francesco; Pozzoni, Pietro; Del Vecchio, Lucia (Department of Nephrology and Dialysis, A. Manzoni Hospital, Lecco, Italy). Therapeutics and Clinical Risk Management, 3(3), 433-439 (English) 2007. CODEN: TCMA6. ISSN: 1176-6336. Publisher: Dove Medical Press (WZ) Ltd..

AB A review. Cardiovascular disease is the leading cause of the poor long-term survival of patients with chronic kidney disease (CKD). Anemia complicating CKD not only impairs patients' quality of life, but is also an independent risk factor for adverse cardiovascular outcomes. The availability of recombinant human erythropoietin (rHuEPO) has greatly changed the management of anemia in CKD patients. Besides improving Hb levels, rHuEPO therapy has been demonstrated to significantly improve quality of life and decrease morbidity and mortality in patients with CKD. Epoetin beta, together with epoetin alfa and darbepoetin alfa, is one of the erythropoiesis-stimulating agents now available on the market. Different studies have shown that epoetin beta once-weekly administration to hemodialysis patients is as effective as three-times-weekly administration in maintaining Hb levels at equivalent weekly doses. This raises the possibility of reducing the frequency of administration of rHuEPO therapy, thus increasing the alternatives available for tailoring anemia therapy to patients needs, and at the same time reducing nursing times and treatment costs. This is expected to potentially enhance patient compliance, thus helping more patients achieve their target Hb levels.

10537407.ttn

L10 ANSWER 3 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN

2007:579414 Document No. 147:64622 Effects of erythropoietin treatment for renal anemia on function of

endocrine systems. Shoji, Shigeichi; Nishizawa, Yoshiki (Dep. of Internal Medicine, Minami Osaka Hospital, Japan). Jin to Iseki, 62(4), 735-740 (Japanese) 2007. CODEN: JIIOAA. ISSN: 0385-2156. Publisher: Tokyo Igakusha.

AB A review on effects of erythropoietin (rHuEPO) for renal anemia treatment on function of endocrine systems.

10537407.ttn

L10 ANSWER 4 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN

2007:579380 Document No. 147:64621 Effect of treatment of renal anemia with recombinant human erythropoietin on central nervous system. Tsuruya, Kazuhiko; Hirakata, Hideki (Grad. Sch. Medical Science, Dep. of Integrated Therapy for Chronic Kidney Diseases, Kyushu Univ., Fukuoka, Japan). Jin to Toseki, 62(4), 729-734 (Japanese) 2007. CODEN: JTIOAA. ISSN: 0385-2156. Publisher: Tokyo Igakusha.

AB A review discussing effect of treatment of renal anemia with recombinant human erythropoietin (rHUEPO) on central nervous system.

10537407.ttn

L10 ANSWER 5 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN

2007:480267 Document No. 147:85990 Clinical guide for the treatment of anemia for patient under dialysis. Kato, Noriyuki; Suzuki, Hirotaka; Akizawa, Tadao (Sch. of Medicine, Showa Univ., 1-5-8 Hatanodai, Shinjyawa-ku, Tokyo, 142-8666, Japan). Jin to Toseki, 62(3), 623-629 (Japanese) 2007. CODEN: JTIOAA. ISSN: 0385-2156. Publisher: Tokyo Igakusha.

AB A review, discussing the pathogenesis, diagnosis, and guidelines for treatment of renal anemia for patients under dialysis and therapy with erythropoietin and iron preps.

10537407.tzn

L10 ANSWER 6 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STM
2006:590332 Document No. 145:56058 New treatment for renal
anemia. Iino, Yasuhiko (Dep. of Renal Diseases, Nippon Medical
School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan). Jin to Toseki,
60(5), 789-793 (Japanese) 2006. CODEN: JTIIOA. ISSN: 0385-2156.
Publisher: Tokyo Igakusha.

AB A review discussing the development of novel treatments for renal
anemia. The subtitles include (1) mechanism of erythropoiesis,
(2) strategy for treatment of renal anemia by
Erythropoietin (EPO); (3) development of novel drug for renal
anemia treatment, such as novel erythropoiesis stimulating protein
(NESP), continuous erythropoietin receptor activator (CERA), GATA
inhibitors, and HIF-1 inhibitors.

10537407.tzn

L10 ANSWER 7 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STM
2006:157375 Document No. 144:266193 Treatment of renal
anemia. Weji, Shigeo; Akizawa, Tadao (Dep. Nephrol. Intern. Med.,
Wakayama Medical University, Japan). Nippon Naika Gakkai Zasshi, 95(1),
140-147 (Japanese) 2006. CODEN: NNGAAS. ISSN: 0021-5384. Publisher:
Nippon Naika Gakkai.

AB A review on the diagnosis and treatment of renal anemia
, discussing concept and diagnosis, treatment with recombinant human
erythropoietin and iron replacement therapy in hemodialysis patients,
treatment in predialysis patients, erythropoietin resistance, novel
erythropoietin preps. including NESP (novel erythropoiesis stimulating
protein) and CERA (continuous erythropoiesis receptor activator),
treatment by GATA inhibitors and hypoxia-inducible factor-prolyl
hydroxylase inhibitors, and gene therapy.

10537407.ttn

L10 ANSWER 8 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN

2005:1332422 Document No. 144:363178 Brain dysfunction in elderly hemodialysis patients: effects of rHuEPO treatment. Hirakata, Hideki (Dep. of Renal Diseases, Kyushu University Hospital, Higashi-ku, Fukuoka-shi, 812-8582, Japan). Jin to Toseki, 59(5), 886-890 (Japanese) 2005. CODEN: JTI0AA. ISSN: 0385-2156. Publisher: Tokyo Igakusha.

AB A review, on the title subject, discussing cerebral circulatory and metabolic disorders in chronic kidney failure; effects of recombinant human erythropoietin (rHuEPO) on renal anemia; and brain oxygen supply in management of anemia.

10537407.ttn

L10 ANSWER 9 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN

2005:1092749 Document No. 144:64419 Darbepoetin alfa: novel treatment for anemia. Savada, Naoki (Pharmaceutical Div. Project Management Section, Kirin Brewery Co., Ltd., Japan). BIO Clinica, 20(11), 1008-1012 (Japanese) 2005. CODEN: BCILCY. ISSN: 0919-8237. Publisher: Hokuryukan.

AB A review, on the structure and pharmacol. effects of darbepoetin alfa; clin. application of darbepoetin alfa; and the renal anemia therapeutic target of darbepoetin alfa.

10537407.tzn

L10 ANSWER 10 OF 25 HCAPLUS COPYRIGHT 2008 ACS ON STN

2005:1040806 Document No. 144:101143 Exploring dosing frequency and administration routes in the treatment of anaemia in CKD patients. Portoles, Jose; Kriesper, Peter; Choukroun, Gabriel; de Francisco, Angel L. M. (Nephrology Unit, Fundacion Hospital Alcorcon, Madrid, Spain). Nephrology, Dialysis, Transplantation, 20(Suppl. 8), viii13-viii17 (English) 2005. CODEN: NDTREA. ISSN: 0931-0509. Publisher: Oxford University Press.

AB A review. Erythropoiesis-stimulating agents have dramatically changed the management of renal anemia since their introduction almost 20 years ago. However, optimal dosing route and frequency are still a matter of debate. I.v. application of recombinant human erythropoietin should be limited to hemodialysis patients and must be given three times weekly, as any reduction to this dosing frequency leads to a major increase in dose requirements. Administering recombinant human erythropoietin- β once weekly via the s.c. route is effective. If conversion from the s.c. to the i.v. route is required, dose requirements for recombinant human erythropoietin therapy remain a subject of discussion.

10537407.tzn

L10 ANSWER 11 OF 25 HCAPLUS COPYRIGHT 2008 ACS ON STN

2005:889601 Document No. 143:453052 Once weekly treatment with epoetin- β . Locatelli, Francesco (A. Manzoni Hospital, Lecco, Italy). Nephrology, Dialysis, Transplantation, 20(Suppl. 6), vi26-vi30 (English) 2005. CODEN: NDTREA. ISSN: 0931-0509. Publisher: Oxford University Press.

AB A review. Studies have shown that both i.v. and s.c. administration of epoetin- β therapy are effective and well tolerated in the treatment of renal anemia; however, the s.c. route provides enhanced efficacy with a lower dose compared with the i.v. route and it is more cost-effective. Epoetin dosing frequency is an important issue for health care professionals and patients. Recent studies have shown that epoetin- β administered once weekly and once every 2 wk can maintain stable target Hb and hematocrit levels in dialysis patients. Such reduced dosing frequencies may improve patient satisfaction and compliance with treatment, and encourage patients to self-administer. Furthermore, less frequent dosing administration would be associated with economic benefits in terms of reduced nursing time in the clinic or out-patient setting. Where this is clin. practice, fewer injections and visits to the clinic should also improve patients' quality of life. A range of effective dosing regimens with epoetin- β administered via either pre-filled syringes, multidose vials or injector pens allows physicians to tailor treatment to an individual patient's preference.

L10 ANSWER 12 OF 25 HCAPLUS COPYRIGHT 2008 ACS ON STN
 2005:333456 Document No. 144:45536 Optimal treatment of renal
 anemia (OPTA): improving the efficacy and efficiency of renal anaemia
 therapy in haemodialysis patients receiving intravenous epoetin. Hoerl,
 Walter E.; Vanrenterghem, Yves (UK). *Nephrology, Dialysis,
 Transplantation*, 20(Suppl. 3), ii125-ii132 (English) 2005. CODEN: NDTREA.
 ISSN: 0931-0509. Publisher: Oxford University Press.

AB A review. The medical care of renal anemia has
 received much attention over the past decade, as nephrologists have
 recognized the increased therapeutic value of erythropoiesis-stimulating
 agents. The European Best Practice Guidelines and the US National Kidney
 Foundation's Kidney Disease Outcome Quality Initiative Guidelines have
 provided evidence-based advice on the optimal treatment of renal
 anemia, and have recommended a target Hb (Hb) level of 11 g/dL or
 11-12 g/dL. Achieving this target Hb level has been shown to improve
 quality of life and reduce the rate of hospitalization; there is also good
 evidence to suggest that achieving adequate Hb levels reduces morbidity
 and mortality in patients with end-stage renal disease. In recent years,
 a number of factors have been identified that may counteract the pos. action
 of epoetin therapy. These treatment-influencing factors include
 inadequate hemodialysis, absolute and functional iron deficiency,
 anticoagulant use, inflammation and infection. Each factor on its own may
 result in a substantial decrease in Hb levels, or an increase in epoetin
 requirements of up to 100%. Therefore, optimal and cost-effective
 treatment can only be achieved by adequately managing all of the factors
 that potentially can influence anemia in patients with chronic kidney
 disease. Large-scale, cross-sectional surveys, such as the European
 Survey on Anemia Management and the Dialysis Outcomes and Practice
 Patterns Study, have shown that there is still room for improving the
 efficacy and efficiency of anemia therapy. The Optimal Treatment of
 Renal Anemia (OPTA) initiative aims to help both
 physicians and nurses improve renal anemia management
 by translating the stds. set in published guidelines into practical clin.
 advice.

L10 ANSWER 13 OF 25 HCAPLUS COPYRIGHT 2008 ACS ON STN
 2003:317028 Document No. 139:62432 L-carnitine treatment of
 anemia. Golper, Thomas A.; Goral, Simin; Becker, Bryan N.; Langman, Craig
 B. (Department of Medicine, Division of Nephrology, Department of
 Medicine, Vanderbilt University Medical Center, Nashville, TN, USA).
American Journal of Kidney Diseases, 41(4, Suppl. 4), S27-S34 (English)
 2003. CODEN: AJKDPE. ISSN: 0272-6396. Publisher: W. B. Saunders Co..

AB A review. Recombinant human erythropoietin (rHuEPO) and iron
 supplementation have had a profoundly pos. impact on the anemia of
 patients with chronic kidney disease. However, a significant number of
 patients remain hyporesponsive to rHuEPO, with Hb values less than target
 levels. A suboptimal response to rHuEPO is associated with complications
 that can reduce quality of life and increase morbidity, mortality, and
 costs. There are a number of other metabolic derangements associated with
 uremia that can have an impact on the production and survival of red blood
 cells. Dialysis-related carnitine disorder is a functional metabolic
 deficiency, common in chronic dialysis patients, that can have a neg.
 impact on erythrocyte production and survival. This article reviews the role
 of L-carnitine in the pathogenesis and adjunctive treatment of anemia
 associated with kidney failure. After a comprehensive database search,
 primary and secondary reports were analyzed. Laboratory studies examining the
 influence of carnitine on red blood cell function and clin. trials of
 L-carnitine in dialysis patients support the use of L-carnitine in the
 setting of rHuEPO hyporesponsiveness. Consensus groups, including the
 National Kidney Foundation-Kidney Disease Outcome Quality Initiative
 (K/DOQI), consider the use of L-carnitine for hyporesponsive
 rHuEPO-dependent anemia a promising application of this therapy,
 recommending an empiric trial of L-carnitine in these patients.

10537407.tzn

L10 ANSWER 14 OF 25 HCAPLUS COPYRIGHT 2008 ACS ON STN
2001:906792 Document No. 136:178035 Individualizing target haemoglobin concentrations-tailoring treatment for renal anaemia.
MacDougall, Iain C. (King's College Hospital, London, SE22 8PT, UK).
Nephrology, Dialysis, Transplantation, 16(Suppl. 7), 9-14 (English) 2001.
CODEN: NDTREA. ISSN: 0931-0509. Publisher: Oxford University Press.

AB A review. Despite the publication of National Kidney Foundation and European Best Practice Guidelines, there is still uncertainty among nephrologists regarding the optimum target Hb concentration for patients

treated with erythropoietin. For most patients, the target Hb concentration is 11-12 g/dL, resulting in only partial correction of anaemia. However, there is a link between subnormal Hb concentration and the development of cardiovascular disease. Thus, it may be more beneficial to normalise Hb, although this has to be balanced against the concern that full correction of anaemia may result in adverse effects, such as hypertension and progression of renal disease. There is increasing evidence that it may be appropriate to treat each patient individually, and to tailor treatment according to a number of physiologic and lifestyle variables, avoiding higher Hb concns. in certain patient groups (such as those with cardiac problems). This was supported by the results of a survey of nephrologists and specialists in the field of renal anaemia. It was generally agreed that a higher target Hb concentration (12-14 g/dL) might be appropriate for a fit,

young patient with no significant co-morbidity, whereas a lower target Hb (10-12 g/dL) might be appropriate for an elderly patient with multiple medical problems. In conclusion, guidelines for target Hb in the US and Europe are probably not applicable to all patients. It is important that renal anaemia patients are considered as individuals, and their treatment tailored accordingly. It is time to establish evidence-based criteria for individualizing renal anaemia treatment.

10537407.tzn

L10 ANSWER 15 OF 25 HCAPLUS COPYRIGHT 2008 ACS ON STN
2001:660210 Document No. 136:722 Present and future strategies in the treatment of renal anaemia. MacDougall, Iain C. (Department of Renal Medicine, King's College Hospital, London, SE22, UK). Nephrology, Dialysis, Transplantation, 16(Suppl. 5), 50-55 (English) 2001. CODEN: NDTREA. ISSN: 0931-0509. Publisher: Oxford University Press.

AB A review, with refs. Recombinant human erythropoietin therapy has transformed the management of renal anaemia over the last decade or so. The authors have learned much about the optimum regimens for using this drug, including the route of administration, dosage frequency, use of iron supplementation, and management of poor response. Thus, dosage requirements of epoetin are generally lower if the drug is administered s.c., and the most commonly used dosage frequency is two or three times weekly. The vast majority of patients respond very well to treatment, but approx. 5-10% of patients show some resistance to epoetin, the most common cause of which is iron deficiency. The presence of infection or inflammation and under-dialysis are other important causes of a poor response to epoetin. There is increasing interest in treating renal anaemia at an earlier stage in the course of the disease, and there is much circumstantial evidence to support this strategy. This usually involves giving epoetin to pre-dialysis patients, and a study has also recently commenced to investigate the effects of preventing renal anaemia ever developing. Other erythropoietic substances are being developed, and the first of these to be ready for clin. use is novel erythropoiesis stimulating protein (NESP), which is an analog of erythropoietin containing two extra N-linked carbohydrate side-chains. Other potential erythropoietic substances are still at the laboratory stage of development, but may be available for therapeutic use in the next decade or so.

L10 ANSWER 16 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN

2001:660209 Document No. 136:721 The importance of early treatment of the anemia of chronic kidney disease. Eknoyan, Garabed (Renal Section, Department of Medicine, Baylor College of Medicine, Houston, TX, 77030, USA). Nephrology, Dialysis, Transplantation, 16(Suppl. 5), 45-49 (English) 2001. CODEN: NDTREA. ISSN: 0931-0509. Publisher: Oxford University Press.

AB A review, with refs. The beneficial effects of treating the anemia of dialysis-dependent patients with erythropoietin on the improvement of cardiac status, exercise capacity, cognitive function and quality of life are well established. Equally, if not more important is the reduction in morbidity and mortality that accompanies the treatment of anemia with epoetin. These documented improvements in outcomes of care notwithstanding, mortality and morbidity due to cardiovascular disease (CVD) remain high in dialysis patients. Recent epidemiol. evidence indicates that: (i) the prevalence of CVD is very high in patients at the start of dialysis; (ii) pre-existing CVD is the major risk factor for mortality and morbidity on dialysis; (iii) CVD begins early in the course of kidney disease, shows an inverse relationship to kidney function and increases in prevalence and severity with progression of kidney disease; and (iv) corrective measures, which take 3-5 yr to show a favorable effect, must be instituted well before the initiation of dialysis. Hypertension and anemia, which develop in the course of progressive reduction in kidney function, are the principal risk factors for the prevalence of left ventricular hypertrophy (LVH) in those with chronic kidney disease, and their treatment has been shown to arrest or reverse LVH in these individuals. Whereas the treatment of hypertension early in the course of kidney disease has been incorporated into clin. practice, there has been reluctance in the treatment of anemia because of the possibility of worsening kidney function with epoetin, as shown in rats. There is now convincing evidence that epoetin has no potential adverse effect on kidney function in humans. While the most compelling reason for the early treatment of the anemia of kidney disease is its beneficial effect on cardiovascular function, other documented potential benefits are improvements in exercise capacity, cognitive function and quality of life.

L10 ANSWER 17 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN

2000:743619 Document No. 134:320890 Recombinant human erythropoietin treatment in chronic renal failure: Effects on hemostasis and vasculature. Cases, Aleix (Department of Nephrology, Hospital Clinic i Universitari, IDIBAPS, Barcelona, 08036, Spain). Drugs of Today, 36(8), 541-556 (English) 2000. CODEN: MDACAP. ISSN: 0025-7656. Publisher: Probus Science.

AB A review with 158 refs. The use of recombinant human erythropoietin (rhuEPO) for the treatment of renal anemia improves the altered primary hemostasis frequently observed in uremia, through both an increase in hematocrit (rheol. effect) and an improvement in uremic platelet function. Although the in vitro vascular effects of rhuEPO are complex and may cause hypertensive and thrombotic complications in patients with end-stage renal disease, in vivo and clin. studies have not confirmed these findings. Therefore, the long-term effects of anemia correction with rhuEPO treatment on endothelial and vascular function in uremic patients merits further investigation.

10537407.tzn

L10 ANSWER 18 OF 25 HCAPLUS COPYRIGHT 2008 ACS ON STN

2000:717333 Document No. 134:275788 Early epoetin treatment in patients with renal insufficiency. Ritz, Eberhard; Eisenhardt, Antje (Department of Internal Medicine, Ruperto Carola University, Heidelberg, Germany). Nephrology, Dialysis, Transplantation, 15(Suppl. 3), 40-44 (English) 2000. CODEN: NDTREA. ISSN: 0931-0509. Publisher: Oxford University Press.

AB A review with 32 refs. Historically, epoetin has been used to treat anemia in patients already receiving renal replacement therapy. For many years, however, the results of early animal expts. raised considerable concern among nephrologists that disease progression would be accelerated if epoetin therapy were initiated in the predialysis phase of renal failure. In retrospect, it has become clear that the results of these early animal expts. were confounded by a concomitant and uncontrolled rise in blood pressure. In subsequent studies in rat models, antihypertensive treatment effectively prevented the adverse effect on disease progression. In addition, the results of several small observational studies and one large controlled study suggest that the glomerular filtration rate is not adversely affected in pre-dialysis patients treated with epoetin as long as blood pressure is well controlled. There are several observations, though not definitive, which suggest that disease progression may even be slower when anemia is reversed. The benefits of early anemia treatment with epoetin include increased exercise capacity and improved quality of life, cognitive function, and sexual function. Anemia has also been identified as an important etiol. factor in the development of left ventricular hypertrophy. Whether pre-emptive treatment of anemia is indicated in all pre-dialysis patients, or at least in those who develop progressive left ventricular hypertrophy, is currently under investigation.

10537407.tzn

L10 ANSWER 19 OF 25 HCAPLUS COPYRIGHT 2008 ACS ON STN

2000:504615 Document No. 133:232574 Iron therapy during erythropoietin treatment in haemodialysis patients. Sunder-Plassmann, Gere; Hori, Walter H. (Department of Medicine III, University of Vienna, Vienna, Austria). Kidney Forum, 2(1), 23-25 (English) 2000. CODEN: KIFOF2. ISSN: 1369-3050. Publisher: Sheffield Academic Press.

AB A review with 17 refs. in which several studies demonstrate the high efficacy and benefit of recombinant human erythropoietin (r-HuEPO) treatment in patients with renal anemia. However, though effective, a considerable number of patients with r-HuEPO hyporesponsiveness have been described. Today, iron deficiency is established as the most common and most easily treatable cause of sub-optimal response to r-HuEPO.

10537407.ttn

L10 ANSWER 20 OF 25 HCAPLUS COPYRIGHT 2008 ACS ON STN

1998:691241 Document No. 130:105337 The safety of treatment with recombinant human erythropoietin in clinical use: a review of controlled studies. Sowade, Birgit; Sowade, Olaf; Mocks, Joachim; Franke, Werner; Warneke, Harry (Klinik für Anesthesiologie und Intensivmedizin, Krankenhaus Berlin-Kaulsdorf; Abteilung für Herzchirurgie, Havelklinik Berlin-Spandau; Abteilung für Klinische Forschung, Boehringer Mannheim GmbH, Mannheim, Germany). International Journal of Molecular Medicine, 1(2), 303-314 (English) 1998. CODEN: IJMEFG. ISSN: 1107-3756. Publisher: International Journal of Molecular Medicine.

AB A review with 96 refs. Recombinant human erythropoietin (rHPEO) has now been approved for the treatment of renal anemia, anemia of prematurity, cancer-associated anemia, AIDS-associated anemia and as concomitant treatment for patients with or without autologous blood donation awaiting elective surgery. The purpose of this review is to provide an overview, based on the results of controlled studies, of the anticipated safety profile of rHPEO in various indications and to assess whether treatment with rHPEO influences the incidences of certain adverse events in these indications. The anticipated adverse events differ from indication to indication and generally reflect the corresponding underlying illness. With most indications, no relevant differences in the incidences of adverse events are observed between rHPEO and placebo-control/patients. Only in the rHPEO therapy of renal anemia is an increased incidence of hypertensive events observed in the rHPEO groups, a finding that is not reproduced with the other indications. The controlled studies forming the basis of this review provide no evidence of a relevant increase in the risk of thromboembolic events during rHPEO therapy. Overall, it may be stated that rHPEO treatment, where strictly indicated, is a safe form of therapy. As with any other treatment, the risk of side effects in certain predisposed patients must also be weighed against the desired clin. benefits.

10537407.ttn

L10 ANSWER 21 OF 25 HCAPLUS COPYRIGHT 2008 ACS ON STN

1998:556805 Document No. 129:325560 Original Reference No. 129:66213a,66214a Cytokine for the treatment of anemia and its problems. Bessho, Masami (First Medical Building, Saitama Medical University, Japan). Nippon Ishikai Zasshi, 120(1), 59-62 (Japanese) 1998. CODEN: NITAEU. ISSN: 0021-4493. Publisher: Nippon Ishikai.

AB A review with 12 refs. on the treatment of anemia such as renal anemia, anemia of premature infants, myelodysplastic syndrome, etc. with erythropoietin and its problems is presented. Treatment with other cytokines such as GM-CSF and IL-3 is also discussed.

10537407.ttn

- L10 ANSWER 22 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN
1998:2432 Document No. 128:70203 Original Reference No. 128:13555a,13558a
Pathogenesis, diagnosis, and treatment of renal
anemia. Urabe, Akio (Dep. Blood Med., Kanto Teishin Hospital,
Japan). Jissen Rinsho Waika Sirizu, 5(Rinketsu: Wadai no Shikkan), 29-32
(Japanese) 1995. CODEN: JRNSF4. Publisher: Medikaru AI Shuppan.
- AB A review, with 5 refs., of the pathogenesis, diagnosis, and treatment with
erythropoietin of renal anemia.

10537407.ttn

- L10 ANSWER 23 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN
1997:772718 Document No. 128:10036 Original Reference No. 128:1869a,1872a
Clinical application and outcome of hemodiafiltration treatment.
Kim, Sung Teh (Jinzobyo Senta, Kitakyushu Nefurokurinikku, Kitakyushu,
807, Japan). Igaku no Ayumi, 183(5), 314-319 (Japanese) 1997. CODEN:
IGAYZM. ISSN: 0039-2359. Publisher: Ishiyaku Shuppan.
- AB A review with 10 refs., on characterization and clin. application of
hemodiafiltration for removal of large-mol.-weight uremic toxins.
Improvement of incurable complications, such as dialysis-related
amyloidosis and renal anemia, by hemodiafiltration
treatment is also discussed.

10537407.ttn

L10 ANSWER 24 OF 25 HCAPLUS COPYRIGHT 2008 ACS ON STN

1996:17716 Document No. 124:135771 Original Reference No. 124:24995a,24996a

Treatment of renal anemia by erythropoietin

substitution: The effects on the cardiovascular system. Radermacher, J.; Koch, K. M. (Department Nephrology, Hannover Medical School, Hannover, Germany). Clinical Nephrology, 44(Suppl. 1), 556-560 (English) 1995. CODEN: CLNHEI. ISSN: 0301-0430. Publisher: Dustri-Verlag Dr. Karl Festsche.

AB A review with 51 refs. Recombinant human erythropoietin (r-HuEPO) effectively corrects the anemia of end stage renal disease (ESRD). Development or aggravation of hypertension has been the most commonly reported side-effect of r-HuEPO treatment. Placebo controlled trials have shown incidence rates ranging from 15 - 21%. Renal failure itself obviously is a prerequisite in the pathogenesis of r-HuEPO-induced hypertension, since it was never observed in anemic patients without renal disease. Increased whole blood viscosity and/or reduced hypoxic vasodilatation due to the rise in hematocrit may play a role in the development of hypertension at high concns. of hematocrit. However, at hematocrit levels around 30% adnl. hypertensinogenic effects of r-HuEPO treatment seem likely. Endothelin and prostanooids are possible mediators of this effect. Left ventricular hypertrophy (concentric and eccentric), which can be due to hypertension and anemia, is commonly observed in ESRD patients and has been shown to be a predictor of cardiac morbidity and mortality in these patients. Following correction of anemia with r-HuEPO measures of left ventricular hypertrophy decrease by about 18% within a year. Normalization, though, is generally not achieved and in patients with r-HuEPO induced hypertension the increase of blood pressure may oppose the beneficial effects of r-HuEPO treatment on cardiac hypertrophy.

10537407.ttn

L10 ANSWER 25 OF 25 HCAPLUS COPYRIGHT 2008 ACS ON STN

1988:49376 Document No. 108:49376 Original Reference No. 108:8077a,8080a

Recombinant erythropoietin, a new drug for the treatment of

renal anemia. Scigalla, P.; Wiecek, L.; Hirth, P. (Produktentwickl. Ther., Boehringer Mannheim, Fed. Rep. Ger.). Nieren- und Hochdruckkrankheiten, 16(11), 487-92 (German) 1987. CODEN: NIHOJ9. ISSN: 0300-5224.

AB A review, with 47 refs., is given on the composition and structure of recombinant human erythropoietin, and on the therapeutic use of this preparation in the treatment of anemia in patients with chronic renal insufficiency.

10537407.ten

=>